Humanized  ||| S:359 E:369 ||| JJ
monoclonal  ||| S:369 E:380 ||| JJ
antibodies  ||| S:380 E:391 ||| NNS
that  ||| S:391 E:396 ||| WDT
protect  ||| S:396 E:404 ||| VBP
against  ||| S:404 E:412 ||| IN
shiga  ||| S:412 E:418 ||| FW
toxin  ||| S:418 E:424 ||| FW
induced  ||| S:424 E:432 ||| FW
disease  ||| S:432 E:445 ||| FW
PENDING  ||| S:467 E:478 ||| VBG
Stinson  ||| S:536 E:544 ||| NNP
Jeffrey  ||| S:544 E:552 ||| NNP
R ||| S:552 E:553 ||| NNP
.  ||| S:553 E:556 ||| .
Davie  ||| S:556 E:562 ||| NNP
FL  ||| S:562 E:565 ||| NNP
US  ||| S:565 E:571 ||| NNP
Weston  ||| S:594 E:601 ||| NNP
FL  ||| S:601 E:604 ||| NNP
US  ||| S:604 E:610 ||| NNP
Bethesda  ||| S:641 E:650 ||| NNP
MD  ||| S:650 E:653 ||| NNP
US  ||| S:653 E:659 ||| NNP
Rockville  ||| S:689 E:699 ||| NNP
MD  ||| S:699 E:702 ||| NNP
US  ||| S:702 E:708 ||| NNP
Sterling  ||| S:741 E:750 ||| NNP
VA  ||| S:750 E:753 ||| NNP
US  ||| S:753 E:759 ||| NNP
The  ||| S:841 E:845 ||| DT
present  ||| S:845 E:853 ||| JJ
invention  ||| S:853 E:863 ||| NN
describes  ||| S:863 E:873 ||| VBZ
the  ||| S:873 E:877 ||| DT
preparation  ||| S:877 E:889 ||| NN
and  ||| S:889 E:893 ||| CC
use  ||| S:893 E:897 ||| NN
of  ||| S:897 E:900 ||| IN
biologically  ||| S:900 E:913 ||| NN
and  ||| S:913 E:917 ||| CC
immunologically  ||| S:917 E:933 ||| JJ
active  ||| S:933 E:940 ||| JJ
humanized  ||| S:940 E:950 ||| JJ
monoclonal  ||| S:950 E:961 ||| JJ
antibodies  ||| S:961 E:972 ||| NNS
to  ||| S:972 E:975 ||| TO
Shiga  ||| S:975 E:981 ||| NNP
toxin ||| S:981 E:986 ||| NN
,  ||| S:986 E:988 ||| ,
a  ||| S:988 E:990 ||| DT
toxin  ||| S:990 E:996 ||| NN
associated  ||| S:996 E:1007 ||| VBN
with  ||| S:1007 E:1012 ||| IN
HC  ||| S:1012 E:1015 ||| NNP
and  ||| S:1015 E:1019 ||| CC
the  ||| S:1019 E:1023 ||| DT
potentially  ||| S:1023 E:1035 ||| RB
life-threatening  ||| S:1035 E:1052 ||| JJ
sequela  ||| S:1052 E:1060 ||| JJ
HUS  ||| S:1060 E:1064 ||| NNP
transmitted  ||| S:1064 E:1076 ||| VBD
by  ||| S:1076 E:1079 ||| IN
strains  ||| S:1079 E:1087 ||| NNS
of  ||| S:1087 E:1090 ||| IN
pathogenic  ||| S:1090 E:1101 ||| JJ
bacteria ||| S:1101 E:1109 ||| NNS
.  ||| S:1109 E:1111 ||| .
The  ||| S:1111 E:1115 ||| DT
present  ||| S:1115 E:1123 ||| JJ
invention  ||| S:1123 E:1133 ||| NN
describes  ||| S:1133 E:1143 ||| VBZ
how  ||| S:1143 E:1147 ||| WRB
these  ||| S:1147 E:1153 ||| DT
humanized  ||| S:1153 E:1163 ||| JJ
antibodies  ||| S:1163 E:1174 ||| NNS
may  ||| S:1174 E:1178 ||| MD
be  ||| S:1178 E:1181 ||| VB
used  ||| S:1181 E:1186 ||| VBN
in  ||| S:1186 E:1189 ||| IN
the  ||| S:1189 E:1193 ||| DT
treatment  ||| S:1193 E:1203 ||| NN
or  ||| S:1203 E:1206 ||| CC
prevention  ||| S:1206 E:1217 ||| NN
of  ||| S:1217 E:1220 ||| IN
Shiga  ||| S:1220 E:1226 ||| NNP
toxin  ||| S:1226 E:1232 ||| NN
induced  ||| S:1232 E:1240 ||| NN
diseases ||| S:1240 E:1248 ||| NNS
.  ||| S:1248 E:1250 ||| .
One  ||| S:1250 E:1254 ||| CD
aspect  ||| S:1254 E:1261 ||| NN
of  ||| S:1261 E:1264 ||| IN
the  ||| S:1264 E:1268 ||| DT
invention  ||| S:1268 E:1278 ||| NN
is  ||| S:1278 E:1281 ||| VBZ
the  ||| S:1281 E:1285 ||| DT
humanized  ||| S:1285 E:1295 ||| JJ
monoclonal  ||| S:1295 E:1306 ||| JJ
antibody  ||| S:1306 E:1315 ||| NN
which  ||| S:1315 E:1321 ||| WDT
binds  ||| S:1321 E:1327 ||| VBZ
Shiga  ||| S:1327 E:1333 ||| JJ
toxin  ||| S:1333 E:1339 ||| NN
where  ||| S:1339 E:1345 ||| WRB
the  ||| S:1345 E:1349 ||| DT
constant  ||| S:1349 E:1358 ||| JJ
regions  ||| S:1358 E:1366 ||| NNS
are  ||| S:1366 E:1370 ||| VBP
IgG1-kappa  ||| S:1370 E:1381 ||| NNP
and  ||| S:1381 E:1385 ||| CC
the  ||| S:1385 E:1389 ||| DT
variable  ||| S:1389 E:1398 ||| JJ
regions  ||| S:1398 E:1406 ||| NNS
are  ||| S:1406 E:1410 ||| VBP
murine  ||| S:1410 E:1417 ||| VBN
in  ||| S:1417 E:1420 ||| IN
origin ||| S:1420 E:1426 ||| NN
.  ||| S:1426 E:1428 ||| .
Yet  ||| S:1428 E:1432 ||| RB
another  ||| S:1432 E:1440 ||| DT
aspect  ||| S:1440 E:1447 ||| NN
of  ||| S:1447 E:1450 ||| IN
the  ||| S:1450 E:1454 ||| DT
invention  ||| S:1454 E:1464 ||| NN
is  ||| S:1464 E:1467 ||| VBZ
expression  ||| S:1467 E:1478 ||| JJ
vectors  ||| S:1478 E:1486 ||| NN
and  ||| S:1486 E:1490 ||| CC
host  ||| S:1490 E:1495 ||| NN
cells  ||| S:1495 E:1501 ||| NNS
transformed  ||| S:1501 E:1513 ||| VBN
with  ||| S:1513 E:1518 ||| IN
such  ||| S:1518 E:1523 ||| JJ
vectors  ||| S:1523 E:1531 ||| NN
which  ||| S:1531 E:1537 ||| WDT
express  ||| S:1537 E:1545 ||| VBP
the  ||| S:1545 E:1549 ||| DT
humanized  ||| S:1549 E:1559 ||| JJ
monoclonal  ||| S:1559 E:1570 ||| JJ
antibodies  ||| S:1570 E:1581 ||| NNS
of  ||| S:1581 E:1584 ||| IN
the  ||| S:1584 E:1588 ||| DT
present  ||| S:1588 E:1596 ||| JJ
invention ||| S:1596 E:1605 ||| NN
.  ||| S:1605 E:1661 ||| .
The  ||| S:1979 E:1983 ||| DT
invention  ||| S:1983 E:1993 ||| NN
relates  ||| S:1993 E:2001 ||| VBZ
to  ||| S:2001 E:2004 ||| TO
a  ||| S:2004 E:2006 ||| DT
family  ||| S:2006 E:2013 ||| NN
of  ||| S:2013 E:2016 ||| IN
multi-unit  ||| S:2016 E:2027 ||| JJ
bacterial  ||| S:2027 E:2037 ||| JJ
proteins  ||| S:2037 E:2046 ||| NNS
that  ||| S:2046 E:2051 ||| WDT
are  ||| S:2051 E:2055 ||| VBP
associated  ||| S:2055 E:2066 ||| VBN
with  ||| S:2066 E:2071 ||| IN
hemorrhagic  ||| S:2071 E:2083 ||| JJ
colitis  ||| S:2083 E:2091 ||| NN
and  ||| S:2091 E:2095 ||| CC
the  ||| S:2095 E:2099 ||| DT
life-threatening  ||| S:2099 E:2116 ||| JJ
sequela ||| S:2116 E:2123 ||| NN
,  ||| S:2123 E:2125 ||| ,
hemolytic  ||| S:2125 E:2135 ||| JJ
uremic  ||| S:2135 E:2142 ||| JJ
syndrome ||| S:2142 E:2150 ||| NN
.  ||| S:2150 E:2152 ||| .
These  ||| S:2152 E:2158 ||| DT
proteins ||| S:2158 E:2166 ||| NNS
,  ||| S:2166 E:2168 ||| ,
defined  ||| S:2168 E:2176 ||| VBN
as  ||| S:2176 E:2179 ||| IN
members  ||| S:2179 E:2187 ||| NNS
of  ||| S:2187 E:2190 ||| IN
the  ||| S:2190 E:2202 ||| DT
Shiga  ||| S:2202 E:2208 ||| JJ
toxin  ||| S:2208 E:2214 ||| NN
family  ||| S:2214 E:2228 ||| NN
,  ||| S:2228 E:2230 ||| ,
have  ||| S:2230 E:2235 ||| VBP
been  ||| S:2235 E:2240 ||| VBN
utilized  ||| S:2240 E:2249 ||| VBN
in  ||| S:2249 E:2252 ||| IN
the  ||| S:2252 E:2256 ||| DT
isolation  ||| S:2256 E:2266 ||| NN
and  ||| S:2266 E:2270 ||| CC
identification  ||| S:2270 E:2285 ||| NN
of  ||| S:2285 E:2288 ||| IN
murine  ||| S:2288 E:2295 ||| JJ
monoclonal  ||| S:2295 E:2306 ||| JJ
antibodies ||| S:2306 E:2316 ||| NNS
.  ||| S:2316 E:2318 ||| .
The  ||| S:2318 E:2322 ||| DT
invention  ||| S:2322 E:2332 ||| NN
further  ||| S:2332 E:2340 ||| RBR
relates  ||| S:2340 E:2348 ||| JJ
to  ||| S:2348 E:2351 ||| TO
the  ||| S:2351 E:2355 ||| DT
construction  ||| S:2355 E:2368 ||| NN
of  ||| S:2368 E:2371 ||| IN
humanized  ||| S:2371 E:2381 ||| JJ
monoclonal  ||| S:2381 E:2392 ||| JJ
antibodies  ||| S:2392 E:2403 ||| NNS
which  ||| S:2403 E:2409 ||| WDT
incorporate  ||| S:2409 E:2421 ||| VBZ
the  ||| S:2421 E:2425 ||| DT
mouse  ||| S:2425 E:2431 ||| NN
variable  ||| S:2431 E:2440 ||| NN
regions ||| S:2440 E:2447 ||| NNS
.  ||| S:2447 E:2449 ||| .
It  ||| S:2449 E:2452 ||| PRP
also  ||| S:2452 E:2457 ||| RB
relates  ||| S:2457 E:2465 ||| VBZ
to  ||| S:2465 E:2468 ||| TO
antibodies  ||| S:2468 E:2479 ||| VB
to  ||| S:2479 E:2482 ||| TO
Shiga  ||| S:2482 E:2488 ||| NNP
toxins  ||| S:2488 E:2495 ||| NN
or  ||| S:2495 E:2498 ||| CC
toxoids ||| S:2498 E:2505 ||| NN
,  ||| S:2505 E:2507 ||| ,
both  ||| S:2507 E:2512 ||| DT
monoclonal  ||| S:2512 E:2523 ||| NN
and  ||| S:2523 E:2527 ||| CC
polyclonal ||| S:2527 E:2537 ||| NN
,  ||| S:2537 E:2539 ||| ,
and  ||| S:2539 E:2543 ||| CC
their  ||| S:2543 E:2549 ||| PRP$
use  ||| S:2549 E:2553 ||| NN
in  ||| S:2553 E:2556 ||| IN
treating ||| S:2556 E:2564 ||| VBG
,  ||| S:2564 E:2566 ||| ,
diagnosing ||| S:2566 E:2576 ||| VBG
,  ||| S:2576 E:2578 ||| ,
and  ||| S:2578 E:2582 ||| CC
preventing  ||| S:2582 E:2593 ||| VBG
of  ||| S:2593 E:2596 ||| IN
disease  ||| S:2596 E:2604 ||| NN
and  ||| S:2604 E:2608 ||| CC
infections  ||| S:2608 E:2619 ||| NNS
caused  ||| S:2619 E:2626 ||| VBN
by  ||| S:2626 E:2629 ||| IN
pathogenic  ||| S:2629 E:2640 ||| JJ
E.  ||| S:2640 E:2643 ||| NNP
coli ||| S:2643 E:2647 ||| NNS
.  ||| S:2647 E:2649 ||| .
Finally ||| S:2649 E:2656 ||| RB
,  ||| S:2656 E:2658 ||| ,
the  ||| S:2658 E:2662 ||| DT
invention  ||| S:2662 E:2672 ||| NN
relates  ||| S:2672 E:2680 ||| VBZ
to  ||| S:2680 E:2683 ||| TO
preparing  ||| S:2683 E:2693 ||| VBG
the  ||| S:2693 E:2697 ||| DT
humanized  ||| S:2697 E:2707 ||| JJ
monoclonal  ||| S:2707 E:2718 ||| JJ
antibodies  ||| S:2718 E:2729 ||| NNS
to  ||| S:2729 E:2732 ||| TO
proteins  ||| S:2732 E:2741 ||| NNS
of  ||| S:2741 E:2744 ||| IN
the  ||| S:2744 E:2748 ||| DT
Shiga  ||| S:2748 E:2754 ||| JJ
toxin  ||| S:2754 E:2760 ||| NN
family ||| S:2760 E:2766 ||| NN
.  ||| S:2766 E:2769 ||| .
For  ||| S:5438 E:5442 ||| IN
the  ||| S:5442 E:5446 ||| DT
purposes  ||| S:5446 E:5455 ||| NNS
of  ||| S:5455 E:5458 ||| IN
this  ||| S:5458 E:5463 ||| DT
application  ||| S:5463 E:5475 ||| NN
the  ||| S:5475 E:5479 ||| DT
term  ||| S:5479 E:5492 ||| NN
Shiga  ||| S:5492 E:5498 ||| FW
toxin  ||| S:5498 E:5512 ||| FW
encompasses  ||| S:5512 E:5524 ||| FW
Shiga  ||| S:5524 E:5530 ||| FW
toxin  ||| S:5530 E:5536 ||| NN
and  ||| S:5536 E:5540 ||| CC
any  ||| S:5540 E:5544 ||| DT
other  ||| S:5544 E:5550 ||| JJ
toxins  ||| S:5550 E:5557 ||| NN
in  ||| S:5557 E:5560 ||| IN
the  ||| S:5560 E:5564 ||| DT
Stx1  ||| S:5564 E:5569 ||| NNP
or  ||| S:5569 E:5572 ||| CC
Stx2  ||| S:5572 E:5577 ||| CD
group  ||| S:5577 E:5583 ||| NN
or  ||| S:5583 E:5586 ||| CC
their  ||| S:5586 E:5592 ||| PRP$
variants ||| S:5592 E:5600 ||| NN
.  ||| S:5600 E:5602 ||| .
The  ||| S:5602 E:5606 ||| DT
abbreviation  ||| S:5606 E:5627 ||| JJ
Stx  ||| S:5627 E:5639 ||| NNP
will  ||| S:5639 E:5644 ||| MD
refer  ||| S:5644 E:5650 ||| VB
to  ||| S:5650 E:5653 ||| TO
the  ||| S:5653 E:5657 ||| DT
toxin  ||| S:5657 E:5663 ||| NN
protein  ||| S:5663 E:5671 ||| NN
itself ||| S:5671 E:5677 ||| PRP
.  ||| S:5677 E:5681 ||| .
Despite  ||| S:5681 E:5689 ||| IN
this  ||| S:5689 E:5694 ||| DT
knowledge  ||| S:5694 E:5704 ||| NN
about  ||| S:5704 E:5710 ||| IN
the  ||| S:5710 E:5714 ||| DT
results  ||| S:5714 E:5722 ||| NNS
of  ||| S:5722 E:5725 ||| IN
exposure  ||| S:5725 E:5734 ||| NN
to  ||| S:5734 E:5737 ||| TO
these  ||| S:5737 E:5743 ||| DT
toxins ||| S:5743 E:5749 ||| NN
,  ||| S:5749 E:5751 ||| ,
currently  ||| S:5751 E:5761 ||| RB
there  ||| S:5761 E:5767 ||| EX
is  ||| S:5767 E:5770 ||| VBZ
no  ||| S:5770 E:5773 ||| DT
known  ||| S:5773 E:5779 ||| JJ
cure  ||| S:5779 E:5784 ||| NN
or  ||| S:5784 E:5787 ||| CC
vaccine  ||| S:5787 E:5795 ||| NN
for  ||| S:5795 E:5799 ||| IN
HC  ||| S:5799 E:5802 ||| NNP
or  ||| S:5802 E:5805 ||| CC
HUS ||| S:5805 E:5808 ||| NNP
.  ||| S:5808 E:5810 ||| .
Antibiotics  ||| S:5810 E:5822 ||| NNP
may  ||| S:5822 E:5826 ||| MD
even  ||| S:5826 E:5831 ||| RB
make  ||| S:5831 E:5836 ||| VB
the  ||| S:5836 E:5840 ||| DT
severe  ||| S:5840 E:5847 ||| JJ
complications  ||| S:5847 E:5861 ||| NNS
worse  ||| S:5861 E:5867 ||| JJR
by  ||| S:5867 E:5870 ||| IN
increasing  ||| S:5870 E:5881 ||| VBG
toxin  ||| S:5881 E:5887 ||| NN
release  ||| S:5887 E:5895 ||| NN
from  ||| S:5895 E:5900 ||| IN
bacteria ||| S:5900 E:5908 ||| NNS
.  ||| S:5908 E:5910 ||| .
Thus ||| S:5910 E:5914 ||| RB
,  ||| S:5914 E:5916 ||| ,
there  ||| S:5916 E:5922 ||| EX
is  ||| S:5922 E:5925 ||| VBZ
a  ||| S:5925 E:5927 ||| DT
need  ||| S:5927 E:5932 ||| NN
for  ||| S:5932 E:5936 ||| IN
a  ||| S:5936 E:5938 ||| DT
compound  ||| S:5938 E:5947 ||| NN
to  ||| S:5947 E:5950 ||| TO
prevent  ||| S:5950 E:5958 ||| VB
or  ||| S:5958 E:5961 ||| CC
to  ||| S:5961 E:5964 ||| TO
treat  ||| S:5964 E:5970 ||| VB
the  ||| S:5970 E:5974 ||| DT
complications  ||| S:5974 E:5988 ||| NNS
of  ||| S:5988 E:5991 ||| IN
EHEC  ||| S:5991 E:5996 ||| NNP
produced  ||| S:5996 E:6005 ||| VBD
by  ||| S:6005 E:6008 ||| IN
Shiga  ||| S:6008 E:6014 ||| NNP
toxin ||| S:6014 E:6019 ||| NN
.  ||| S:6019 E:6021 ||| .
Such  ||| S:6021 E:6026 ||| PDT
a  ||| S:6026 E:6028 ||| DT
compound  ||| S:6028 E:6037 ||| NN
could  ||| S:6037 E:6043 ||| MD
be  ||| S:6043 E:6046 ||| VB
used  ||| S:6046 E:6051 ||| VBN
to  ||| S:6051 E:6054 ||| TO
treat  ||| S:6054 E:6060 ||| VB
infected  ||| S:6060 E:6069 ||| JJ
patients  ||| S:6069 E:6078 ||| NNS
and  ||| S:6078 E:6082 ||| CC
decrease  ||| S:6082 E:6091 ||| VB
the  ||| S:6091 E:6095 ||| DT
systemic  ||| S:6095 E:6104 ||| JJ
effects  ||| S:6104 E:6112 ||| NNS
of  ||| S:6112 E:6115 ||| IN
toxin  ||| S:6115 E:6121 ||| NN
on  ||| S:6121 E:6124 ||| IN
the  ||| S:6124 E:6128 ||| DT
CNS ||| S:6128 E:6131 ||| NNP
,  ||| S:6131 E:6133 ||| ,
blood  ||| S:6133 E:6139 ||| NN
and  ||| S:6139 E:6143 ||| CC
kidneys ||| S:6143 E:6150 ||| NN
.  ||| S:6150 E:6152 ||| .
In  ||| S:6152 E:6155 ||| IN
addition ||| S:6155 E:6163 ||| NN
,  ||| S:6163 E:6165 ||| ,
if  ||| S:6165 E:6168 ||| IN
the  ||| S:6168 E:6172 ||| DT
toxin  ||| S:6172 E:6178 ||| NN
could  ||| S:6178 E:6184 ||| MD
be  ||| S:6184 E:6187 ||| VB
neutralized ||| S:6187 E:6198 ||| NNS
,  ||| S:6198 E:6200 ||| ,
antibiotics  ||| S:6200 E:6212 ||| NNS
could  ||| S:6212 E:6218 ||| MD
be  ||| S:6218 E:6221 ||| VB
safely  ||| S:6221 E:6228 ||| RB
given  ||| S:6228 E:6234 ||| VBN
to  ||| S:6234 E:6237 ||| TO
kill  ||| S:6237 E:6242 ||| VB
the  ||| S:6242 E:6246 ||| DT
bacteria  ||| S:6246 E:6255 ||| NNS
in  ||| S:6255 E:6258 ||| IN
the  ||| S:6258 E:6262 ||| DT
GI  ||| S:6262 E:6265 ||| NNP
tract ||| S:6265 E:6270 ||| NN
.  ||| S:6270 E:6272 ||| .
Such  ||| S:6272 E:6277 ||| PDT
a  ||| S:6277 E:6279 ||| DT
compound  ||| S:6279 E:6288 ||| NN
could  ||| S:6288 E:6294 ||| MD
also  ||| S:6294 E:6299 ||| RB
be  ||| S:6299 E:6302 ||| VB
used  ||| S:6302 E:6307 ||| VBN
to  ||| S:6307 E:6310 ||| TO
prevent  ||| S:6310 E:6318 ||| VB
infectious  ||| S:6318 E:6329 ||| JJ
complications ||| S:6329 E:6342 ||| NNS
,  ||| S:6342 E:6344 ||| ,
by  ||| S:6344 E:6347 ||| IN
treating  ||| S:6347 E:6356 ||| VBG
exposed  ||| S:6356 E:6364 ||| VBN
or  ||| S:6364 E:6367 ||| CC
high  ||| S:6367 E:6372 ||| JJ
risk  ||| S:6372 E:6377 ||| NN
individuals  ||| S:6377 E:6389 ||| NNS
before  ||| S:6389 E:6396 ||| IN
they  ||| S:6396 E:6401 ||| PRP
acquire  ||| S:6401 E:6409 ||| VB
EHEC  ||| S:6409 E:6414 ||| JJ
infection ||| S:6414 E:6423 ||| NN
.  ||| S:6423 E:6425 ||| .
Such  ||| S:6425 E:6430 ||| JJ
individuals  ||| S:6430 E:6442 ||| NNS
would  ||| S:6442 E:6448 ||| MD
include  ||| S:6448 E:6456 ||| VB
children  ||| S:6456 E:6465 ||| NNS
in  ||| S:6465 E:6468 ||| IN
day  ||| S:6468 E:6472 ||| NN
care  ||| S:6472 E:6477 ||| NN
or  ||| S:6477 E:6480 ||| CC
the  ||| S:6480 E:6484 ||| DT
elderly  ||| S:6484 E:6492 ||| JJ
in  ||| S:6492 E:6495 ||| IN
nursing  ||| S:6495 E:6503 ||| NN
homes ||| S:6503 E:6508 ||| NNS
,  ||| S:6508 E:6510 ||| ,
where  ||| S:6510 E:6516 ||| WRB
a  ||| S:6516 E:6518 ||| DT
case  ||| S:6518 E:6523 ||| NN
of  ||| S:6523 E:6526 ||| IN
EHEC  ||| S:6526 E:6531 ||| NNP
diarrhea  ||| S:6531 E:6540 ||| NN
has  ||| S:6540 E:6544 ||| VBZ
been  ||| S:6544 E:6549 ||| VBN
detected ||| S:6549 E:6557 ||| VBN
.  ||| S:6557 E:6559 ||| .
These  ||| S:6559 E:6565 ||| DT
individuals  ||| S:6565 E:6577 ||| NNS
are  ||| S:6577 E:6581 ||| VBP
at  ||| S:6581 E:6584 ||| IN
increased  ||| S:6584 E:6594 ||| JJ
risk  ||| S:6594 E:6599 ||| NN
to  ||| S:6599 E:6602 ||| TO
develop  ||| S:6602 E:6610 ||| VB
severe  ||| S:6610 E:6617 ||| JJ
complications  ||| S:6617 E:6631 ||| NNS
and  ||| S:6631 E:6635 ||| CC
spread  ||| S:6635 E:6642 ||| NN
of  ||| S:6642 E:6645 ||| IN
EHEC  ||| S:6645 E:6650 ||| NNP
in  ||| S:6650 E:6653 ||| IN
these  ||| S:6653 E:6659 ||| DT
environments  ||| S:6659 E:6672 ||| NN
is  ||| S:6672 E:6675 ||| VBZ
not  ||| S:6675 E:6679 ||| RB
unusual ||| S:6679 E:6686 ||| JJ
.  ||| S:6686 E:6690 ||| .
The  ||| S:6690 E:6694 ||| DT
knowledge  ||| S:6694 E:6704 ||| NN
of  ||| S:6704 E:6707 ||| IN
the  ||| S:6707 E:6711 ||| DT
immunological  ||| S:6711 E:6725 ||| NNS
cross  ||| S:6725 E:6731 ||| VBP
reactivity  ||| S:6731 E:6742 ||| VBN
of  ||| S:6742 E:6745 ||| IN
the  ||| S:6745 E:6749 ||| DT
Shiga  ||| S:6749 E:6755 ||| JJ
toxins  ||| S:6755 E:6762 ||| NN
offers  ||| S:6762 E:6769 ||| VBZ
a  ||| S:6769 E:6771 ||| DT
tantalizing  ||| S:6771 E:6783 ||| JJ
prospect  ||| S:6783 E:6792 ||| NN
for  ||| S:6792 E:6796 ||| IN
pharmacological  ||| S:6796 E:6812 ||| JJ
approaches  ||| S:6812 E:6823 ||| NNS
to  ||| S:6823 E:6826 ||| TO
EHEC  ||| S:6826 E:6831 ||| NNP
treatment ||| S:6831 E:6840 ||| NN
.  ||| S:6840 E:6842 ||| .
Currently ||| S:6842 E:6851 ||| RB
,  ||| S:6851 E:6853 ||| ,
there  ||| S:6853 E:6859 ||| EX
are  ||| S:6859 E:6863 ||| VBP
no  ||| S:6863 E:6866 ||| RB
known  ||| S:6866 E:6872 ||| VBN
prophylactic  ||| S:6872 E:6885 ||| NNS
or  ||| S:6885 E:6888 ||| CC
therapeutic  ||| S:6888 E:6900 ||| JJ
agents  ||| S:6900 E:6907 ||| NNS
available  ||| S:6907 E:6917 ||| JJ
for  ||| S:6917 E:6921 ||| IN
this  ||| S:6921 E:6926 ||| DT
disease ||| S:6926 E:6933 ||| NN
.  ||| S:6933 E:6935 ||| .
Accordingly ||| S:6935 E:6946 ||| RB
,  ||| S:6946 E:6948 ||| ,
there  ||| S:6948 E:6954 ||| EX
is  ||| S:6954 E:6957 ||| VBZ
a  ||| S:6957 E:6959 ||| DT
need  ||| S:6959 E:6964 ||| NN
in  ||| S:6964 E:6967 ||| IN
the  ||| S:6967 E:6971 ||| DT
art  ||| S:6971 E:6975 ||| NN
to  ||| S:6975 E:6978 ||| TO
provide  ||| S:6978 E:6986 ||| VB
monoclonal  ||| S:6986 E:6997 ||| JJ
antibodies  ||| S:6997 E:7008 ||| NNS
that  ||| S:7008 E:7013 ||| WDT
can  ||| S:7013 E:7017 ||| MD
bind  ||| S:7017 E:7022 ||| VB
to  ||| S:7022 E:7025 ||| TO
Shiga  ||| S:7025 E:7031 ||| NNP
toxins  ||| S:7031 E:7038 ||| NN
which  ||| S:7038 E:7044 ||| WDT
could  ||| S:7044 E:7050 ||| MD
prevent  ||| S:7050 E:7058 ||| VB
or  ||| S:7058 E:7061 ||| CC
lessen  ||| S:7061 E:7068 ||| VB
the  ||| S:7068 E:7072 ||| DT
devastating  ||| S:7072 E:7084 ||| JJ
effects  ||| S:7084 E:7092 ||| NNS
of  ||| S:7092 E:7095 ||| IN
these  ||| S:7095 E:7101 ||| DT
toxins ||| S:7101 E:7107 ||| NN
.  ||| S:7107 E:7109 ||| .
There  ||| S:7109 E:7115 ||| EX
is  ||| S:7115 E:7118 ||| VBZ
also  ||| S:7118 E:7123 ||| RB
a  ||| S:7123 E:7125 ||| DT
need  ||| S:7125 E:7130 ||| NN
in  ||| S:7130 E:7133 ||| IN
the  ||| S:7133 E:7137 ||| DT
art  ||| S:7137 E:7141 ||| NN
for  ||| S:7141 E:7145 ||| IN
data  ||| S:7145 E:7150 ||| NNS
concerning  ||| S:7150 E:7161 ||| VBG
the  ||| S:7161 E:7165 ||| DT
binding  ||| S:7165 E:7173 ||| JJ
site  ||| S:7173 E:7178 ||| NN
of  ||| S:7178 E:7181 ||| IN
such  ||| S:7181 E:7186 ||| JJ
antibodies  ||| S:7186 E:7197 ||| NNS
so  ||| S:7197 E:7200 ||| RB
that  ||| S:7200 E:7205 ||| IN
other  ||| S:7205 E:7211 ||| JJ
antibodies  ||| S:7211 E:7222 ||| NNS
with  ||| S:7222 E:7227 ||| IN
similar  ||| S:7227 E:7235 ||| JJ
abilities  ||| S:7235 E:7245 ||| NNS
can  ||| S:7245 E:7249 ||| MD
be  ||| S:7249 E:7252 ||| VB
identified  ||| S:7252 E:7263 ||| VBN
and  ||| S:7263 E:7267 ||| CC
isolated ||| S:7267 E:7275 ||| VBN
.  ||| S:7275 E:7279 ||| .
There  ||| S:7279 E:7285 ||| EX
is  ||| S:7285 E:7288 ||| VBZ
a  ||| S:7288 E:7290 ||| DT
related  ||| S:7290 E:7298 ||| JJ
need  ||| S:7298 E:7303 ||| NN
in  ||| S:7303 E:7306 ||| IN
the  ||| S:7306 E:7310 ||| DT
art  ||| S:7310 E:7314 ||| NN
for  ||| S:7314 E:7318 ||| IN
humanized  ||| S:7318 E:7328 ||| NN
or  ||| S:7328 E:7331 ||| CC
other  ||| S:7331 E:7337 ||| JJ
chimeric  ||| S:7337 E:7346 ||| FW
human ||| S:7346 E:7351 ||| FW
/ ||| S:7351 E:7352 ||| FW
mouse  ||| S:7352 E:7358 ||| FW
monoclonal  ||| S:7358 E:7369 ||| FW
antibodies ||| S:7369 E:7379 ||| FW
.  ||| S:7379 E:7381 ||| .
In  ||| S:7381 E:7384 ||| IN
well  ||| S:7384 E:7389 ||| RB
publicized  ||| S:7389 E:7400 ||| VBN
studies ||| S:7400 E:7407 ||| NNS
,  ||| S:7407 E:7409 ||| ,
patients  ||| S:7409 E:7418 ||| FW
administered  ||| S:7418 E:7431 ||| FW
murine  ||| S:7431 E:7438 ||| FW
anti-TNF  ||| S:7438 E:7447 ||| FW
( ||| S:7447 E:7448 ||| -LRB-
tumor  ||| S:7448 E:7454 ||| NN
necrosis  ||| S:7454 E:7463 ||| NN
factor ||| S:7463 E:7469 ||| NN
)  ||| S:7469 E:7471 ||| -RRB-
monoclonal  ||| S:7471 E:7482 ||| JJ
antibodies  ||| S:7482 E:7493 ||| NNS
developed  ||| S:7493 E:7503 ||| VBD
anti-murine  ||| S:7503 E:7515 ||| JJ
antibody  ||| S:7515 E:7524 ||| NN
responses  ||| S:7524 E:7534 ||| NNS
to  ||| S:7534 E:7537 ||| TO
the  ||| S:7537 E:7541 ||| DT
administered  ||| S:7541 E:7554 ||| JJ
antibody ||| S:7554 E:7562 ||| NN
.  ||| S:7562 E:7564 ||| .
( ||| S:7564 E:7565 ||| -LRB-
See ||| S:7565 E:7568 ||| VB
,  ||| S:7568 E:7570 ||| ,
e.g. ||| S:7570 E:7574 ||| NNP
,  ||| S:7574 E:7576 ||| ,
Exley  ||| S:7576 E:7582 ||| NNP
A.  ||| S:7582 E:7585 ||| NNP
R. ||| S:7585 E:7587 ||| NNP
,  ||| S:7587 E:7589 ||| ,
et  ||| S:7589 E:7592 ||| FW
al. ||| S:7592 E:7595 ||| FW
,  ||| S:7595 E:7597 ||| ,
Lancet  ||| S:7597 E:7604 ||| NNP
335 ||| S:7604 E:7607 ||| CD
: ||| S:7607 E:7608 ||| :
1275-1277  ||| S:7608 E:7618 ||| CD
( ||| S:7618 E:7619 ||| -LRB-
1990 ||| S:7619 E:7623 ||| CD
) ||| S:7623 E:7624 ||| -RRB-
) ||| S:7624 E:7625 ||| -RRB-
.  ||| S:7625 E:7627 ||| .
This  ||| S:7627 E:7632 ||| DT
type  ||| S:7632 E:7637 ||| NN
of  ||| S:7637 E:7640 ||| IN
immune  ||| S:7640 E:7647 ||| JJ
response  ||| S:7647 E:7656 ||| NN
to  ||| S:7656 E:7659 ||| TO
the  ||| S:7659 E:7663 ||| DT
treatment  ||| S:7663 E:7673 ||| NN
regimen ||| S:7673 E:7680 ||| NN
,  ||| S:7680 E:7682 ||| ,
commonly  ||| S:7682 E:7691 ||| RB
referred  ||| S:7691 E:7700 ||| VBN
to  ||| S:7700 E:7703 ||| TO
as  ||| S:7703 E:7706 ||| IN
the  ||| S:7706 E:7710 ||| DT
HAMA  ||| S:7710 E:7715 ||| NNP
response  ||| S:7715 E:7724 ||| NN
( ||| S:7724 E:7725 ||| -LRB-
for  ||| S:7725 E:7729 ||| IN
human  ||| S:7729 E:7735 ||| JJ
anti-mouse  ||| S:7735 E:7746 ||| JJ
antibodies ||| S:7746 E:7756 ||| NNS
) ||| S:7756 E:7757 ||| -RRB-
,  ||| S:7757 E:7759 ||| ,
decreases  ||| S:7759 E:7769 ||| VBZ
the  ||| S:7769 E:7773 ||| DT
effectiveness  ||| S:7773 E:7787 ||| NN
of  ||| S:7787 E:7790 ||| IN
the  ||| S:7790 E:7794 ||| DT
treatment  ||| S:7794 E:7804 ||| NN
and  ||| S:7804 E:7808 ||| CC
may  ||| S:7808 E:7812 ||| MD
even  ||| S:7812 E:7817 ||| RB
render  ||| S:7817 E:7824 ||| VB
the  ||| S:7824 E:7828 ||| DT
treatment  ||| S:7828 E:7838 ||| NN
completely  ||| S:7838 E:7849 ||| RB
ineffective ||| S:7849 E:7860 ||| JJ
.  ||| S:7860 E:7862 ||| .
Humanized  ||| S:7862 E:7872 ||| NNP
or  ||| S:7872 E:7875 ||| CC
chimeric  ||| S:7875 E:7884 ||| JJ
human ||| S:7884 E:7889 ||| JJ
/ ||| S:7889 E:7890 ||| CD
mouse  ||| S:7890 E:7896 ||| NN
monoclonal  ||| S:7896 E:7907 ||| NN
antibodies  ||| S:7907 E:7918 ||| NNS
have  ||| S:7918 E:7923 ||| VBP
been  ||| S:7923 E:7928 ||| VBN
shown  ||| S:7928 E:7934 ||| VBN
to  ||| S:7934 E:7937 ||| TO
significantly  ||| S:7937 E:7951 ||| RB
decrease  ||| S:7951 E:7960 ||| VB
the  ||| S:7960 E:7964 ||| DT
HAMA  ||| S:7964 E:7969 ||| NNP
response  ||| S:7969 E:7978 ||| NN
and  ||| S:7978 E:7982 ||| CC
to  ||| S:7982 E:7985 ||| TO
increase  ||| S:7985 E:7994 ||| VB
the  ||| S:7994 E:7998 ||| DT
therapeutic  ||| S:7998 E:8010 ||| JJ
effectiveness ||| S:8010 E:8023 ||| NN
.  ||| S:8023 E:8025 ||| .
( ||| S:8025 E:8026 ||| -LRB-
LoBuglio  ||| S:8026 E:8035 ||| FW
et  ||| S:8035 E:8038 ||| FW
al. ||| S:8038 E:8041 ||| FW
,  ||| S:8041 E:8043 ||| ,
P.N.A.S.  ||| S:8043 E:8052 ||| CD
86 ||| S:8052 E:8054 ||| CD
: ||| S:8054 E:8055 ||| :
4220-4224  ||| S:8055 E:8065 ||| CD
( ||| S:8065 E:8066 ||| -LRB-
June  ||| S:8066 E:8071 ||| NNP
1989 ||| S:8071 E:8075 ||| CD
) ||| S:8075 E:8076 ||| -RRB-
) ||| S:8076 E:8077 ||| -RRB-
.  ||| S:8077 E:8080 ||| .
To  ||| S:8107 E:8110 ||| TO
satisfy  ||| S:8110 E:8118 ||| VB
these  ||| S:8118 E:8124 ||| DT
needs  ||| S:8124 E:8130 ||| NNS
in  ||| S:8130 E:8133 ||| IN
the  ||| S:8133 E:8137 ||| DT
art ||| S:8137 E:8140 ||| NN
,  ||| S:8140 E:8142 ||| ,
applicants  ||| S:8142 E:8153 ||| NNS
provide  ||| S:8153 E:8161 ||| VBP
humanized  ||| S:8161 E:8171 ||| JJ
mouse  ||| S:8171 E:8177 ||| NN
monoclonal  ||| S:8177 E:8188 ||| NN
antibodies  ||| S:8188 E:8199 ||| NNS
to  ||| S:8199 E:8202 ||| TO
Shiga  ||| S:8202 E:8208 ||| NNP
toxin  ||| S:8208 E:8214 ||| NN
1  ||| S:8214 E:8216 ||| CD
and  ||| S:8216 E:8220 ||| CC
Shiga  ||| S:8220 E:8226 ||| NNP
toxin  ||| S:8226 E:8232 ||| NN
2 ||| S:8232 E:8233 ||| CD
.  ||| S:8233 E:8235 ||| .
In  ||| S:8235 E:8238 ||| IN
addition ||| S:8238 E:8246 ||| NN
,  ||| S:8246 E:8248 ||| ,
this  ||| S:8248 E:8253 ||| DT
invention  ||| S:8253 E:8263 ||| NN
sets  ||| S:8263 E:8268 ||| VBZ
forth  ||| S:8268 E:8274 ||| RB
the  ||| S:8274 E:8278 ||| DT
variable  ||| S:8278 E:8287 ||| JJ
region  ||| S:8287 E:8294 ||| NN
associated  ||| S:8294 E:8305 ||| VBN
with  ||| S:8305 E:8310 ||| IN
Shiga  ||| S:8310 E:8316 ||| NNP
toxin  ||| S:8316 E:8322 ||| NN
neutralization  ||| S:8322 E:8337 ||| NN
as  ||| S:8337 E:8340 ||| IN
well  ||| S:8340 E:8345 ||| RB
as  ||| S:8345 E:8348 ||| IN
the  ||| S:8348 E:8352 ||| DT
specific  ||| S:8352 E:8361 ||| JJ
complementarity  ||| S:8361 E:8377 ||| NNS
determining  ||| S:8377 E:8389 ||| VBG
regions  ||| S:8389 E:8397 ||| NNS
( ||| S:8397 E:8398 ||| -LRB-
CDRs ||| S:8398 E:8402 ||| NNP
)  ||| S:8402 E:8404 ||| -RRB-
of  ||| S:8404 E:8407 ||| IN
the  ||| S:8407 E:8411 ||| DT
variable  ||| S:8411 E:8420 ||| JJ
region ||| S:8420 E:8426 ||| NN
.  ||| S:8426 E:8428 ||| .
The  ||| S:8428 E:8432 ||| DT
present  ||| S:8432 E:8440 ||| JJ
invention  ||| S:8440 E:8450 ||| NN
particularly  ||| S:8450 E:8463 ||| RB
provides  ||| S:8463 E:8472 ||| VBZ
human  ||| S:8472 E:8478 ||| JJ
monoclonal  ||| S:8478 E:8489 ||| JJ
antibodies ||| S:8489 E:8499 ||| NNS
,  ||| S:8499 E:8501 ||| ,
derived  ||| S:8501 E:8509 ||| VBN
from  ||| S:8509 E:8514 ||| IN
the  ||| S:8514 E:8518 ||| DT
mouse  ||| S:8518 E:8524 ||| FW
monoclonal  ||| S:8524 E:8535 ||| FW
antibodies  ||| S:8535 E:8546 ||| FW
13C4  ||| S:8546 E:8551 ||| FW
and  ||| S:8551 E:8555 ||| CC
11E10 ||| S:8555 E:8560 ||| NNP
,  ||| S:8560 E:8562 ||| ,
which  ||| S:8562 E:8568 ||| WDT
are  ||| S:8568 E:8572 ||| VBP
specifically  ||| S:8572 E:8585 ||| RB
reactive  ||| S:8585 E:8594 ||| VBN
with  ||| S:8594 E:8599 ||| IN
Stx1  ||| S:8599 E:8604 ||| NNP
and  ||| S:8604 E:8608 ||| CC
Stx2 ||| S:8608 E:8612 ||| NNP
,  ||| S:8612 E:8614 ||| ,
respectively ||| S:8614 E:8626 ||| RB
.  ||| S:8626 E:8630 ||| .
In  ||| S:8630 E:8633 ||| IN
another  ||| S:8633 E:8641 ||| DT
aspect ||| S:8641 E:8647 ||| NN
,  ||| S:8647 E:8649 ||| ,
the  ||| S:8649 E:8653 ||| DT
invention  ||| S:8653 E:8663 ||| NN
includes  ||| S:8663 E:8672 ||| VBZ
a  ||| S:8672 E:8674 ||| DT
pharmaceutical  ||| S:8674 E:8689 ||| JJ
composition  ||| S:8689 E:8701 ||| NN
and  ||| S:8701 E:8705 ||| CC
a  ||| S:8705 E:8707 ||| DT
method  ||| S:8707 E:8714 ||| NN
of  ||| S:8714 E:8717 ||| IN
treatment  ||| S:8717 E:8727 ||| NN
with  ||| S:8727 E:8732 ||| IN
such  ||| S:8732 E:8737 ||| JJ
composition  ||| S:8737 E:8749 ||| NN
which  ||| S:8749 E:8755 ||| WDT
will  ||| S:8755 E:8760 ||| MD
prevent  ||| S:8760 E:8768 ||| VB
or  ||| S:8768 E:8771 ||| CC
treat  ||| S:8771 E:8777 ||| VB
Shiga  ||| S:8777 E:8783 ||| JJ
toxin  ||| S:8783 E:8789 ||| NN
induced  ||| S:8789 E:8797 ||| NN
disease ||| S:8797 E:8804 ||| NN
.  ||| S:8804 E:8808 ||| .
It  ||| S:8808 E:8811 ||| PRP
is  ||| S:8811 E:8814 ||| VBZ
to  ||| S:8814 E:8817 ||| TO
be  ||| S:8817 E:8820 ||| VB
understood  ||| S:8820 E:8831 ||| VBN
that  ||| S:8831 E:8836 ||| IN
both  ||| S:8836 E:8841 ||| PDT
the  ||| S:8841 E:8845 ||| DT
foregoing  ||| S:8845 E:8855 ||| JJ
general  ||| S:8855 E:8863 ||| JJ
description  ||| S:8863 E:8875 ||| NN
and  ||| S:8875 E:8879 ||| CC
the  ||| S:8879 E:8883 ||| DT
following  ||| S:8883 E:8893 ||| JJ
detailed  ||| S:8893 E:8902 ||| JJ
description  ||| S:8902 E:8914 ||| NNS
are  ||| S:8914 E:8918 ||| VBP
exemplary  ||| S:8918 E:8928 ||| JJ
and  ||| S:8928 E:8932 ||| CC
explanatory  ||| S:8932 E:8944 ||| JJ
and  ||| S:8944 E:8948 ||| CC
are  ||| S:8948 E:8952 ||| VBP
intended  ||| S:8952 E:8961 ||| VBN
to  ||| S:8961 E:8964 ||| TO
provide  ||| S:8964 E:8972 ||| VB
further  ||| S:8972 E:8980 ||| JJ
explanation  ||| S:8980 E:8992 ||| NN
of  ||| S:8992 E:8995 ||| IN
the  ||| S:8995 E:8999 ||| DT
invention  ||| S:8999 E:9009 ||| NN
as  ||| S:9009 E:9012 ||| IN
claimed ||| S:9012 E:9019 ||| VBN
.  ||| S:9019 E:9023 ||| .
The  ||| S:9023 E:9027 ||| DT
accompanying  ||| S:9027 E:9040 ||| JJ
drawings  ||| S:9040 E:9049 ||| NNS
are  ||| S:9049 E:9053 ||| VBP
included  ||| S:9053 E:9062 ||| VBN
to  ||| S:9062 E:9065 ||| TO
provide  ||| S:9065 E:9073 ||| VB
a  ||| S:9073 E:9075 ||| DT
further  ||| S:9075 E:9083 ||| JJ
understanding  ||| S:9083 E:9097 ||| NN
of  ||| S:9097 E:9100 ||| IN
the  ||| S:9100 E:9104 ||| DT
invention  ||| S:9104 E:9114 ||| NN
and  ||| S:9114 E:9118 ||| CC
are  ||| S:9118 E:9122 ||| VBP
incorporated  ||| S:9122 E:9135 ||| VBN
in  ||| S:9135 E:9138 ||| IN
and  ||| S:9138 E:9142 ||| CC
constitute  ||| S:9142 E:9153 ||| VB
a  ||| S:9153 E:9155 ||| DT
part  ||| S:9155 E:9160 ||| NN
of  ||| S:9160 E:9163 ||| IN
this  ||| S:9163 E:9168 ||| DT
specification ||| S:9168 E:9181 ||| NN
.  ||| S:9181 E:9183 ||| .
They  ||| S:9183 E:9188 ||| PRP
illustrate  ||| S:9188 E:9199 ||| VBP
several  ||| S:9199 E:9207 ||| JJ
embodiments  ||| S:9207 E:9219 ||| NN
of  ||| S:9219 E:9222 ||| IN
the  ||| S:9222 E:9226 ||| DT
invention  ||| S:9226 E:9236 ||| NN
and ||| S:9236 E:9239 ||| CC
,  ||| S:9239 E:9241 ||| ,
together  ||| S:9241 E:9250 ||| RB
with  ||| S:9250 E:9255 ||| IN
the  ||| S:9255 E:9259 ||| DT
description ||| S:9259 E:9270 ||| NN
,  ||| S:9270 E:9272 ||| ,
serve  ||| S:9272 E:9278 ||| VBP
to  ||| S:9278 E:9281 ||| TO
explain  ||| S:9281 E:9289 ||| VB
the  ||| S:9289 E:9293 ||| DT
principles  ||| S:9293 E:9304 ||| NNS
of  ||| S:9304 E:9307 ||| IN
the  ||| S:9307 E:9311 ||| DT
invention ||| S:9311 E:9320 ||| NN
.  ||| S:9320 E:9324 ||| .
FIG.  ||| S:9360 E:9365 ||| CD
1  ||| S:9365 E:9367 ||| CD
provides  ||| S:9367 E:9376 ||| VBZ
a  ||| S:9376 E:9378 ||| DT
schematic  ||| S:9378 E:9388 ||| JJ
representation  ||| S:9388 E:9403 ||| NN
of  ||| S:9403 E:9406 ||| IN
the  ||| S:9406 E:9410 ||| DT
general  ||| S:9410 E:9418 ||| JJ
cloning  ||| S:9418 E:9426 ||| JJ
strategy  ||| S:9426 E:9435 ||| NN
used  ||| S:9435 E:9440 ||| VBN
for  ||| S:9440 E:9444 ||| IN
cloning  ||| S:9444 E:9452 ||| VBG
the  ||| S:9452 E:9456 ||| DT
variable  ||| S:9456 E:9465 ||| JJ
region  ||| S:9465 E:9472 ||| NN
gene  ||| S:9472 E:9477 ||| NN
fragments  ||| S:9477 E:9487 ||| NNS
of  ||| S:9487 E:9490 ||| IN
both  ||| S:9490 E:9495 ||| PDT
the  ||| S:9495 E:9499 ||| DT
11E10  ||| S:9499 E:9505 ||| NNP
and  ||| S:9505 E:9509 ||| CC
13C4  ||| S:9509 E:9514 ||| CD
antibodies ||| S:9514 E:9524 ||| NNS
.  ||| S:9524 E:9528 ||| .
FIG.  ||| S:9528 E:9533 ||| CD
2  ||| S:9533 E:9535 ||| CD
lists  ||| S:9535 E:9541 ||| NNS
the  ||| S:9541 E:9545 ||| DT
oligonucleotide  ||| S:9545 E:9561 ||| JJ
sequences  ||| S:9561 E:9571 ||| NNS
used  ||| S:9571 E:9576 ||| VBN
for  ||| S:9576 E:9580 ||| IN
PCR  ||| S:9580 E:9584 ||| NNP
amplification  ||| S:9584 E:9598 ||| NN
of  ||| S:9598 E:9601 ||| IN
the  ||| S:9601 E:9605 ||| DT
variable  ||| S:9605 E:9614 ||| JJ
regions  ||| S:9614 E:9622 ||| NNS
of  ||| S:9622 E:9625 ||| IN
the  ||| S:9625 E:9629 ||| DT
13C4  ||| S:9629 E:9634 ||| JJ
antibody ||| S:9634 E:9642 ||| NN
.  ||| S:9642 E:9646 ||| .
FIG.  ||| S:9646 E:9651 ||| CD
3  ||| S:9651 E:9653 ||| CD
recites  ||| S:9653 E:9661 ||| CD
the  ||| S:9661 E:9665 ||| DT
DNA  ||| S:9665 E:9669 ||| NN
and  ||| S:9669 E:9673 ||| CC
amino  ||| S:9673 E:9679 ||| JJ
acid  ||| S:9679 E:9684 ||| NN
consensus  ||| S:9684 E:9694 ||| NN
sequences  ||| S:9694 E:9704 ||| NN
for  ||| S:9704 E:9708 ||| IN
the  ||| S:9708 E:9712 ||| DT
variable  ||| S:9712 E:9721 ||| JJ
regions  ||| S:9721 E:9729 ||| NNS
of  ||| S:9729 E:9732 ||| IN
both  ||| S:9732 E:9737 ||| PDT
the  ||| S:9737 E:9741 ||| DT
heavy  ||| S:9741 E:9747 ||| JJ
and  ||| S:9747 E:9751 ||| CC
light  ||| S:9751 E:9757 ||| JJ
chains  ||| S:9757 E:9764 ||| NNS
of  ||| S:9764 E:9767 ||| IN
the  ||| S:9767 E:9771 ||| DT
13C4  ||| S:9771 E:9776 ||| JJ
antibody ||| S:9776 E:9784 ||| NN
.  ||| S:9784 E:9786 ||| .
The  ||| S:9786 E:9790 ||| DT
DNA  ||| S:9790 E:9794 ||| NN
consensus  ||| S:9794 E:9804 ||| NN
sequence  ||| S:9804 E:9813 ||| NN
was  ||| S:9813 E:9817 ||| VBD
determined  ||| S:9817 E:9828 ||| VBN
using  ||| S:9828 E:9834 ||| VBG
automated  ||| S:9834 E:9844 ||| JJ
fluorescent  ||| S:9844 E:9856 ||| JJ
dye-terminator  ||| S:9856 E:9871 ||| JJ
sequence  ||| S:9871 E:9880 ||| NN
reactions  ||| S:9880 E:9890 ||| NNS
of  ||| S:9890 E:9893 ||| IN
the  ||| S:9893 E:9897 ||| DT
amplified  ||| S:9897 E:9907 ||| JJ
cDNAs  ||| S:9907 E:9913 ||| JJ
analyzed  ||| S:9913 E:9922 ||| NN
with  ||| S:9922 E:9927 ||| IN
an  ||| S:9927 E:9930 ||| DT
ABI  ||| S:9930 E:9934 ||| NNP
373  ||| S:9934 E:9938 ||| CD
sequencing  ||| S:9938 E:9949 ||| JJ
instrument ||| S:9949 E:9959 ||| NN
.  ||| S:9959 E:9961 ||| .
The  ||| S:9961 E:9965 ||| DT
CDRs  ||| S:9965 E:9970 ||| NN
were  ||| S:9970 E:9975 ||| VBD
identified  ||| S:9975 E:9986 ||| VBN
according  ||| S:9986 E:9996 ||| VBG
to  ||| S:9996 E:9999 ||| TO
the  ||| S:9999 E:10003 ||| DT
nomenclature  ||| S:10003 E:10016 ||| NN
of  ||| S:10016 E:10019 ||| IN
Kabat  ||| S:10019 E:10025 ||| NNP
and  ||| S:10025 E:10029 ||| CC
Wu  ||| S:10029 E:10032 ||| NNP
( ||| S:10032 E:10033 ||| -LRB-
Kabat ||| S:10033 E:10038 ||| NNP
,  ||| S:10038 E:10040 ||| ,
et  ||| S:10040 E:10043 ||| FW
al.  ||| S:10043 E:10047 ||| FW
( ||| S:10047 E:10048 ||| -LRB-
1991 ||| S:10048 E:10052 ||| CD
) ||| S:10052 E:10053 ||| -RRB-
,  ||| S:10053 E:10055 ||| ,
Sequences  ||| S:10055 E:10065 ||| NNP
of  ||| S:10065 E:10068 ||| IN
Proteins  ||| S:10068 E:10077 ||| NNPS
of  ||| S:10077 E:10080 ||| IN
Immunological  ||| S:10080 E:10094 ||| NNP
Interest ||| S:10094 E:10102 ||| NNP
,  ||| S:10102 E:10104 ||| ,
Vol ||| S:10104 E:10107 ||| NNP
.  ||| S:10107 E:10109 ||| .
I ||| S:10109 E:10110 ||| PRP
,  ||| S:10110 E:10112 ||| ,
5th  ||| S:10112 E:10116 ||| JJ
edition ||| S:10116 E:10123 ||| NN
,  ||| S:10123 E:10125 ||| ,
U.S.  ||| S:10125 E:10130 ||| NNP
Department  ||| S:10130 E:10141 ||| NNP
of  ||| S:10141 E:10144 ||| IN
Health  ||| S:10144 E:10151 ||| NNP
and  ||| S:10151 E:10155 ||| CC
Human  ||| S:10155 E:10161 ||| NNP
Services ||| S:10161 E:10169 ||| NNPS
)  ||| S:10169 E:10171 ||| -RRB-
and  ||| S:10171 E:10175 ||| CC
are  ||| S:10175 E:10179 ||| VBP
located  ||| S:10179 E:10187 ||| VBN
as  ||| S:10187 E:10190 ||| RB
follows ||| S:10190 E:10197 ||| VBZ
:  ||| S:10197 E:10220 ||| :
FIG.  ||| S:10544 E:10549 ||| CD
5  ||| S:10549 E:10551 ||| CD
lists  ||| S:10551 E:10557 ||| NNS
the  ||| S:10557 E:10561 ||| DT
oligonucleotides  ||| S:10561 E:10578 ||| NN
used  ||| S:10578 E:10583 ||| VBN
for  ||| S:10583 E:10587 ||| IN
PCR  ||| S:10587 E:10591 ||| NNP
amplification  ||| S:10591 E:10605 ||| NN
of  ||| S:10605 E:10608 ||| IN
the  ||| S:10608 E:10612 ||| DT
variable  ||| S:10612 E:10621 ||| JJ
regions  ||| S:10621 E:10629 ||| NNS
of  ||| S:10629 E:10632 ||| IN
the  ||| S:10632 E:10636 ||| DT
11E10  ||| S:10636 E:10642 ||| JJ
antibody ||| S:10642 E:10650 ||| NN
.  ||| S:10650 E:10654 ||| .
FIG.  ||| S:10654 E:10659 ||| CD
6  ||| S:10659 E:10661 ||| CD
recites  ||| S:10661 E:10669 ||| CD
the  ||| S:10669 E:10673 ||| DT
DNA  ||| S:10673 E:10677 ||| NN
and  ||| S:10677 E:10681 ||| CC
amino  ||| S:10681 E:10687 ||| JJ
acid  ||| S:10687 E:10692 ||| NN
consensus  ||| S:10692 E:10702 ||| NN
sequences  ||| S:10702 E:10712 ||| NN
for  ||| S:10712 E:10716 ||| IN
the  ||| S:10716 E:10720 ||| DT
variable  ||| S:10720 E:10729 ||| JJ
regions  ||| S:10729 E:10737 ||| NNS
of  ||| S:10737 E:10740 ||| IN
both  ||| S:10740 E:10745 ||| PDT
the  ||| S:10745 E:10749 ||| DT
heavy  ||| S:10749 E:10755 ||| JJ
and  ||| S:10755 E:10759 ||| CC
light  ||| S:10759 E:10765 ||| JJ
chains  ||| S:10765 E:10772 ||| NNS
of  ||| S:10772 E:10775 ||| IN
the  ||| S:10775 E:10779 ||| DT
11E10  ||| S:10779 E:10785 ||| JJ
antibody ||| S:10785 E:10793 ||| NN
.  ||| S:10793 E:10795 ||| .
The  ||| S:10795 E:10799 ||| DT
DNA  ||| S:10799 E:10803 ||| NN
consensus  ||| S:10803 E:10813 ||| NN
sequence  ||| S:10813 E:10822 ||| NN
was  ||| S:10822 E:10826 ||| VBD
determined  ||| S:10826 E:10837 ||| VBN
using  ||| S:10837 E:10843 ||| VBG
automated  ||| S:10843 E:10853 ||| JJ
fluorescent  ||| S:10853 E:10865 ||| JJ
dye-terminator  ||| S:10865 E:10880 ||| JJ
sequence  ||| S:10880 E:10889 ||| NN
reactions  ||| S:10889 E:10899 ||| NNS
of  ||| S:10899 E:10902 ||| IN
the  ||| S:10902 E:10906 ||| DT
amplified  ||| S:10906 E:10916 ||| JJ
cDNAs  ||| S:10916 E:10922 ||| JJ
analyzed  ||| S:10922 E:10931 ||| NN
with  ||| S:10931 E:10936 ||| IN
an  ||| S:10936 E:10939 ||| DT
ABI  ||| S:10939 E:10943 ||| NNP
373  ||| S:10943 E:10947 ||| CD
sequencing  ||| S:10947 E:10958 ||| JJ
instrument ||| S:10958 E:10968 ||| NN
.  ||| S:10968 E:10970 ||| .
The  ||| S:10970 E:10974 ||| DT
CDRs  ||| S:10974 E:10979 ||| NN
were  ||| S:10979 E:10984 ||| VBD
identified  ||| S:10984 E:10995 ||| VBN
according  ||| S:10995 E:11005 ||| VBG
to  ||| S:11005 E:11008 ||| TO
the  ||| S:11008 E:11012 ||| DT
nomenclature  ||| S:11012 E:11025 ||| NN
of  ||| S:11025 E:11028 ||| IN
Kabat  ||| S:11028 E:11034 ||| NNP
and  ||| S:11034 E:11038 ||| CC
Wu  ||| S:11038 E:11041 ||| NNP
( ||| S:11041 E:11042 ||| -LRB-
Kabat  ||| S:11042 E:11048 ||| NNP
and  ||| S:11048 E:11052 ||| CC
Wu ||| S:11052 E:11054 ||| NNP
;  ||| S:11054 E:11056 ||| :
supra ||| S:11056 E:11061 ||| LS
)  ||| S:11061 E:11063 ||| -RRB-
and  ||| S:11063 E:11067 ||| CC
are  ||| S:11067 E:11071 ||| VBP
located  ||| S:11071 E:11079 ||| VBN
as  ||| S:11079 E:11082 ||| RB
follows ||| S:11082 E:11089 ||| VBZ
:  ||| S:11089 E:11112 ||| :
FIG.  ||| S:11288 E:11293 ||| CD
7  ||| S:11293 E:11295 ||| CD
illustrates  ||| S:11295 E:11307 ||| VBZ
the  ||| S:11307 E:11311 ||| DT
strategy  ||| S:11311 E:11320 ||| NN
for  ||| S:11320 E:11324 ||| IN
construction  ||| S:11324 E:11337 ||| NN
of  ||| S:11337 E:11340 ||| IN
the  ||| S:11340 E:11344 ||| DT
mammalian  ||| S:11344 E:11354 ||| JJ
expression  ||| S:11354 E:11365 ||| NN
vector  ||| S:11365 E:11372 ||| NNS
pACE4  ||| S:11372 E:11378 ||| VBP
containing  ||| S:11378 E:11389 ||| VBG
the  ||| S:11389 E:11393 ||| DT
variable  ||| S:11393 E:11402 ||| JJ
regions  ||| S:11402 E:11410 ||| NNS
of  ||| S:11410 E:11413 ||| IN
the  ||| S:11413 E:11417 ||| DT
11E10  ||| S:11417 E:11423 ||| JJ
antibody ||| S:11423 E:11431 ||| NN
.  ||| S:11431 E:11435 ||| .
FIG.  ||| S:12453 E:12458 ||| CD
16  ||| S:12458 E:12461 ||| CD
illustrates  ||| S:12461 E:12473 ||| VBZ
the  ||| S:12473 E:12477 ||| DT
strategy  ||| S:12477 E:12486 ||| NN
for  ||| S:12486 E:12490 ||| IN
construction  ||| S:12490 E:12503 ||| NN
of  ||| S:12503 E:12506 ||| IN
the  ||| S:12506 E:12510 ||| DT
plasmid  ||| S:12510 E:12518 ||| JJ
pJRS311 ||| S:12518 E:12525 ||| NN
.  ||| S:12525 E:12529 ||| .
FIG.  ||| S:12529 E:12534 ||| CD
17  ||| S:12534 E:12537 ||| CD
illustrates  ||| S:12537 E:12549 ||| VBZ
the  ||| S:12549 E:12553 ||| DT
strategy  ||| S:12553 E:12562 ||| NN
for  ||| S:12562 E:12566 ||| IN
construction  ||| S:12566 E:12579 ||| NN
of  ||| S:12579 E:12582 ||| IN
the  ||| S:12582 E:12586 ||| DT
plasmid  ||| S:12586 E:12594 ||| JJ
pJRS315 ||| S:12594 E:12601 ||| NN
.  ||| S:12601 E:12606 ||| .
Additional  ||| S:12606 E:12617 ||| JJ
features  ||| S:12617 E:12626 ||| NNS
and  ||| S:12626 E:12630 ||| CC
advantages  ||| S:12630 E:12641 ||| NNS
of  ||| S:12641 E:12644 ||| IN
the  ||| S:12644 E:12648 ||| DT
invention  ||| S:12648 E:12658 ||| NN
will  ||| S:12658 E:12663 ||| MD
be  ||| S:12663 E:12666 ||| VB
set  ||| S:12666 E:12670 ||| VBN
forth  ||| S:12670 E:12676 ||| RB
in  ||| S:12676 E:12679 ||| IN
the  ||| S:12679 E:12683 ||| DT
description  ||| S:12683 E:12695 ||| NN
which  ||| S:12695 E:12701 ||| WDT
follows ||| S:12701 E:12708 ||| VBZ
.  ||| S:12708 E:12710 ||| .
The  ||| S:12710 E:12714 ||| DT
objectives  ||| S:12714 E:12725 ||| NNS
and  ||| S:12725 E:12729 ||| CC
other  ||| S:12729 E:12735 ||| JJ
advantages  ||| S:12735 E:12746 ||| NNS
of  ||| S:12746 E:12749 ||| IN
the  ||| S:12749 E:12753 ||| DT
invention  ||| S:12753 E:12763 ||| NN
will  ||| S:12763 E:12768 ||| MD
be  ||| S:12768 E:12771 ||| VB
realized  ||| S:12771 E:12780 ||| VBN
and  ||| S:12780 E:12784 ||| CC
attained  ||| S:12784 E:12793 ||| VBN
by  ||| S:12793 E:12796 ||| IN
the  ||| S:12796 E:12800 ||| DT
composition  ||| S:12800 E:12812 ||| NN
of  ||| S:12812 E:12815 ||| IN
matter  ||| S:12815 E:12822 ||| NN
and  ||| S:12822 E:12826 ||| CC
process  ||| S:12826 E:12834 ||| NN
particularly  ||| S:12834 E:12847 ||| RB
pointed  ||| S:12847 E:12855 ||| VBD
out  ||| S:12855 E:12859 ||| RP
in  ||| S:12859 E:12862 ||| IN
the  ||| S:12862 E:12866 ||| DT
written  ||| S:12866 E:12874 ||| JJ
description  ||| S:12874 E:12886 ||| NN
and  ||| S:12886 E:12890 ||| CC
the  ||| S:12890 E:12894 ||| DT
claims  ||| S:12894 E:12901 ||| NNS
hereof  ||| S:12901 E:12908 ||| VBP
as  ||| S:12908 E:12911 ||| RB
well  ||| S:12911 E:12916 ||| RB
as  ||| S:12916 E:12919 ||| IN
the  ||| S:12919 E:12923 ||| DT
appended  ||| S:12923 E:12932 ||| JJ
drawings ||| S:12932 E:12940 ||| NNS
.  ||| S:12940 E:12942 ||| .
To  ||| S:12942 E:12945 ||| TO
achieve  ||| S:12945 E:12953 ||| VB
these  ||| S:12953 E:12959 ||| DT
and  ||| S:12959 E:12963 ||| CC
other  ||| S:12963 E:12969 ||| JJ
advantages  ||| S:12969 E:12980 ||| NNS
and  ||| S:12980 E:12984 ||| CC
in  ||| S:12984 E:12987 ||| IN
accordance  ||| S:12987 E:12998 ||| NN
with  ||| S:12998 E:13003 ||| IN
the  ||| S:13003 E:13007 ||| DT
purpose  ||| S:13007 E:13015 ||| NN
of  ||| S:13015 E:13018 ||| IN
the  ||| S:13018 E:13022 ||| DT
invention ||| S:13022 E:13031 ||| NN
,  ||| S:13031 E:13033 ||| ,
as  ||| S:13033 E:13036 ||| RB
embodied  ||| S:13036 E:13045 ||| VBN
and  ||| S:13045 E:13049 ||| CC
broadly  ||| S:13049 E:13057 ||| RB
described ||| S:13057 E:13066 ||| VBN
,  ||| S:13066 E:13068 ||| ,
the  ||| S:13068 E:13072 ||| DT
invention  ||| S:13072 E:13082 ||| NN
describes  ||| S:13082 E:13092 ||| VBZ
monoclonal  ||| S:13092 E:13103 ||| JJ
humanized  ||| S:13103 E:13113 ||| JJ
antibodies  ||| S:13113 E:13124 ||| NNS
which  ||| S:13124 E:13130 ||| WDT
bind  ||| S:13130 E:13135 ||| VBZ
Shiga  ||| S:13135 E:13141 ||| JJ
toxin  ||| S:13141 E:13147 ||| NN
proteins ||| S:13147 E:13155 ||| NNS
.  ||| S:13155 E:13158 ||| .
The  ||| S:13198 E:13202 ||| DT
present  ||| S:13202 E:13210 ||| JJ
invention  ||| S:13210 E:13220 ||| NN
relates  ||| S:13220 E:13228 ||| VBZ
to  ||| S:13228 E:13231 ||| TO
humanized  ||| S:13231 E:13241 ||| VB
monoclonal  ||| S:13241 E:13252 ||| JJ
antibodies  ||| S:13252 E:13263 ||| NNS
that  ||| S:13263 E:13268 ||| IN
bind  ||| S:13268 E:13273 ||| NN
to  ||| S:13273 E:13276 ||| TO
Shiga  ||| S:13276 E:13282 ||| NNP
toxin  ||| S:13282 E:13288 ||| NN
proteins ||| S:13288 E:13296 ||| NNS
,  ||| S:13296 E:13298 ||| ,
and  ||| S:13298 E:13302 ||| CC
the  ||| S:13302 E:13306 ||| DT
use  ||| S:13306 E:13310 ||| NN
of  ||| S:13310 E:13313 ||| IN
such  ||| S:13313 E:13318 ||| JJ
antibodies  ||| S:13318 E:13329 ||| NNS
in  ||| S:13329 E:13332 ||| IN
the  ||| S:13332 E:13336 ||| DT
treatment  ||| S:13336 E:13346 ||| NN
or  ||| S:13346 E:13349 ||| CC
prevention  ||| S:13349 E:13360 ||| NN
of  ||| S:13360 E:13363 ||| IN
Shiga  ||| S:13363 E:13369 ||| NNP
toxin-induced  ||| S:13369 E:13383 ||| JJ
diseases ||| S:13383 E:13391 ||| NNS
.  ||| S:13391 E:13393 ||| .
Antibodies  ||| S:13393 E:13404 ||| NNS
are  ||| S:13404 E:13408 ||| VBP
proteinaceous  ||| S:13408 E:13422 ||| JJ
structures  ||| S:13422 E:13433 ||| NNS
made  ||| S:13433 E:13438 ||| VBD
up  ||| S:13438 E:13441 ||| RP
of  ||| S:13441 E:13444 ||| IN
two  ||| S:13444 E:13448 ||| CD
heavy  ||| S:13448 E:13454 ||| JJ
and  ||| S:13454 E:13458 ||| CC
two  ||| S:13458 E:13462 ||| CD
light  ||| S:13462 E:13468 ||| JJ
chains ||| S:13468 E:13474 ||| NNS
.  ||| S:13474 E:13476 ||| .
The  ||| S:13476 E:13480 ||| DT
five  ||| S:13480 E:13485 ||| CD
different  ||| S:13485 E:13495 ||| JJ
classes  ||| S:13495 E:13503 ||| NNS
of  ||| S:13503 E:13506 ||| IN
higher  ||| S:13506 E:13513 ||| JJR
vertebrate  ||| S:13513 E:13524 ||| JJ
antibodies  ||| S:13524 E:13542 ||| NNS
IgM ||| S:13542 E:13545 ||| JJ
,  ||| S:13545 E:13547 ||| ,
IgD ||| S:13547 E:13550 ||| NNP
,  ||| S:13550 E:13552 ||| ,
IgG ||| S:13552 E:13555 ||| NNP
,  ||| S:13555 E:13557 ||| ,
IgA  ||| S:13557 E:13561 ||| JJ
and  ||| S:13561 E:13565 ||| CC
IgE  ||| S:13565 E:13576 ||| NNS
are  ||| S:13576 E:13580 ||| VBP
distinguished  ||| S:13580 E:13594 ||| VBN
by  ||| S:13594 E:13597 ||| IN
their  ||| S:13597 E:13603 ||| PRP$
heavy  ||| S:13603 E:13609 ||| JJ
chains  ||| S:13609 E:13616 ||| NNS
( ||| S:13616 E:13617 ||| -LRB-
mu ||| S:13617 E:13619 ||| UH
,  ||| S:13619 E:13621 ||| ,
delta ||| S:13621 E:13626 ||| NN
,  ||| S:13626 E:13628 ||| ,
gamma ||| S:13628 E:13633 ||| NN
,  ||| S:13633 E:13635 ||| ,
alpha  ||| S:13635 E:13641 ||| NN
and  ||| S:13641 E:13645 ||| CC
epsilon ||| S:13645 E:13652 ||| NN
,  ||| S:13652 E:13654 ||| ,
respectively ||| S:13654 E:13666 ||| RB
) ||| S:13666 E:13667 ||| -RRB-
.  ||| S:13667 E:13669 ||| .
Each  ||| S:13669 E:13674 ||| DT
class  ||| S:13674 E:13680 ||| NN
has  ||| S:13680 E:13684 ||| VBZ
further  ||| S:13684 E:13692 ||| JJ
subclasses ||| S:13692 E:13702 ||| NN
;  ||| S:13702 E:13704 ||| :
IgG ||| S:13704 E:13707 ||| NNP
,  ||| S:13707 E:13709 ||| ,
for  ||| S:13709 E:13713 ||| IN
example ||| S:13713 E:13720 ||| NN
,  ||| S:13720 E:13722 ||| ,
may  ||| S:13722 E:13726 ||| MD
be  ||| S:13726 E:13729 ||| VB
IgG1 ||| S:13729 E:13733 ||| CD
,  ||| S:13733 E:13735 ||| ,
IgG2 ||| S:13735 E:13739 ||| NNP
,  ||| S:13739 E:13741 ||| ,
IgG3 ||| S:13741 E:13745 ||| NNP
,  ||| S:13745 E:13747 ||| ,
or  ||| S:13747 E:13750 ||| CC
IgG4 ||| S:13750 E:13754 ||| NNP
,  ||| S:13754 E:13756 ||| ,
where  ||| S:13756 E:13762 ||| WRB
the  ||| S:13762 E:13766 ||| DT
heavy  ||| S:13766 E:13772 ||| JJ
chain  ||| S:13772 E:13778 ||| NN
is  ||| S:13778 E:13781 ||| VBZ
gamma  ||| S:13781 E:13787 ||| CD
1 ||| S:13787 E:13788 ||| CD
,  ||| S:13788 E:13790 ||| ,
gamma  ||| S:13790 E:13796 ||| CD
2 ||| S:13796 E:13797 ||| CD
,  ||| S:13797 E:13799 ||| ,
gamma  ||| S:13799 E:13805 ||| CD
3  ||| S:13805 E:13807 ||| CD
or  ||| S:13807 E:13810 ||| CC
gamma  ||| S:13810 E:13816 ||| CD
4 ||| S:13816 E:13817 ||| CD
,  ||| S:13817 E:13819 ||| ,
respectively ||| S:13819 E:13831 ||| RB
.  ||| S:13831 E:13833 ||| .
The  ||| S:13833 E:13837 ||| DT
pair  ||| S:13837 E:13842 ||| NN
of  ||| S:13842 E:13845 ||| IN
light  ||| S:13845 E:13851 ||| JJ
chains  ||| S:13851 E:13858 ||| NNS
in  ||| S:13858 E:13861 ||| IN
these  ||| S:13861 E:13867 ||| DT
classes  ||| S:13867 E:13875 ||| NNS
or  ||| S:13875 E:13878 ||| CC
subclasses  ||| S:13878 E:13889 ||| NNS
may  ||| S:13889 E:13893 ||| MD
be  ||| S:13893 E:13896 ||| VB
either  ||| S:13896 E:13903 ||| DT
kappa  ||| S:13903 E:13909 ||| NN
or  ||| S:13909 E:13912 ||| CC
lambda ||| S:13912 E:13918 ||| NN
.  ||| S:13918 E:13922 ||| .
Antibodies  ||| S:13922 E:13933 ||| NNS
are  ||| S:13933 E:13937 ||| VBP
further  ||| S:13937 E:13945 ||| RB
divided  ||| S:13945 E:13953 ||| VBN
into  ||| S:13953 E:13958 ||| IN
a  ||| S:13958 E:13960 ||| DT
constant  ||| S:13960 E:13969 ||| JJ
region  ||| S:13969 E:13976 ||| NN
and  ||| S:13976 E:13980 ||| CC
a  ||| S:13980 E:13982 ||| DT
variable  ||| S:13982 E:13991 ||| JJ
region ||| S:13991 E:13997 ||| NN
.  ||| S:13997 E:13999 ||| .
For  ||| S:13999 E:14003 ||| IN
both  ||| S:14003 E:14008 ||| PDT
the  ||| S:14008 E:14012 ||| DT
heavy  ||| S:14012 E:14018 ||| JJ
and  ||| S:14018 E:14022 ||| CC
light  ||| S:14022 E:14028 ||| JJ
chains ||| S:14028 E:14034 ||| NNS
,  ||| S:14034 E:14036 ||| ,
the  ||| S:14036 E:14040 ||| DT
carboxy-terminal  ||| S:14040 E:14057 ||| JJ
ends  ||| S:14057 E:14062 ||| NNS
make  ||| S:14062 E:14067 ||| VBP
up  ||| S:14067 E:14070 ||| RP
the  ||| S:14070 E:14074 ||| DT
constant  ||| S:14074 E:14083 ||| JJ
sequence  ||| S:14083 E:14092 ||| NN
region ||| S:14092 E:14098 ||| NN
,  ||| S:14098 E:14100 ||| ,
while  ||| S:14100 E:14106 ||| IN
the  ||| S:14106 E:14110 ||| DT
amino  ||| S:14110 E:14116 ||| JJ
terminal  ||| S:14116 E:14125 ||| NN
ends  ||| S:14125 E:14130 ||| NNS
contain  ||| S:14130 E:14138 ||| VBP
the  ||| S:14138 E:14142 ||| DT
variable  ||| S:14142 E:14151 ||| JJ
sequence  ||| S:14151 E:14160 ||| NN
region ||| S:14160 E:14166 ||| NN
.  ||| S:14166 E:14168 ||| .
Within  ||| S:14168 E:14175 ||| IN
these  ||| S:14175 E:14181 ||| DT
variable  ||| S:14181 E:14190 ||| JJ
regions ||| S:14190 E:14197 ||| NNS
,  ||| S:14197 E:14199 ||| ,
the  ||| S:14199 E:14203 ||| DT
complementarity  ||| S:14203 E:14219 ||| NN
determining  ||| S:14219 E:14231 ||| VBG
regions  ||| S:14231 E:14239 ||| NNS
( ||| S:14239 E:14240 ||| -LRB-
CDRs ||| S:14240 E:14244 ||| NNP
)  ||| S:14244 E:14246 ||| -RRB-
are  ||| S:14246 E:14250 ||| VBP
located  ||| S:14250 E:14258 ||| VBN
which  ||| S:14258 E:14264 ||| WDT
are  ||| S:14264 E:14268 ||| VBP
primarily  ||| S:14268 E:14278 ||| RB
responsible  ||| S:14278 E:14290 ||| JJ
for  ||| S:14290 E:14294 ||| IN
the  ||| S:14294 E:14298 ||| DT
observed  ||| S:14298 E:14307 ||| JJ
antigen  ||| S:14307 E:14315 ||| NN
binding  ||| S:14315 E:14323 ||| NNS
which  ||| S:14323 E:14329 ||| WDT
is  ||| S:14329 E:14332 ||| VBZ
characteristic  ||| S:14332 E:14347 ||| VBN
of  ||| S:14347 E:14350 ||| IN
antibodies ||| S:14350 E:14360 ||| NNS
.  ||| S:14360 E:14372 ||| .
Humanized  ||| S:14372 E:14390 ||| JJ
monoclonal  ||| S:14390 E:14401 ||| JJ
antibodies  ||| S:14401 E:14412 ||| NNS
mean  ||| S:14412 E:14417 ||| VBP
monoclonal  ||| S:14417 E:14428 ||| JJ
antibodies  ||| S:14428 E:14439 ||| NNS
originally  ||| S:14439 E:14450 ||| RB
from  ||| S:14450 E:14455 ||| IN
a  ||| S:14455 E:14457 ||| DT
non-human  ||| S:14457 E:14467 ||| JJ
source  ||| S:14467 E:14474 ||| NN
to  ||| S:14474 E:14477 ||| TO
which  ||| S:14477 E:14483 ||| WDT
human  ||| S:14483 E:14489 ||| JJ
components  ||| S:14489 E:14500 ||| NNS
have  ||| S:14500 E:14505 ||| VBP
been  ||| S:14505 E:14510 ||| VBN
substituted ||| S:14510 E:14521 ||| VBN
.  ||| S:14521 E:14523 ||| .
In  ||| S:14523 E:14526 ||| IN
a  ||| S:14526 E:14528 ||| DT
preferred  ||| S:14528 E:14538 ||| JJ
embodiment ||| S:14538 E:14548 ||| NN
,  ||| S:14548 E:14550 ||| ,
the  ||| S:14550 E:14554 ||| DT
humanized  ||| S:14554 E:14564 ||| JJ
monoclonal  ||| S:14564 E:14575 ||| JJ
antibodies  ||| S:14575 E:14586 ||| NNS
of  ||| S:14586 E:14589 ||| IN
this  ||| S:14589 E:14594 ||| DT
invention  ||| S:14594 E:14604 ||| NNS
comprise  ||| S:14604 E:14613 ||| VBP
variable  ||| S:14613 E:14622 ||| JJ
regions  ||| S:14622 E:14630 ||| NNS
which  ||| S:14630 E:14636 ||| WDT
derive  ||| S:14636 E:14643 ||| VBZ
from  ||| S:14643 E:14648 ||| IN
non-human  ||| S:14648 E:14658 ||| JJ
sources  ||| S:14658 E:14666 ||| NNS
and  ||| S:14666 E:14670 ||| CC
constant  ||| S:14670 E:14679 ||| JJ
regions  ||| S:14679 E:14687 ||| NNS
which  ||| S:14687 E:14693 ||| WDT
derive  ||| S:14693 E:14700 ||| VBZ
from  ||| S:14700 E:14705 ||| IN
human  ||| S:14705 E:14711 ||| JJ
sources ||| S:14711 E:14718 ||| NNS
.  ||| S:14718 E:14722 ||| .
As  ||| S:14722 E:14725 ||| RB
set  ||| S:14725 E:14729 ||| VBN
forth  ||| S:14729 E:14735 ||| RB
above ||| S:14735 E:14740 ||| RB
,  ||| S:14740 E:14742 ||| ,
Shiga  ||| S:14742 E:14748 ||| NNP
toxin  ||| S:14748 E:14754 ||| NN
proteins  ||| S:14754 E:14763 ||| NNS
( ||| S:14763 E:14764 ||| -LRB-
Stx ||| S:14764 E:14767 ||| NNP
)  ||| S:14767 E:14769 ||| -RRB-
refer  ||| S:14769 E:14775 ||| VBP
to  ||| S:14775 E:14778 ||| TO
the  ||| S:14778 E:14782 ||| DT
family  ||| S:14782 E:14789 ||| NN
of  ||| S:14789 E:14792 ||| IN
multi-unit  ||| S:14792 E:14803 ||| JJ
bacterial  ||| S:14803 E:14813 ||| JJ
proteins  ||| S:14813 E:14822 ||| NNS
produced  ||| S:14822 E:14831 ||| VBN
by  ||| S:14831 E:14834 ||| IN
EHEC  ||| S:14834 E:14839 ||| NNP
and  ||| S:14839 E:14843 ||| CC
Shigella  ||| S:14843 E:14852 ||| NNP
dysenteriae  ||| S:14852 E:14864 ||| NN
which  ||| S:14864 E:14870 ||| WDT
are  ||| S:14870 E:14874 ||| VBP
associated  ||| S:14874 E:14885 ||| VBN
with  ||| S:14885 E:14890 ||| IN
outbreaks  ||| S:14890 E:14900 ||| NNS
of  ||| S:14900 E:14903 ||| IN
Shiga  ||| S:14903 E:14909 ||| NNP
toxin  ||| S:14909 E:14915 ||| NN
induced  ||| S:14915 E:14923 ||| NN
diseases ||| S:14923 E:14931 ||| NNS
.  ||| S:14931 E:14933 ||| .
Shiga  ||| S:14933 E:14939 ||| JJ
toxin  ||| S:14939 E:14945 ||| NN
proteins  ||| S:14945 E:14954 ||| NNS
are  ||| S:14954 E:14958 ||| VBP
meant  ||| S:14958 E:14964 ||| VBN
to  ||| S:14964 E:14967 ||| TO
encompass  ||| S:14967 E:14977 ||| VB
Stx  ||| S:14977 E:14981 ||| NNP
of  ||| S:14981 E:14984 ||| IN
Shigella  ||| S:14984 E:14993 ||| NNP
dysenteriae-type  ||| S:14993 E:15010 ||| NNP
1  ||| S:15010 E:15012 ||| CD
and  ||| S:15012 E:15016 ||| CC
Stx  ||| S:15016 E:15020 ||| NNP
type  ||| S:15020 E:15025 ||| NN
1  ||| S:15025 E:15027 ||| CD
and  ||| S:15027 E:15031 ||| CC
type  ||| S:15031 E:15036 ||| NN
2 ||| S:15036 E:15037 ||| CD
,  ||| S:15037 E:15039 ||| ,
and  ||| S:15039 E:15043 ||| CC
type  ||| S:15043 E:15048 ||| NN
2  ||| S:15048 E:15050 ||| CD
variant  ||| S:15050 E:15058 ||| JJ
toxins  ||| S:15058 E:15065 ||| NN
of  ||| S:15065 E:15068 ||| IN
E.  ||| S:15068 E:15071 ||| NNP
coli ||| S:15071 E:15075 ||| NNS
.  ||| S:15075 E:15079 ||| .
Shiga  ||| S:15079 E:15085 ||| JJ
toxin-induced  ||| S:15085 E:15099 ||| JJ
diseases  ||| S:15099 E:15108 ||| NNS
of  ||| S:15108 E:15111 ||| IN
humans  ||| S:15111 E:15118 ||| NNS
include  ||| S:15118 E:15126 ||| VBP
bloody  ||| S:15126 E:15133 ||| JJ
diarrhea ||| S:15133 E:15141 ||| NN
,  ||| S:15141 E:15143 ||| ,
hemorrhagic  ||| S:15143 E:15155 ||| JJ
colitis ||| S:15155 E:15162 ||| NN
,  ||| S:15162 E:15164 ||| ,
hemolytic  ||| S:15164 E:15174 ||| JJ
uremic  ||| S:15174 E:15181 ||| JJ
syndrome ||| S:15181 E:15189 ||| NN
,  ||| S:15189 E:15191 ||| ,
and  ||| S:15191 E:15195 ||| CC
thrombotic  ||| S:15195 E:15206 ||| JJ
thrombocytopenic  ||| S:15206 E:15223 ||| JJ
purpura ||| S:15223 E:15230 ||| NN
.  ||| S:15230 E:15234 ||| .
By  ||| S:15719 E:15730 ||| IN
same  ||| S:15730 E:15735 ||| JJ
binding  ||| S:15735 E:15743 ||| JJ
specificity  ||| S:15743 E:15763 ||| NN
is  ||| S:15763 E:15766 ||| VBZ
meant  ||| S:15766 E:15772 ||| VBN
a  ||| S:15772 E:15774 ||| DT
level  ||| S:15774 E:15780 ||| NN
of  ||| S:15780 E:15783 ||| IN
binding  ||| S:15783 E:15791 ||| VBG
sufficiently  ||| S:15791 E:15804 ||| RB
detectable  ||| S:15804 E:15815 ||| VBN
in  ||| S:15815 E:15818 ||| IN
a  ||| S:15818 E:15820 ||| DT
standard  ||| S:15820 E:15829 ||| JJ
binding  ||| S:15829 E:15837 ||| JJ
assay  ||| S:15837 E:15843 ||| NN
to  ||| S:15843 E:15846 ||| TO
distinguish  ||| S:15846 E:15858 ||| VB
between  ||| S:15858 E:15866 ||| IN
toxin  ||| S:15866 E:15872 ||| NN
binding  ||| S:15872 E:15880 ||| NNS
and  ||| S:15880 E:15884 ||| CC
non-specific  ||| S:15884 E:15897 ||| JJ
background  ||| S:15897 E:15908 ||| NN
binding  ||| S:15908 E:15916 ||| NN
as  ||| S:15916 E:15919 ||| IN
exemplified  ||| S:15919 E:15931 ||| NN
by  ||| S:15931 E:15934 ||| IN
appropriate  ||| S:15934 E:15946 ||| JJ
controls  ||| S:15946 E:15955 ||| NNS
( ||| S:15955 E:15956 ||| -LRB-
for  ||| S:15956 E:15960 ||| IN
examples ||| S:15960 E:15968 ||| NNS
,  ||| S:15968 E:15970 ||| ,
see  ||| S:15970 E:15974 ||| VB
FIG.  ||| S:15974 E:15979 ||| CD
9  ||| S:15979 E:15981 ||| CD
and  ||| S:15981 E:15985 ||| CC
FIG.  ||| S:15985 E:15990 ||| CD
11 ||| S:15990 E:15992 ||| CD
) ||| S:15992 E:15993 ||| -RRB-
.  ||| S:15993 E:15995 ||| .
Those  ||| S:15995 E:16001 ||| DT
of  ||| S:16001 E:16004 ||| IN
ordinary  ||| S:16004 E:16013 ||| JJ
skill  ||| S:16013 E:16019 ||| NN
in  ||| S:16019 E:16022 ||| IN
the  ||| S:16022 E:16026 ||| DT
art  ||| S:16026 E:16030 ||| NN
can  ||| S:16030 E:16034 ||| MD
readily  ||| S:16034 E:16042 ||| RB
test  ||| S:16042 E:16047 ||| VB
for  ||| S:16047 E:16051 ||| IN
binding  ||| S:16051 E:16059 ||| JJ
levels  ||| S:16059 E:16066 ||| NNS
using  ||| S:16066 E:16072 ||| VBG
routine  ||| S:16072 E:16080 ||| JJ
skills  ||| S:16080 E:16087 ||| NNS
and  ||| S:16087 E:16091 ||| CC
techniques ||| S:16091 E:16101 ||| NNS
.  ||| S:16101 E:16105 ||| .
In  ||| S:16105 E:16108 ||| IN
another  ||| S:16108 E:16116 ||| DT
preferred  ||| S:16116 E:16126 ||| JJ
embodiment ||| S:16126 E:16136 ||| NN
,  ||| S:16136 E:16138 ||| ,
the  ||| S:16138 E:16142 ||| DT
humanized  ||| S:16142 E:16152 ||| JJ
antibodies  ||| S:16152 E:16163 ||| NNS
are  ||| S:16163 E:16167 ||| VBP
characterized  ||| S:16167 E:16181 ||| VBN
by  ||| S:16181 E:16184 ||| IN
their  ||| S:16184 E:16190 ||| PRP$
structural  ||| S:16190 E:16201 ||| JJ
features ||| S:16201 E:16209 ||| NNS
.  ||| S:16209 E:16211 ||| .
In  ||| S:16211 E:16214 ||| IN
one  ||| S:16214 E:16218 ||| CD
aspect  ||| S:16218 E:16225 ||| NN
of  ||| S:16225 E:16228 ||| IN
this  ||| S:16228 E:16233 ||| DT
embodiment ||| S:16233 E:16243 ||| NN
,  ||| S:16243 E:16245 ||| ,
the  ||| S:16245 E:16249 ||| DT
constant  ||| S:16249 E:16258 ||| JJ
region  ||| S:16258 E:16265 ||| NN
is  ||| S:16265 E:16268 ||| VBZ
a  ||| S:16268 E:16270 ||| DT
human  ||| S:16270 E:16276 ||| JJ
constant  ||| S:16276 E:16285 ||| JJ
region  ||| S:16285 E:16292 ||| NN
and  ||| S:16292 E:16296 ||| CC
the  ||| S:16296 E:16300 ||| DT
variable  ||| S:16300 E:16309 ||| JJ
region  ||| S:16309 E:16316 ||| NN
derives  ||| S:16316 E:16324 ||| VBZ
from  ||| S:16324 E:16329 ||| IN
a  ||| S:16329 E:16331 ||| DT
rodent ||| S:16331 E:16337 ||| NN
,  ||| S:16337 E:16339 ||| ,
preferably  ||| S:16339 E:16350 ||| RB
a  ||| S:16350 E:16352 ||| DT
mouse ||| S:16352 E:16357 ||| NN
.  ||| S:16357 E:16359 ||| .
Although  ||| S:16359 E:16368 ||| IN
not  ||| S:16368 E:16372 ||| RB
limited  ||| S:16372 E:16380 ||| VBN
to  ||| S:16380 E:16383 ||| TO
these ||| S:16383 E:16388 ||| DT
,  ||| S:16388 E:16390 ||| ,
the  ||| S:16390 E:16394 ||| DT
four  ||| S:16394 E:16399 ||| CD
variable  ||| S:16399 E:16408 ||| CD
regions  ||| S:16408 E:16416 ||| NNS
set  ||| S:16416 E:16420 ||| VBD
forth  ||| S:16420 E:16426 ||| RB
in  ||| S:16426 E:16429 ||| IN
the  ||| S:16429 E:16433 ||| DT
specification ||| S:16433 E:16446 ||| NN
,  ||| S:16446 E:16448 ||| ,
particularly  ||| S:16448 E:16461 ||| RB
in  ||| S:16461 E:16464 ||| IN
FIG.  ||| S:16464 E:16469 ||| CD
3  ||| S:16469 E:16471 ||| CD
and  ||| S:16471 E:16475 ||| CC
FIG.  ||| S:16475 E:16480 ||| CD
6 ||| S:16480 E:16481 ||| CD
,  ||| S:16481 E:16483 ||| ,
are  ||| S:16483 E:16487 ||| VBP
preferred ||| S:16487 E:16496 ||| VBN
.  ||| S:16496 E:16498 ||| .
Of  ||| S:16498 E:16501 ||| IN
course ||| S:16501 E:16507 ||| NN
,  ||| S:16507 E:16509 ||| ,
the  ||| S:16509 E:16513 ||| DT
invention  ||| S:16513 E:16523 ||| NN
includes  ||| S:16523 E:16532 ||| VBZ
modifications  ||| S:16532 E:16546 ||| NNS
( ||| S:16546 E:16547 ||| -LRB-
i.e. ||| S:16547 E:16551 ||| FW
,  ||| S:16551 E:16553 ||| ,
deletions ||| S:16553 E:16562 ||| NNS
,  ||| S:16562 E:16564 ||| ,
additions ||| S:16564 E:16573 ||| NNS
,  ||| S:16573 E:16575 ||| ,
and  ||| S:16575 E:16579 ||| CC
substitutions ||| S:16579 E:16592 ||| CD
)  ||| S:16592 E:16594 ||| -RRB-
that  ||| S:16594 E:16599 ||| WDT
do  ||| S:16599 E:16602 ||| VBP
not  ||| S:16602 E:16606 ||| RB
appreciably  ||| S:16606 E:16618 ||| RB
diminish  ||| S:16618 E:16627 ||| VB
the  ||| S:16627 E:16631 ||| DT
characteristic  ||| S:16631 E:16646 ||| JJ
binding  ||| S:16646 E:16654 ||| NNS
associated  ||| S:16654 E:16665 ||| VBN
with  ||| S:16665 E:16670 ||| IN
the  ||| S:16670 E:16674 ||| DT
exemplified  ||| S:16674 E:16686 ||| JJ
variable  ||| S:16686 E:16695 ||| JJ
regions ||| S:16695 E:16702 ||| NNS
.  ||| S:16702 E:16706 ||| .
In  ||| S:16706 E:16709 ||| IN
yet  ||| S:16709 E:16713 ||| RB
another  ||| S:16713 E:16721 ||| DT
embodiment ||| S:16721 E:16731 ||| NN
,  ||| S:16731 E:16733 ||| ,
the  ||| S:16733 E:16737 ||| DT
CDRs  ||| S:16737 E:16742 ||| JJ
of  ||| S:16742 E:16745 ||| IN
the  ||| S:16745 E:16749 ||| DT
variable  ||| S:16749 E:16758 ||| JJ
region  ||| S:16758 E:16765 ||| NN
are  ||| S:16765 E:16769 ||| VBP
employed  ||| S:16769 E:16778 ||| VBN
in  ||| S:16778 E:16781 ||| IN
the  ||| S:16781 E:16785 ||| DT
invention ||| S:16785 E:16794 ||| NN
.  ||| S:16794 E:16796 ||| .
As  ||| S:16796 E:16799 ||| RB
noted  ||| S:16799 E:16805 ||| VBD
above ||| S:16805 E:16810 ||| RB
,  ||| S:16810 E:16812 ||| ,
CDRs  ||| S:16812 E:16817 ||| NNS
are  ||| S:16817 E:16821 ||| VBP
located  ||| S:16821 E:16829 ||| VBN
in  ||| S:16829 E:16832 ||| IN
the  ||| S:16832 E:16836 ||| DT
variable  ||| S:16836 E:16845 ||| JJ
regions  ||| S:16845 E:16853 ||| NNS
of  ||| S:16853 E:16856 ||| IN
both  ||| S:16856 E:16861 ||| PDT
the  ||| S:16861 E:16865 ||| DT
light  ||| S:16865 E:16871 ||| NN
and  ||| S:16871 E:16875 ||| CC
heavy  ||| S:16875 E:16881 ||| JJ
chains  ||| S:16881 E:16888 ||| NNS
and  ||| S:16888 E:16892 ||| CC
are  ||| S:16892 E:16896 ||| VBP
responsible  ||| S:16896 E:16908 ||| JJ
for  ||| S:16908 E:16912 ||| IN
antigen  ||| S:16912 E:16920 ||| JJ
binding ||| S:16920 E:16927 ||| NN
.  ||| S:16927 E:16929 ||| .
In  ||| S:16929 E:16932 ||| IN
view  ||| S:16932 E:16937 ||| NN
of  ||| S:16937 E:16940 ||| IN
the  ||| S:16940 E:16944 ||| DT
ready  ||| S:16944 E:16950 ||| JJ
ability  ||| S:16950 E:16958 ||| NN
of  ||| S:16958 E:16961 ||| IN
those  ||| S:16961 E:16967 ||| DT
in  ||| S:16967 E:16970 ||| IN
this  ||| S:16970 E:16975 ||| DT
art  ||| S:16975 E:16979 ||| NN
to  ||| S:16979 E:16982 ||| TO
determine  ||| S:16982 E:16992 ||| VB
the  ||| S:16992 E:16996 ||| DT
CDR  ||| S:16996 E:17000 ||| NNP
regions ||| S:17000 E:17007 ||| NNS
,  ||| S:17007 E:17009 ||| ,
the  ||| S:17009 E:17013 ||| DT
present  ||| S:17013 E:17021 ||| JJ
invention  ||| S:17021 E:17031 ||| NN
is  ||| S:17031 E:17034 ||| VBZ
not  ||| S:17034 E:17038 ||| RB
limited  ||| S:17038 E:17046 ||| VBN
to  ||| S:17046 E:17049 ||| TO
the  ||| S:17049 E:17053 ||| DT
CDRs  ||| S:17053 E:17058 ||| JJ
specifically  ||| S:17058 E:17071 ||| RB
set  ||| S:17071 E:17075 ||| VBN
forth ||| S:17075 E:17080 ||| RB
.  ||| S:17080 E:17082 ||| .
Indeed ||| S:17082 E:17088 ||| RB
,  ||| S:17088 E:17090 ||| ,
the  ||| S:17090 E:17094 ||| DT
vectors  ||| S:17094 E:17102 ||| NN
created  ||| S:17102 E:17110 ||| VBN
by  ||| S:17110 E:17113 ||| IN
the  ||| S:17113 E:17117 ||| DT
applicants  ||| S:17117 E:17128 ||| NNS
and  ||| S:17128 E:17132 ||| CC
described  ||| S:17132 E:17142 ||| VBN
in  ||| S:17142 E:17145 ||| IN
great  ||| S:17145 E:17151 ||| JJ
detail  ||| S:17151 E:17158 ||| NN
below  ||| S:17158 E:17164 ||| RB
are  ||| S:17164 E:17168 ||| VBP
sufficient  ||| S:17168 E:17179 ||| JJ
for  ||| S:17179 E:17183 ||| IN
use  ||| S:17183 E:17187 ||| NN
with  ||| S:17187 E:17192 ||| IN
any  ||| S:17192 E:17196 ||| DT
CDRs  ||| S:17196 E:17201 ||| JJ
of  ||| S:17201 E:17204 ||| IN
non-human  ||| S:17204 E:17214 ||| JJ
antibodies  ||| S:17214 E:17225 ||| NNS
to  ||| S:17225 E:17228 ||| TO
Shiga  ||| S:17228 E:17234 ||| NNP
toxins ||| S:17234 E:17240 ||| NN
.  ||| S:17240 E:17244 ||| .
In  ||| S:17244 E:17247 ||| IN
the  ||| S:17247 E:17251 ||| DT
most  ||| S:17251 E:17256 ||| RBS
preferred  ||| S:17256 E:17266 ||| JJ
embodiment  ||| S:17266 E:17277 ||| NN
of  ||| S:17277 E:17280 ||| IN
the  ||| S:17280 E:17284 ||| DT
present  ||| S:17284 E:17292 ||| JJ
invention ||| S:17292 E:17301 ||| NN
,  ||| S:17301 E:17303 ||| ,
the  ||| S:17303 E:17307 ||| DT
humanized  ||| S:17307 E:17317 ||| JJ
monoclonal  ||| S:17317 E:17328 ||| JJ
antibody  ||| S:17328 E:17337 ||| NN
derives  ||| S:17337 E:17345 ||| VBZ
its  ||| S:17345 E:17349 ||| PRP$
constant  ||| S:17349 E:17358 ||| JJ
regions  ||| S:17358 E:17366 ||| NNS
from  ||| S:17366 E:17371 ||| IN
IgG1-kappa  ||| S:17371 E:17382 ||| NNP
and  ||| S:17382 E:17386 ||| CC
its  ||| S:17386 E:17390 ||| PRP$
variable  ||| S:17390 E:17399 ||| JJ
regions  ||| S:17399 E:17407 ||| NNS
from  ||| S:17407 E:17412 ||| IN
all  ||| S:17412 E:17416 ||| DT
or  ||| S:17416 E:17419 ||| CC
part  ||| S:17419 E:17424 ||| NN
of  ||| S:17424 E:17427 ||| IN
the  ||| S:17427 E:17431 ||| DT
sequences  ||| S:17431 E:17441 ||| NN
as  ||| S:17441 E:17444 ||| IN
set  ||| S:17444 E:17448 ||| VBN
forth  ||| S:17448 E:17454 ||| RB
in  ||| S:17454 E:17457 ||| IN
FIGS.  ||| S:17457 E:17463 ||| CD
3  ||| S:17463 E:17465 ||| CD
and  ||| S:17465 E:17469 ||| CC
6 ||| S:17469 E:17470 ||| CD
.  ||| S:17470 E:17472 ||| .
In  ||| S:17472 E:17475 ||| IN
further  ||| S:17475 E:17483 ||| JJ
embodiments ||| S:17483 E:17494 ||| NN
,  ||| S:17494 E:17496 ||| ,
the  ||| S:17496 E:17500 ||| DT
invention  ||| S:17500 E:17510 ||| NN
also  ||| S:17510 E:17515 ||| RB
relates  ||| S:17515 E:17523 ||| VBZ
to  ||| S:17523 E:17526 ||| TO
the  ||| S:17526 E:17530 ||| DT
expression  ||| S:17530 E:17541 ||| NN
vectors  ||| S:17541 E:17549 ||| NNS
which  ||| S:17549 E:17555 ||| WDT
code  ||| S:17555 E:17560 ||| NN
for  ||| S:17560 E:17564 ||| IN
these  ||| S:17564 E:17570 ||| DT
monoclonal  ||| S:17570 E:17581 ||| JJ
humanized  ||| S:17581 E:17591 ||| JJ
antibodies ||| S:17591 E:17601 ||| NNS
,  ||| S:17601 E:17603 ||| ,
and  ||| S:17603 E:17607 ||| CC
to  ||| S:17607 E:17610 ||| TO
host  ||| S:17610 E:17615 ||| VB
cells  ||| S:17615 E:17621 ||| NNS
which  ||| S:17621 E:17627 ||| WDT
have  ||| S:17627 E:17632 ||| VBP
been  ||| S:17632 E:17637 ||| VBN
transformed  ||| S:17637 E:17649 ||| VBN
with  ||| S:17649 E:17654 ||| IN
such  ||| S:17654 E:17659 ||| JJ
expression  ||| S:17659 E:17670 ||| NN
vectors ||| S:17670 E:17677 ||| NN
.  ||| S:17677 E:17681 ||| .
Finally ||| S:17681 E:17688 ||| RB
,  ||| S:17688 E:17690 ||| ,
the  ||| S:17690 E:17694 ||| DT
invention  ||| S:17694 E:17704 ||| NN
comprises  ||| S:17704 E:17714 ||| VBZ
the  ||| S:17714 E:17718 ||| DT
pharmaceutical  ||| S:17718 E:17733 ||| JJ
compositions  ||| S:17733 E:17746 ||| NNS
and  ||| S:17746 E:17750 ||| CC
the  ||| S:17750 E:17754 ||| DT
methods  ||| S:17754 E:17762 ||| NNS
of  ||| S:17762 E:17765 ||| IN
use  ||| S:17765 E:17769 ||| NN
of  ||| S:17769 E:17772 ||| IN
these  ||| S:17772 E:17778 ||| DT
humanized  ||| S:17778 E:17788 ||| JJ
monoclonal  ||| S:17788 E:17799 ||| JJ
antibodies  ||| S:17799 E:17810 ||| NNS
to  ||| S:17810 E:17813 ||| TO
treat  ||| S:17813 E:17819 ||| VB
or  ||| S:17819 E:17822 ||| CC
prevent  ||| S:17822 E:17830 ||| VB
Shiga  ||| S:17830 E:17836 ||| JJ
toxin-producing  ||| S:17836 E:17852 ||| JJ
bacterial  ||| S:17852 E:17862 ||| JJ
infections ||| S:17862 E:17872 ||| NNS
.  ||| S:17872 E:17874 ||| .
As  ||| S:17874 E:17877 ||| IN
a  ||| S:17877 E:17879 ||| DT
pharmaceutical ||| S:17879 E:17893 ||| JJ
,  ||| S:17893 E:17895 ||| ,
this  ||| S:17895 E:17900 ||| DT
invention  ||| S:17900 E:17910 ||| NN
includes  ||| S:17910 E:17919 ||| VBZ
but  ||| S:17919 E:17923 ||| CC
is  ||| S:17923 E:17926 ||| VBZ
not  ||| S:17926 E:17930 ||| RB
limited  ||| S:17930 E:17938 ||| VBN
to  ||| S:17938 E:17941 ||| TO
diluents  ||| S:17941 E:17950 ||| VB
and  ||| S:17950 E:17954 ||| CC
carriers  ||| S:17954 E:17963 ||| NNS
known  ||| S:17963 E:17969 ||| VBN
in  ||| S:17969 E:17972 ||| IN
the  ||| S:17972 E:17976 ||| DT
art ||| S:17976 E:17979 ||| NN
,  ||| S:17979 E:17981 ||| ,
such  ||| S:17981 E:17986 ||| JJ
as  ||| S:17986 E:17989 ||| IN
saline  ||| S:17989 E:17996 ||| NN
and  ||| S:17996 E:18000 ||| CC
sucrose  ||| S:18000 E:18008 ||| JJ
solutions  ||| S:18008 E:18018 ||| NNS
appropriate  ||| S:18018 E:18030 ||| JJ
for  ||| S:18030 E:18034 ||| IN
application  ||| S:18034 E:18046 ||| NN
to  ||| S:18046 E:18049 ||| TO
patients ||| S:18049 E:18057 ||| NNS
.  ||| S:18057 E:18059 ||| .
As  ||| S:18059 E:18062 ||| RB
used  ||| S:18062 E:18067 ||| VBN
herein ||| S:18067 E:18073 ||| NN
,  ||| S:18073 E:18083 ||| ,
patients  ||| S:18083 E:18100 ||| NNS
refers  ||| S:18100 E:18107 ||| VBZ
to  ||| S:18107 E:18110 ||| TO
any  ||| S:18110 E:18114 ||| DT
susceptible  ||| S:18114 E:18126 ||| JJ
mammal ||| S:18126 E:18132 ||| NN
,  ||| S:18132 E:18134 ||| ,
such  ||| S:18134 E:18139 ||| JJ
as  ||| S:18139 E:18142 ||| IN
dogs ||| S:18142 E:18146 ||| NNS
,  ||| S:18146 E:18148 ||| ,
horses ||| S:18148 E:18154 ||| NNS
,  ||| S:18154 E:18156 ||| ,
mice ||| S:18156 E:18160 ||| NNS
,  ||| S:18160 E:18162 ||| ,
etc. ||| S:18162 E:18166 ||| FW
,  ||| S:18166 E:18168 ||| ,
but  ||| S:18168 E:18172 ||| CC
is  ||| S:18172 E:18175 ||| VBZ
particularly  ||| S:18175 E:18188 ||| RB
preferred  ||| S:18188 E:18198 ||| VBN
to  ||| S:18198 E:18201 ||| TO
mean  ||| S:18201 E:18206 ||| VB
humans ||| S:18206 E:18212 ||| NNS
.  ||| S:18212 E:18216 ||| .
The  ||| S:18216 E:18220 ||| DT
invention  ||| S:18220 E:18230 ||| NN
further  ||| S:18230 E:18238 ||| RB
involves  ||| S:18238 E:18247 ||| VBZ
the  ||| S:18247 E:18251 ||| DT
administration  ||| S:18251 E:18266 ||| NN
of  ||| S:18266 E:18269 ||| IN
a  ||| S:18269 E:18271 ||| DT
therapeutically  ||| S:18271 E:18287 ||| JJ
effective  ||| S:18287 E:18297 ||| JJ
amount ||| S:18297 E:18303 ||| NN
,  ||| S:18303 E:18305 ||| ,
as  ||| S:18305 E:18308 ||| RB
well  ||| S:18308 E:18313 ||| RB
as  ||| S:18313 E:18316 ||| IN
a  ||| S:18316 E:18318 ||| DT
prophylatically  ||| S:18318 E:18334 ||| JJ
effective  ||| S:18334 E:18344 ||| JJ
amount ||| S:18344 E:18350 ||| NN
,  ||| S:18350 E:18352 ||| ,
of  ||| S:18352 E:18355 ||| IN
the  ||| S:18355 E:18359 ||| DT
humanized  ||| S:18359 E:18369 ||| JJ
monoclonal  ||| S:18369 E:18380 ||| JJ
antibody  ||| S:18380 E:18389 ||| NN
of  ||| S:18389 E:18392 ||| IN
the  ||| S:18392 E:18396 ||| DT
invention ||| S:18396 E:18405 ||| NN
.  ||| S:18405 E:18407 ||| .
As  ||| S:18407 E:18410 ||| IN
those  ||| S:18410 E:18416 ||| DT
in  ||| S:18416 E:18419 ||| IN
the  ||| S:18419 E:18423 ||| DT
art  ||| S:18423 E:18427 ||| NN
would  ||| S:18427 E:18433 ||| MD
recognize ||| S:18433 E:18442 ||| VB
,  ||| S:18442 E:18444 ||| ,
a  ||| S:18444 E:18446 ||| DT
therapeutically  ||| S:18446 E:18462 ||| JJ
effective  ||| S:18462 E:18472 ||| JJ
amount  ||| S:18472 E:18479 ||| NN
is  ||| S:18479 E:18482 ||| VBZ
a  ||| S:18482 E:18484 ||| DT
dose  ||| S:18484 E:18489 ||| NN
that  ||| S:18489 E:18494 ||| IN
ameliorates  ||| S:18494 E:18506 ||| JJ
edema ||| S:18506 E:18511 ||| NN
,  ||| S:18511 E:18513 ||| ,
thrombocytopenia ||| S:18513 E:18529 ||| NN
,  ||| S:18529 E:18531 ||| ,
and  ||| S:18531 E:18535 ||| CC
uremia  ||| S:18535 E:18542 ||| VB
associated  ||| S:18542 E:18553 ||| VBN
with  ||| S:18553 E:18558 ||| IN
EHEC-mediated  ||| S:18558 E:18572 ||| NNP
HUS ||| S:18572 E:18575 ||| NNP
.  ||| S:18575 E:18577 ||| .
Similarly ||| S:18577 E:18586 ||| RB
,  ||| S:18586 E:18588 ||| ,
a  ||| S:18588 E:18590 ||| DT
prophylactically  ||| S:18590 E:18607 ||| JJ
effective  ||| S:18607 E:18617 ||| JJ
amount  ||| S:18617 E:18624 ||| NN
is  ||| S:18624 E:18627 ||| VBZ
a  ||| S:18627 E:18629 ||| DT
dose  ||| S:18629 E:18634 ||| NN
that  ||| S:18634 E:18639 ||| WDT
prevents  ||| S:18639 E:18648 ||| VBZ
exposed  ||| S:18648 E:18656 ||| VBN
individuals  ||| S:18656 E:18668 ||| NNS
from  ||| S:18668 E:18673 ||| IN
developing  ||| S:18673 E:18684 ||| VBG
these  ||| S:18684 E:18690 ||| DT
symptoms ||| S:18690 E:18698 ||| NNS
.  ||| S:18698 E:18702 ||| .
The  ||| S:18702 E:18706 ||| DT
following  ||| S:18706 E:18716 ||| JJ
examples  ||| S:18716 E:18725 ||| NNS
illustrate  ||| S:18725 E:18736 ||| VBP
specific  ||| S:18736 E:18745 ||| JJ
embodiments  ||| S:18745 E:18757 ||| NN
of  ||| S:18757 E:18760 ||| IN
the  ||| S:18760 E:18764 ||| DT
invention ||| S:18764 E:18773 ||| NN
.  ||| S:18773 E:18777 ||| .
The  ||| S:21592 E:21596 ||| DT
heavy  ||| S:21596 E:21602 ||| JJ
chain  ||| S:21602 E:21608 ||| NN
and  ||| S:21608 E:21612 ||| CC
light  ||| S:21612 E:21618 ||| JJ
chain  ||| S:21618 E:21624 ||| NN
PCR  ||| S:21624 E:21628 ||| NN
products  ||| S:21628 E:21637 ||| NNS
( ||| S:21637 E:21638 ||| -LRB-
approximately  ||| S:21638 E:21652 ||| RB
400  ||| S:21652 E:21656 ||| CD
bp ||| S:21656 E:21658 ||| CD
)  ||| S:21658 E:21660 ||| -RRB-
were  ||| S:21660 E:21665 ||| VBD
then  ||| S:21665 E:21670 ||| RB
cloned  ||| S:21670 E:21677 ||| VBN
into  ||| S:21677 E:21682 ||| IN
a  ||| S:21682 E:21684 ||| DT
bacterial  ||| S:21684 E:21694 ||| JJ
vector  ||| S:21694 E:21701 ||| NN
for  ||| S:21701 E:21705 ||| IN
DNA  ||| S:21705 E:21709 ||| NNP
sequence  ||| S:21709 E:21718 ||| NN
determination ||| S:21718 E:21731 ||| NN
.  ||| S:21731 E:21733 ||| .
Ligations  ||| S:21733 E:21743 ||| NNP
of  ||| S:21743 E:21746 ||| IN
the  ||| S:21746 E:21750 ||| DT
PCR  ||| S:21750 E:21754 ||| NNP
fragments  ||| S:21754 E:21764 ||| NNS
were  ||| S:21764 E:21769 ||| VBD
carried  ||| S:21769 E:21777 ||| VBN
out  ||| S:21777 E:21781 ||| RP
into  ||| S:21781 E:21786 ||| IN
the  ||| S:21786 E:21790 ||| DT
pCR-2.1  ||| S:21790 E:21798 ||| JJ
T ||| S:21798 E:21799 ||| NN
/ ||| S:21799 E:21800 ||| VBZ
A  ||| S:21800 E:21802 ||| DT
style  ||| S:21802 E:21808 ||| NN
cloning  ||| S:21808 E:21816 ||| NN
vector  ||| S:21816 E:21823 ||| NN
( ||| S:21823 E:21824 ||| -LRB-
Invitrogen ||| S:21824 E:21834 ||| NNP
)  ||| S:21834 E:21836 ||| -RRB-
following  ||| S:21836 E:21846 ||| VBG
the  ||| S:21846 E:21850 ||| DT
manufacturer ||| S:21850 E:21862 ||| NN
's  ||| S:21862 E:21865 ||| POS
procedures  ||| S:21865 E:21876 ||| NNS
using  ||| S:21876 E:21882 ||| VBG
1 ||| S:21882 E:21883 ||| CD
: ||| S:21883 E:21884 ||| :
1 ||| S:21884 E:21885 ||| CD
,  ||| S:21885 E:21887 ||| ,
3 ||| S:21887 E:21888 ||| LS
: ||| S:21888 E:21889 ||| :
1  ||| S:21889 E:21891 ||| CD
and  ||| S:21891 E:21895 ||| CC
5 ||| S:21895 E:21896 ||| CD
: ||| S:21896 E:21897 ||| :
1  ||| S:21897 E:21899 ||| CD
insert  ||| S:21899 E:21906 ||| NN
to  ||| S:21906 E:21909 ||| TO
vector  ||| S:21909 E:21916 ||| VB
molar  ||| S:21916 E:21922 ||| JJ
ratios ||| S:21922 E:21928 ||| NNS
.  ||| S:21928 E:21930 ||| .
One  ||| S:21930 E:21934 ||| CD
half  ||| S:21934 E:21939 ||| NN
of  ||| S:21939 E:21942 ||| IN
each  ||| S:21942 E:21947 ||| DT
of  ||| S:21947 E:21950 ||| IN
the  ||| S:21950 E:21954 ||| DT
ligation  ||| S:21954 E:21963 ||| JJ
reactions  ||| S:21963 E:21973 ||| NNS
was  ||| S:21973 E:21977 ||| VBD
used  ||| S:21977 E:21982 ||| VBN
to  ||| S:21982 E:21985 ||| TO
transform  ||| S:21985 E:21995 ||| VB
competent  ||| S:21995 E:22005 ||| JJ
XL1  ||| S:22005 E:22009 ||| NNP
Blue  ||| S:22009 E:22014 ||| NNP
cells ||| S:22014 E:22019 ||| NNS
.  ||| S:22019 E:22023 ||| .
Heavy  ||| S:22023 E:22029 ||| JJ
chain  ||| S:22029 E:22035 ||| NN
plasmid  ||| S:22035 E:22043 ||| NNS
clones  ||| S:22043 E:22050 ||| VBP
containing  ||| S:22050 E:22061 ||| VBG
DNA  ||| S:22061 E:22065 ||| NN
inserts  ||| S:22065 E:22073 ||| NNS
were  ||| S:22073 E:22078 ||| VBD
identified  ||| S:22078 E:22089 ||| VBN
using  ||| S:22089 E:22095 ||| VBG
diagnostic  ||| S:22095 E:22106 ||| JJ
restriction  ||| S:22106 E:22118 ||| NN
enzyme  ||| S:22118 E:22125 ||| NN
digests  ||| S:22125 E:22133 ||| NN
with  ||| S:22133 E:22138 ||| IN
EcoRI  ||| S:22138 E:22144 ||| NNP
( ||| S:22144 E:22145 ||| -LRB-
New  ||| S:22145 E:22149 ||| NNP
England  ||| S:22149 E:22157 ||| NNP
Biolabs ||| S:22157 E:22164 ||| NNP
) ||| S:22164 E:22165 ||| -RRB-
.  ||| S:22165 E:22167 ||| .
The  ||| S:22167 E:22171 ||| DT
DNA  ||| S:22171 E:22175 ||| NN
sequence  ||| S:22175 E:22184 ||| NN
of  ||| S:22184 E:22187 ||| IN
plasmids  ||| S:22187 E:22196 ||| NNS
( ||| S:22196 E:22197 ||| -LRB-
tKMC217B ||| S:22197 E:22205 ||| NNP
)  ||| S:22205 E:22207 ||| -RRB-
containing  ||| S:22207 E:22218 ||| VBG
inserts  ||| S:22218 E:22226 ||| NNS
of  ||| S:22226 E:22229 ||| IN
the  ||| S:22229 E:22233 ||| DT
appropriate  ||| S:22233 E:22245 ||| JJ
size  ||| S:22245 E:22250 ||| NN
( ||| S:22250 E:22251 ||| -LRB-
400  ||| S:22251 E:22255 ||| CD
bp ||| S:22255 E:22257 ||| CD
)  ||| S:22257 E:22259 ||| -RRB-
were  ||| S:22259 E:22264 ||| VBD
then  ||| S:22264 E:22269 ||| RB
determined ||| S:22269 E:22279 ||| VBN
.  ||| S:22279 E:22281 ||| .
The  ||| S:22281 E:22285 ||| DT
final  ||| S:22285 E:22291 ||| JJ
consensus  ||| S:22291 E:22301 ||| NN
DNA  ||| S:22301 E:22305 ||| NN
sequence  ||| S:22305 E:22314 ||| NN
of  ||| S:22314 E:22317 ||| IN
the  ||| S:22317 E:22321 ||| DT
heavy  ||| S:22321 E:22327 ||| JJ
chain  ||| S:22327 E:22333 ||| NN
variable  ||| S:22333 E:22342 ||| NN
regions  ||| S:22342 E:22350 ||| NNS
is  ||| S:22350 E:22353 ||| VBZ
shown  ||| S:22353 E:22359 ||| VBN
in  ||| S:22359 E:22362 ||| IN
FIG.  ||| S:22362 E:22367 ||| CD
3 ||| S:22367 E:22368 ||| CD
.  ||| S:22368 E:22372 ||| .
The  ||| S:22372 E:22376 ||| DT
light  ||| S:22376 E:22382 ||| JJ
chain  ||| S:22382 E:22388 ||| NN
PCR  ||| S:22388 E:22392 ||| NN
products  ||| S:22392 E:22401 ||| NNS
were  ||| S:22401 E:22406 ||| VBD
identified  ||| S:22406 E:22417 ||| VBN
differently ||| S:22417 E:22428 ||| RB
.  ||| S:22428 E:22430 ||| .
The  ||| S:22430 E:22434 ||| DT
hybridoma  ||| S:22434 E:22444 ||| JJ
cell  ||| S:22444 E:22449 ||| NN
line  ||| S:22449 E:22454 ||| NN
that  ||| S:22454 E:22459 ||| WDT
expresses  ||| S:22459 E:22469 ||| VBZ
the  ||| S:22469 E:22481 ||| DT
13C4  ||| S:22481 E:22494 ||| JJ
antibody  ||| S:22494 E:22503 ||| NN
was  ||| S:22503 E:22507 ||| VBD
made  ||| S:22507 E:22512 ||| VBN
by  ||| S:22512 E:22515 ||| IN
fusing  ||| S:22515 E:22522 ||| JJ
mouse  ||| S:22522 E:22528 ||| NN
splenocytes  ||| S:22528 E:22540 ||| NN
with  ||| S:22540 E:22545 ||| IN
the  ||| S:22545 E:22549 ||| DT
SP2 ||| S:22549 E:22552 ||| CD
/ ||| S:22552 E:22553 ||| CD
0  ||| S:22553 E:22555 ||| CD
myeloma  ||| S:22555 E:22563 ||| JJ
cell  ||| S:22563 E:22568 ||| NN
line ||| S:22568 E:22572 ||| NN
.  ||| S:22572 E:22574 ||| .
The  ||| S:22574 E:22578 ||| DT
SP2 ||| S:22578 E:22581 ||| CD
/ ||| S:22581 E:22582 ||| CD
0  ||| S:22582 E:22584 ||| CD
cell  ||| S:22584 E:22589 ||| NN
line  ||| S:22589 E:22594 ||| NN
transcribes  ||| S:22594 E:22606 ||| VBD
a  ||| S:22606 E:22608 ||| DT
pseudogene  ||| S:22608 E:22619 ||| NN
for  ||| S:22619 E:22623 ||| IN
the  ||| S:22623 E:22627 ||| DT
kappa  ||| S:22627 E:22633 ||| JJ
light  ||| S:22633 E:22639 ||| JJ
chain ||| S:22639 E:22644 ||| NN
.  ||| S:22644 E:22646 ||| .
The  ||| S:22646 E:22650 ||| DT
pseudogene  ||| S:22650 E:22661 ||| JJ
transcript ||| S:22661 E:22671 ||| NN
,  ||| S:22671 E:22673 ||| ,
when  ||| S:22673 E:22678 ||| WRB
converted  ||| S:22678 E:22688 ||| VBN
to  ||| S:22688 E:22691 ||| TO
cDNA  ||| S:22691 E:22696 ||| JJ
by  ||| S:22696 E:22699 ||| IN
RT-PCR ||| S:22699 E:22705 ||| NNP
,  ||| S:22705 E:22707 ||| ,
contains  ||| S:22707 E:22716 ||| VBZ
an  ||| S:22716 E:22719 ||| DT
AflIII  ||| S:22719 E:22726 ||| JJ
restriction  ||| S:22726 E:22738 ||| NN
site ||| S:22738 E:22742 ||| NN
.  ||| S:22742 E:22744 ||| .
Light  ||| S:22744 E:22750 ||| JJ
chain  ||| S:22750 E:22756 ||| NN
candidate  ||| S:22756 E:22766 ||| NN
clones  ||| S:22766 E:22773 ||| NNS
( ||| S:22773 E:22774 ||| -LRB-
tKMC226  ||| S:22774 E:22789 ||| CD
227 ||| S:22789 E:22792 ||| CD
)  ||| S:22792 E:22794 ||| -RRB-
were  ||| S:22794 E:22799 ||| VBD
digested  ||| S:22799 E:22808 ||| VBN
with  ||| S:22808 E:22813 ||| IN
AflIII  ||| S:22813 E:22820 ||| NNP
( ||| S:22820 E:22821 ||| -LRB-
New  ||| S:22821 E:22825 ||| NNP
England  ||| S:22825 E:22833 ||| NNP
Biolabs ||| S:22833 E:22840 ||| NNP
)  ||| S:22840 E:22842 ||| -RRB-
using  ||| S:22842 E:22848 ||| VBG
the  ||| S:22848 E:22852 ||| DT
manufacturer ||| S:22852 E:22864 ||| NN
's  ||| S:22864 E:22867 ||| POS
procedures  ||| S:22867 E:22878 ||| NNS
to  ||| S:22878 E:22881 ||| TO
identify  ||| S:22881 E:22890 ||| VB
clones  ||| S:22890 E:22897 ||| NNS
containing  ||| S:22897 E:22908 ||| VBG
inserts  ||| S:22908 E:22916 ||| NNS
of  ||| S:22916 E:22919 ||| IN
the  ||| S:22919 E:22923 ||| DT
appropriate  ||| S:22923 E:22935 ||| JJ
size  ||| S:22935 E:22940 ||| NN
( ||| S:22940 E:22941 ||| -LRB-
403  ||| S:22941 E:22945 ||| CD
bp ||| S:22945 E:22947 ||| NNS
;  ||| S:22947 E:22949 ||| :
no  ||| S:22949 E:22952 ||| DT
AflIII  ||| S:22952 E:22959 ||| JJ
site  ||| S:22959 E:22964 ||| NN
is  ||| S:22964 E:22967 ||| VBZ
present  ||| S:22967 E:22975 ||| JJ
in  ||| S:22975 E:22978 ||| IN
these  ||| S:22978 E:22984 ||| DT
products ||| S:22984 E:22992 ||| NNS
) ||| S:22992 E:22993 ||| -RRB-
.  ||| S:22993 E:22995 ||| .
The  ||| S:22995 E:22999 ||| DT
final  ||| S:22999 E:23005 ||| JJ
consensus  ||| S:23005 E:23015 ||| NN
DNA  ||| S:23015 E:23019 ||| NN
sequence  ||| S:23019 E:23028 ||| NN
of  ||| S:23028 E:23031 ||| IN
the  ||| S:23031 E:23035 ||| DT
light  ||| S:23035 E:23041 ||| JJ
chain  ||| S:23041 E:23047 ||| NN
variable  ||| S:23047 E:23056 ||| NN
regions  ||| S:23056 E:23064 ||| NNS
is  ||| S:23064 E:23067 ||| VBZ
shown  ||| S:23067 E:23073 ||| VBN
in  ||| S:23073 E:23076 ||| IN
FIG.  ||| S:23076 E:23081 ||| CD
3  ||| S:23081 E:23083 ||| CD
with  ||| S:23083 E:23088 ||| IN
the  ||| S:23088 E:23092 ||| DT
CDRs  ||| S:23092 E:23097 ||| NN
indicated  ||| S:23097 E:23107 ||| VBD
by  ||| S:23107 E:23110 ||| IN
underlining ||| S:23110 E:23121 ||| NN
.  ||| S:23121 E:23124 ||| .
The  ||| S:23184 E:23188 ||| DT
heavy  ||| S:23188 E:23194 ||| JJ
and  ||| S:23194 E:23198 ||| CC
light  ||| S:23198 E:23204 ||| JJ
chain  ||| S:23204 E:23210 ||| NN
variable  ||| S:23210 E:23219 ||| NN
regions  ||| S:23219 E:23227 ||| NNS
were  ||| S:23227 E:23232 ||| VBD
then  ||| S:23232 E:23237 ||| RB
subcloned  ||| S:23237 E:23247 ||| VBN
into  ||| S:23247 E:23252 ||| IN
mammalian  ||| S:23252 E:23262 ||| JJ
expression  ||| S:23262 E:23273 ||| NN
plasmid  ||| S:23273 E:23281 ||| NN
vectors  ||| S:23281 E:23289 ||| NN
for  ||| S:23289 E:23293 ||| IN
the  ||| S:23293 E:23297 ||| DT
production  ||| S:23297 E:23308 ||| NN
of  ||| S:23308 E:23311 ||| IN
recombinant  ||| S:23311 E:23323 ||| FW
chimeric  ||| S:23323 E:23332 ||| FW
mouse ||| S:23332 E:23337 ||| FW
/ ||| S:23337 E:23338 ||| FW
human  ||| S:23338 E:23344 ||| FW
antibody  ||| S:23344 E:23353 ||| FW
molecules ||| S:23353 E:23362 ||| FW
.  ||| S:23362 E:23364 ||| .
The  ||| S:23364 E:23368 ||| DT
vectors  ||| S:23368 E:23376 ||| JJ
result  ||| S:23376 E:23383 ||| NN
in  ||| S:23383 E:23386 ||| IN
the  ||| S:23386 E:23390 ||| DT
production  ||| S:23390 E:23401 ||| NN
of  ||| S:23401 E:23404 ||| IN
recombinant  ||| S:23404 E:23416 ||| JJ
antibody  ||| S:23416 E:23425 ||| NN
molecules  ||| S:23425 E:23435 ||| NNS
under  ||| S:23435 E:23441 ||| IN
the  ||| S:23441 E:23445 ||| DT
control  ||| S:23445 E:23453 ||| NN
of  ||| S:23453 E:23456 ||| IN
CMV  ||| S:23456 E:23460 ||| NNP
transcriptional  ||| S:23460 E:23476 ||| NN
promoters ||| S:23476 E:23485 ||| NNS
.  ||| S:23485 E:23487 ||| .
The  ||| S:23487 E:23491 ||| DT
heavy  ||| S:23491 E:23497 ||| JJ
chain  ||| S:23497 E:23503 ||| NN
molecules  ||| S:23503 E:23513 ||| NNS
are  ||| S:23513 E:23517 ||| VBP
direct  ||| S:23517 E:23524 ||| JJ
cDNA  ||| S:23524 E:23529 ||| JJ
constructs  ||| S:23529 E:23540 ||| NN
that  ||| S:23540 E:23545 ||| IN
fuse  ||| S:23545 E:23550 ||| VBG
the  ||| S:23550 E:23554 ||| DT
variable  ||| S:23554 E:23563 ||| JJ
region  ||| S:23563 E:23570 ||| NN
sequence  ||| S:23570 E:23579 ||| NN
directly  ||| S:23579 E:23588 ||| RB
into  ||| S:23588 E:23593 ||| IN
the  ||| S:23593 E:23597 ||| DT
human  ||| S:23597 E:23603 ||| JJ
IgG1  ||| S:23603 E:23608 ||| CD
constant  ||| S:23608 E:23617 ||| JJ
domain ||| S:23617 E:23623 ||| NN
.  ||| S:23623 E:23625 ||| .
The  ||| S:23625 E:23629 ||| DT
light  ||| S:23629 E:23635 ||| JJ
chain  ||| S:23635 E:23641 ||| NN
molecules ||| S:23641 E:23650 ||| NNS
,  ||| S:23650 E:23652 ||| ,
on  ||| S:23652 E:23655 ||| IN
the  ||| S:23655 E:23659 ||| DT
other  ||| S:23659 E:23665 ||| JJ
hand ||| S:23665 E:23669 ||| NN
,  ||| S:23669 E:23671 ||| ,
have  ||| S:23671 E:23676 ||| VBP
a  ||| S:23676 E:23678 ||| DT
mouse  ||| S:23678 E:23684 ||| NN
kappa  ||| S:23684 E:23690 ||| VBZ
intron  ||| S:23690 E:23697 ||| JJ
region  ||| S:23697 E:23704 ||| NN
3  ||| S:23704 E:23714 ||| CD
of  ||| S:23714 E:23717 ||| IN
the  ||| S:23717 E:23721 ||| DT
variable  ||| S:23721 E:23730 ||| JJ
region  ||| S:23730 E:23737 ||| NN
coding  ||| S:23737 E:23744 ||| NN
fragment ||| S:23744 E:23752 ||| NN
.  ||| S:23752 E:23754 ||| .
After  ||| S:23754 E:23760 ||| IN
splicing ||| S:23760 E:23768 ||| NN
,  ||| S:23768 E:23770 ||| ,
the  ||| S:23770 E:23774 ||| DT
variable  ||| S:23774 E:23783 ||| JJ
region  ||| S:23783 E:23790 ||| NN
becomes  ||| S:23790 E:23798 ||| VBZ
fused  ||| S:23798 E:23804 ||| VBN
to  ||| S:23804 E:23807 ||| TO
a  ||| S:23807 E:23809 ||| DT
human  ||| S:23809 E:23815 ||| JJ
kappa  ||| S:23815 E:23821 ||| JJ
constant  ||| S:23821 E:23830 ||| JJ
region  ||| S:23830 E:23837 ||| NN
exon  ||| S:23837 E:23842 ||| NNS
( ||| S:23842 E:23843 ||| -LRB-
FIG.  ||| S:23843 E:23848 ||| CD
4 ||| S:23848 E:23849 ||| CD
) ||| S:23849 E:23850 ||| -RRB-
.  ||| S:23850 E:23852 ||| .
The  ||| S:23852 E:23856 ||| DT
selectable  ||| S:23856 E:23867 ||| JJ
marker  ||| S:23867 E:23874 ||| NN
for  ||| S:23874 E:23878 ||| IN
the  ||| S:23878 E:23882 ||| DT
vector  ||| S:23882 E:23889 ||| NN
in  ||| S:23889 E:23892 ||| IN
mammalian  ||| S:23892 E:23902 ||| JJ
cells  ||| S:23902 E:23908 ||| NNS
is  ||| S:23908 E:23911 ||| VBZ
aminoglycoside  ||| S:23911 E:23926 ||| JJ
phosphotransferase  ||| S:23926 E:23945 ||| NNS
( ||| S:23945 E:23946 ||| -LRB-
neo ||| S:23946 E:23949 ||| LS
) ||| S:23949 E:23950 ||| -RRB-
,  ||| S:23950 E:23952 ||| ,
using  ||| S:23952 E:23958 ||| VBG
the  ||| S:23958 E:23962 ||| DT
drug  ||| S:23962 E:23967 ||| NN
G418  ||| S:23967 E:23972 ||| NNP
( ||| S:23972 E:23973 ||| -LRB-
CellTech ||| S:23973 E:23981 ||| NNP
) ||| S:23981 E:23982 ||| -RRB-
.  ||| S:23982 E:23986 ||| .
A.  ||| S:23986 E:23989 ||| NNP
Creation  ||| S:23989 E:23998 ||| NNP
of  ||| S:23998 E:24001 ||| IN
the  ||| S:24001 E:24005 ||| DT
Expression  ||| S:24005 E:24016 ||| NNP
Vectors  ||| S:24016 E:24026 ||| NNPS
To  ||| S:24026 E:24029 ||| TO
create  ||| S:24029 E:24036 ||| VB
the  ||| S:24036 E:24040 ||| DT
heavy  ||| S:24040 E:24046 ||| JJ
and  ||| S:24046 E:24050 ||| CC
light  ||| S:24050 E:24056 ||| JJ
chain  ||| S:24056 E:24062 ||| NN
expression  ||| S:24062 E:24073 ||| NN
vectors  ||| S:24073 E:24081 ||| VBZ
required  ||| S:24081 E:24090 ||| VBN
DNA  ||| S:24090 E:24094 ||| NN
fragment  ||| S:24094 E:24103 ||| NN
ligations  ||| S:24103 E:24113 ||| NNS
and  ||| S:24113 E:24117 ||| CC
site  ||| S:24117 E:24122 ||| NN
directed  ||| S:24122 E:24131 ||| VBD
mutagenesis  ||| S:24131 E:24143 ||| JJ
steps ||| S:24143 E:24148 ||| NNS
.  ||| S:24148 E:24150 ||| .
The  ||| S:24150 E:24154 ||| DT
result  ||| S:24154 E:24161 ||| NN
was  ||| S:24161 E:24165 ||| VBD
vectors  ||| S:24165 E:24173 ||| NNS
that  ||| S:24173 E:24178 ||| WDT
express  ||| S:24178 E:24186 ||| VBP
both  ||| S:24186 E:24191 ||| DT
antibody  ||| S:24191 E:24200 ||| NN
chains  ||| S:24200 E:24207 ||| NNS
with  ||| S:24207 E:24212 ||| IN
CMV  ||| S:24212 E:24216 ||| NNP
promoter  ||| S:24216 E:24225 ||| VBD
driven  ||| S:24225 E:24232 ||| VBN
transcription ||| S:24232 E:24245 ||| NN
.  ||| S:24245 E:24247 ||| .
Neomycin  ||| S:24247 E:24256 ||| JJ
resistance  ||| S:24256 E:24267 ||| NN
serves  ||| S:24267 E:24274 ||| VBZ
as  ||| S:24274 E:24277 ||| IN
a  ||| S:24277 E:24279 ||| DT
dominant  ||| S:24279 E:24288 ||| JJ
selectable  ||| S:24288 E:24299 ||| JJ
marker  ||| S:24299 E:24306 ||| NN
for  ||| S:24306 E:24310 ||| IN
transfection  ||| S:24310 E:24323 ||| NN
of  ||| S:24323 E:24326 ||| IN
mammalian  ||| S:24326 E:24336 ||| JJ
cells ||| S:24336 E:24341 ||| NNS
.  ||| S:24341 E:24343 ||| .
In  ||| S:24343 E:24346 ||| IN
addition ||| S:24346 E:24354 ||| NN
,  ||| S:24354 E:24356 ||| ,
these  ||| S:24356 E:24362 ||| DT
vectors  ||| S:24362 E:24370 ||| NNS
have  ||| S:24370 E:24375 ||| VBP
been  ||| S:24375 E:24380 ||| VBN
designed  ||| S:24380 E:24389 ||| VBN
to  ||| S:24389 E:24392 ||| TO
allow  ||| S:24392 E:24398 ||| VB
convenient  ||| S:24398 E:24409 ||| JJ
cloning  ||| S:24409 E:24417 ||| NN
of  ||| S:24417 E:24420 ||| IN
any  ||| S:24420 E:24424 ||| DT
light  ||| S:24424 E:24430 ||| JJ
chain  ||| S:24430 E:24436 ||| NN
variable  ||| S:24436 E:24445 ||| NN
region  ||| S:24445 E:24452 ||| NN
as  ||| S:24452 E:24455 ||| IN
EcoRV ||| S:24455 E:24460 ||| JJ
/ ||| S:24460 E:24461 ||| CD
BstBI  ||| S:24461 E:24467 ||| JJ
fragment ||| S:24467 E:24475 ||| NN
,  ||| S:24475 E:24477 ||| ,
any  ||| S:24477 E:24481 ||| DT
heavy  ||| S:24481 E:24487 ||| JJ
chain  ||| S:24487 E:24493 ||| NN
variable  ||| S:24493 E:24502 ||| NN
region  ||| S:24502 E:24509 ||| NN
as  ||| S:24509 E:24512 ||| IN
a  ||| S:24512 E:24514 ||| DT
NruI ||| S:24514 E:24518 ||| JJ
/ ||| S:24518 E:24519 ||| CD
EcoRI  ||| S:24519 E:24525 ||| JJ
fragment ||| S:24525 E:24533 ||| NN
,  ||| S:24533 E:24535 ||| ,
and  ||| S:24535 E:24539 ||| CC
any  ||| S:24539 E:24543 ||| DT
heavy  ||| S:24543 E:24549 ||| JJ
chain  ||| S:24549 E:24555 ||| NN
constant  ||| S:24555 E:24564 ||| JJ
domain  ||| S:24564 E:24571 ||| NN
as  ||| S:24571 E:24574 ||| IN
an  ||| S:24574 E:24577 ||| DT
EcoRI ||| S:24577 E:24582 ||| JJ
/ ||| S:24582 E:24583 ||| CD
NotI  ||| S:24583 E:24588 ||| JJ
fragment ||| S:24588 E:24596 ||| NN
.  ||| S:24596 E:24598 ||| .
These  ||| S:24598 E:24604 ||| DT
restriction  ||| S:24604 E:24616 ||| NN
sites  ||| S:24616 E:24622 ||| NNS
were  ||| S:24622 E:24627 ||| VBD
chosen  ||| S:24627 E:24634 ||| VBN
because  ||| S:24634 E:24642 ||| IN
they  ||| S:24642 E:24647 ||| PRP
occur  ||| S:24647 E:24653 ||| VBP
rarely  ||| S:24653 E:24660 ||| RB
( ||| S:24660 E:24661 ||| -LRB-
if  ||| S:24661 E:24664 ||| IN
ever ||| S:24664 E:24668 ||| RB
)  ||| S:24668 E:24670 ||| -RRB-
in  ||| S:24670 E:24673 ||| IN
human  ||| S:24673 E:24679 ||| JJ
and  ||| S:24679 E:24683 ||| CC
mouse  ||| S:24683 E:24689 ||| JJ
variable  ||| S:24689 E:24698 ||| JJ
regions ||| S:24698 E:24705 ||| NNS
.  ||| S:24705 E:24707 ||| .
There  ||| S:24707 E:24713 ||| EX
is  ||| S:24713 E:24716 ||| VBZ
a  ||| S:24716 E:24718 ||| DT
mouse  ||| S:24718 E:24724 ||| NN
J  ||| S:24724 E:24726 ||| NNP
region ||| S:24726 E:24732 ||| FW
/ ||| S:24732 E:24733 ||| FW
kappa  ||| S:24733 E:24739 ||| FW
intron  ||| S:24739 E:24746 ||| FW
fragment  ||| S:24746 E:24755 ||| FW
fused  ||| S:24755 E:24761 ||| FW
to  ||| S:24761 E:24764 ||| TO
a  ||| S:24764 E:24766 ||| DT
human  ||| S:24766 E:24772 ||| JJ
kappa  ||| S:24772 E:24778 ||| NNS
exon  ||| S:24778 E:24783 ||| VBP
so  ||| S:24783 E:24786 ||| RB
that  ||| S:24786 E:24791 ||| IN
after  ||| S:24791 E:24797 ||| IN
post-transcriptional  ||| S:24797 E:24818 ||| JJ
splicing  ||| S:24818 E:24827 ||| NNS
a  ||| S:24827 E:24829 ||| DT
mouse  ||| S:24829 E:24835 ||| JJ
human  ||| S:24835 E:24841 ||| JJ
chimeric  ||| S:24841 E:24850 ||| NNS
kappa  ||| S:24850 E:24856 ||| VBP
light  ||| S:24856 E:24862 ||| JJ
chain  ||| S:24862 E:24868 ||| NN
is  ||| S:24868 E:24871 ||| VBZ
produced ||| S:24871 E:24879 ||| VBN
.  ||| S:24879 E:24881 ||| .
Lastly ||| S:24881 E:24887 ||| NNP
,  ||| S:24887 E:24889 ||| ,
the  ||| S:24889 E:24893 ||| DT
vectors  ||| S:24893 E:24901 ||| NN
were  ||| S:24901 E:24906 ||| VBD
designed  ||| S:24906 E:24915 ||| VBN
to  ||| S:24915 E:24918 ||| TO
facilitate  ||| S:24918 E:24929 ||| VB
excision  ||| S:24929 E:24938 ||| NN
( ||| S:24938 E:24939 ||| -LRB-
BglII ||| S:24939 E:24944 ||| NNP
/ ||| S:24944 E:24945 ||| NNP
NheI ||| S:24945 E:24949 ||| NNP
)  ||| S:24949 E:24951 ||| -RRB-
of  ||| S:24951 E:24954 ||| IN
a  ||| S:24954 E:24956 ||| DT
whole  ||| S:24956 E:24962 ||| JJ
antibody  ||| S:24962 E:24971 ||| NN
expression  ||| S:24971 E:24982 ||| NN
cassette  ||| S:24982 E:24991 ||| NN
from  ||| S:24991 E:24996 ||| IN
one  ||| S:24996 E:25000 ||| CD
vector  ||| S:25000 E:25007 ||| NN
to  ||| S:25007 E:25010 ||| TO
be  ||| S:25010 E:25013 ||| VB
ligated  ||| S:25013 E:25021 ||| VBN
into  ||| S:25021 E:25026 ||| IN
a  ||| S:25026 E:25028 ||| DT
second  ||| S:25028 E:25035 ||| JJ
vector  ||| S:25035 E:25042 ||| NN
cut  ||| S:25042 E:25046 ||| NN
with  ||| S:25046 E:25051 ||| IN
BamHI ||| S:25051 E:25056 ||| NNP
/ ||| S:25056 E:25057 ||| NNP
NheI ||| S:25057 E:25061 ||| NNP
,  ||| S:25061 E:25063 ||| ,
creating  ||| S:25063 E:25072 ||| VBG
an  ||| S:25072 E:25075 ||| DT
expression  ||| S:25075 E:25086 ||| NN
vector  ||| S:25086 E:25093 ||| NN
with  ||| S:25093 E:25098 ||| IN
the  ||| S:25098 E:25102 ||| DT
apparatus  ||| S:25102 E:25112 ||| NN
for  ||| S:25112 E:25116 ||| IN
both  ||| S:25116 E:25121 ||| DT
chains ||| S:25121 E:25127 ||| NNS
.  ||| S:25127 E:25131 ||| .
B.  ||| S:27365 E:27368 ||| NNP
Subcloning  ||| S:27368 E:27379 ||| NNP
the  ||| S:27379 E:27383 ||| DT
Variable  ||| S:27383 E:27392 ||| NNP
Regions  ||| S:27392 E:27400 ||| NNP
into  ||| S:27400 E:27405 ||| IN
the  ||| S:27405 E:27409 ||| DT
Expression  ||| S:27409 E:27420 ||| NNP
Vectors  ||| S:27420 E:27430 ||| NNPS
The  ||| S:28936 E:28940 ||| DT
13C4  ||| S:28940 E:28945 ||| JJ
heavy  ||| S:28945 E:28951 ||| JJ
chain  ||| S:28951 E:28957 ||| NN
PCR  ||| S:28957 E:28961 ||| NNP
product  ||| S:28961 E:28969 ||| NN
( ||| S:28969 E:28970 ||| -LRB-
approximately  ||| S:28970 E:28984 ||| RB
400  ||| S:28984 E:28988 ||| CD
bp ||| S:28988 E:28990 ||| CD
)  ||| S:28990 E:28992 ||| -RRB-
was  ||| S:28992 E:28996 ||| VBD
purified  ||| S:28996 E:29005 ||| VBN
using  ||| S:29005 E:29011 ||| VBG
Qiaquick  ||| S:29011 E:29020 ||| NNP
PCR  ||| S:29020 E:29024 ||| NNP
Purification  ||| S:29024 E:29037 ||| NNP
columns  ||| S:29037 E:29045 ||| NNS
( ||| S:29045 E:29046 ||| -LRB-
Qiagen ||| S:29046 E:29052 ||| NNP
)  ||| S:29052 E:29054 ||| -RRB-
as  ||| S:29054 E:29057 ||| RB
described  ||| S:29057 E:29067 ||| VBN
by  ||| S:29067 E:29070 ||| IN
the  ||| S:29070 E:29074 ||| DT
manufacturer ||| S:29074 E:29086 ||| NN
's  ||| S:29086 E:29089 ||| POS
instructions  ||| S:29089 E:29102 ||| NNS
and  ||| S:29102 E:29106 ||| CC
subsequently  ||| S:29106 E:29119 ||| RB
digested  ||| S:29119 E:29128 ||| VBN
with  ||| S:29128 E:29133 ||| IN
NruI  ||| S:29133 E:29138 ||| JJ
and  ||| S:29138 E:29142 ||| CC
EcoRI  ||| S:29142 E:29148 ||| NNP
( ||| S:29148 E:29149 ||| -LRB-
New  ||| S:29149 E:29153 ||| NNP
England  ||| S:29153 E:29161 ||| NNP
Biolabs ||| S:29161 E:29168 ||| NNP
) ||| S:29168 E:29169 ||| -RRB-
.  ||| S:29169 E:29171 ||| .
The  ||| S:29171 E:29175 ||| DT
digested  ||| S:29175 E:29184 ||| JJ
PCR  ||| S:29184 E:29188 ||| NN
products  ||| S:29188 E:29197 ||| NNS
were  ||| S:29197 E:29202 ||| VBD
purified  ||| S:29202 E:29211 ||| VBN
using  ||| S:29211 E:29217 ||| VBG
the  ||| S:29217 E:29221 ||| DT
Wizard  ||| S:29221 E:29228 ||| NNP
PCR  ||| S:29228 E:29232 ||| NNP
Purification  ||| S:29232 E:29245 ||| NNP
system  ||| S:29245 E:29252 ||| NN
( ||| S:29252 E:29253 ||| -LRB-
Promega ||| S:29253 E:29260 ||| NNP
)  ||| S:29260 E:29262 ||| -RRB-
as  ||| S:29262 E:29265 ||| IN
per  ||| S:29265 E:29269 ||| IN
manufacturer ||| S:29269 E:29281 ||| NN
's  ||| S:29281 E:29284 ||| POS
procedure  ||| S:29284 E:29294 ||| NN
and  ||| S:29294 E:29298 ||| CC
ligated  ||| S:29298 E:29306 ||| NN
into  ||| S:29306 E:29311 ||| IN
NruI ||| S:29311 E:29315 ||| JJ
/ ||| S:29315 E:29316 ||| CD
EcoRI  ||| S:29316 E:29322 ||| JJ
digested  ||| S:29322 E:29331 ||| NN
and  ||| S:29331 E:29335 ||| CC
gel-purified  ||| S:29335 E:29348 ||| NNP
pJRS3I3 ||| S:29348 E:29355 ||| NNP
,  ||| S:29355 E:29357 ||| ,
resulting  ||| S:29357 E:29367 ||| VBG
in  ||| S:29367 E:29370 ||| IN
plasmid  ||| S:29370 E:29378 ||| CD
tKMC229C  ||| S:29378 E:29387 ||| CD
( ||| S:29387 E:29388 ||| -LRB-
see  ||| S:29388 E:29392 ||| VB
FIG.  ||| S:29392 E:29397 ||| CD
4 ||| S:29397 E:29398 ||| CD
) ||| S:29398 E:29399 ||| -RRB-
.  ||| S:29399 E:29401 ||| .
The  ||| S:29401 E:29405 ||| DT
final  ||| S:29405 E:29411 ||| JJ
consensus  ||| S:29411 E:29421 ||| NN
DNA  ||| S:29421 E:29425 ||| NN
sequence  ||| S:29425 E:29434 ||| NN
of  ||| S:29434 E:29437 ||| IN
the  ||| S:29437 E:29441 ||| DT
heavy  ||| S:29441 E:29447 ||| JJ
chain  ||| S:29447 E:29453 ||| NN
variable  ||| S:29453 E:29462 ||| NN
region  ||| S:29462 E:29469 ||| NN
and  ||| S:29469 E:29473 ||| CC
proper  ||| S:29473 E:29480 ||| JJ
splicing  ||| S:29480 E:29489 ||| NN
of  ||| S:29489 E:29492 ||| IN
the  ||| S:29492 E:29496 ||| DT
restriction  ||| S:29496 E:29508 ||| NN
sites  ||| S:29508 E:29514 ||| NNS
were  ||| S:29514 E:29519 ||| VBD
confirmed  ||| S:29519 E:29529 ||| VBN
in  ||| S:29529 E:29532 ||| IN
this  ||| S:29532 E:29537 ||| DT
construct ||| S:29537 E:29546 ||| NN
.  ||| S:29546 E:29550 ||| .
The  ||| S:29550 E:29554 ||| DT
13C4  ||| S:29554 E:29559 ||| JJ
light  ||| S:29559 E:29565 ||| JJ
chain  ||| S:29565 E:29571 ||| NN
PCR  ||| S:29571 E:29575 ||| NNP
product  ||| S:29575 E:29583 ||| NN
( ||| S:29583 E:29584 ||| -LRB-
approximately  ||| S:29584 E:29598 ||| RB
350  ||| S:29598 E:29602 ||| CD
bp ||| S:29602 E:29604 ||| CD
)  ||| S:29604 E:29606 ||| -RRB-
was  ||| S:29606 E:29610 ||| VBD
purified  ||| S:29610 E:29619 ||| VBN
using  ||| S:29619 E:29625 ||| VBG
Qiaquick  ||| S:29625 E:29634 ||| NNP
PCR  ||| S:29634 E:29638 ||| NNP
Purification  ||| S:29638 E:29651 ||| NNP
columns  ||| S:29651 E:29659 ||| NNS
( ||| S:29659 E:29660 ||| -LRB-
Qiagen ||| S:29660 E:29666 ||| NNP
)  ||| S:29666 E:29668 ||| -RRB-
as  ||| S:29668 E:29671 ||| RB
described  ||| S:29671 E:29681 ||| VBN
by  ||| S:29681 E:29684 ||| IN
the  ||| S:29684 E:29688 ||| DT
manufacturer ||| S:29688 E:29700 ||| NN
's  ||| S:29700 E:29703 ||| POS
instructions  ||| S:29703 E:29716 ||| NNS
and  ||| S:29716 E:29720 ||| CC
subsequently  ||| S:29720 E:29733 ||| RB
digested  ||| S:29733 E:29742 ||| VBN
with  ||| S:29742 E:29747 ||| IN
EcoRV  ||| S:29747 E:29753 ||| JJ
and  ||| S:29753 E:29757 ||| CC
BstBI  ||| S:29757 E:29763 ||| NNP
( ||| S:29763 E:29764 ||| -LRB-
New  ||| S:29764 E:29768 ||| NNP
England  ||| S:29768 E:29776 ||| NNP
Biolabs ||| S:29776 E:29783 ||| NNP
) ||| S:29783 E:29784 ||| -RRB-
.  ||| S:29784 E:29786 ||| .
The  ||| S:29786 E:29790 ||| DT
digested  ||| S:29790 E:29799 ||| JJ
PCR  ||| S:29799 E:29803 ||| NN
products  ||| S:29803 E:29812 ||| NNS
were  ||| S:29812 E:29817 ||| VBD
purified  ||| S:29817 E:29826 ||| VBN
using  ||| S:29826 E:29832 ||| VBG
Qiaquick  ||| S:29832 E:29841 ||| NNP
PCR  ||| S:29841 E:29845 ||| NNP
Purification  ||| S:29845 E:29858 ||| NNP
columns  ||| S:29858 E:29866 ||| NNS
( ||| S:29866 E:29867 ||| -LRB-
Qiagen ||| S:29867 E:29873 ||| NNP
)  ||| S:29873 E:29875 ||| -RRB-
as  ||| S:29875 E:29878 ||| IN
per  ||| S:29878 E:29882 ||| IN
manufacturer ||| S:29882 E:29894 ||| NN
's  ||| S:29894 E:29897 ||| POS
procedure  ||| S:29897 E:29907 ||| NN
and  ||| S:29907 E:29911 ||| CC
ligated  ||| S:29911 E:29919 ||| NN
into  ||| S:29919 E:29924 ||| IN
EcoRV ||| S:29924 E:29929 ||| JJ
/ ||| S:29929 E:29930 ||| CD
BstBI  ||| S:29930 E:29936 ||| JJ
digested  ||| S:29936 E:29945 ||| NN
and  ||| S:29945 E:29949 ||| CC
gel-purified  ||| S:29949 E:29962 ||| NNP
tKMC180C2  ||| S:29962 E:29972 ||| NNP
( ||| S:29972 E:29973 ||| -LRB-
as  ||| S:29973 E:29976 ||| RB
described  ||| S:29976 E:29986 ||| VBN
above ||| S:29986 E:29991 ||| IN
) ||| S:29991 E:29992 ||| -RRB-
,  ||| S:29992 E:29994 ||| ,
resulting  ||| S:29994 E:30004 ||| VBG
in  ||| S:30004 E:30007 ||| IN
plasmid  ||| S:30007 E:30015 ||| CD
tKMC231D  ||| S:30015 E:30024 ||| CD
( ||| S:30024 E:30025 ||| -LRB-
see  ||| S:30025 E:30029 ||| VB
FIG.  ||| S:30029 E:30034 ||| CD
4 ||| S:30034 E:30035 ||| CD
) ||| S:30035 E:30036 ||| -RRB-
.  ||| S:30036 E:30038 ||| .
The  ||| S:30038 E:30042 ||| DT
final  ||| S:30042 E:30048 ||| JJ
consensus  ||| S:30048 E:30058 ||| NN
DNA  ||| S:30058 E:30062 ||| NN
sequence  ||| S:30062 E:30071 ||| NN
of  ||| S:30071 E:30074 ||| IN
the  ||| S:30074 E:30078 ||| DT
light  ||| S:30078 E:30084 ||| JJ
chain  ||| S:30084 E:30090 ||| NN
variable  ||| S:30090 E:30099 ||| NN
region  ||| S:30099 E:30106 ||| NN
and  ||| S:30106 E:30110 ||| CC
proper  ||| S:30110 E:30117 ||| JJ
splicing  ||| S:30117 E:30126 ||| NN
of  ||| S:30126 E:30129 ||| IN
the  ||| S:30129 E:30133 ||| DT
restriction  ||| S:30133 E:30145 ||| NN
sites  ||| S:30145 E:30151 ||| NNS
were  ||| S:30151 E:30156 ||| VBD
confirmed  ||| S:30156 E:30166 ||| VBN
in  ||| S:30166 E:30169 ||| IN
this  ||| S:30169 E:30174 ||| DT
construct ||| S:30174 E:30183 ||| NN
.  ||| S:30183 E:30186 ||| .
A.  ||| S:30267 E:30270 ||| NNP
Transfection  ||| S:30270 E:30283 ||| NNP
of  ||| S:30283 E:30286 ||| IN
NSO  ||| S:30286 E:30290 ||| NNP
Cells  ||| S:30290 E:30298 ||| NNPS
B.  ||| S:30985 E:30988 ||| NNP
Assay  ||| S:30988 E:30994 ||| NNP
for  ||| S:30994 E:30998 ||| IN
Antibody  ||| S:30998 E:31007 ||| NNP
Production  ||| S:31007 E:31020 ||| NNPS
Antibody  ||| S:31020 E:31029 ||| NN
production  ||| S:31029 E:31040 ||| NN
and  ||| S:31040 E:31044 ||| CC
activity  ||| S:31044 E:31053 ||| NN
assays  ||| S:31053 E:31060 ||| NN
for  ||| S:31060 E:31064 ||| IN
the  ||| S:31064 E:31068 ||| DT
stable  ||| S:31068 E:31075 ||| JJ
transfectants  ||| S:31075 E:31089 ||| NN
were  ||| S:31089 E:31094 ||| VBD
performed  ||| S:31094 E:31104 ||| VBN
as  ||| S:31104 E:31107 ||| RB
described  ||| S:31107 E:31117 ||| VBN
below ||| S:31117 E:31122 ||| RB
.  ||| S:31122 E:31124 ||| .
These  ||| S:31124 E:31130 ||| DT
assays  ||| S:31130 E:31137 ||| JJ
demonstrate  ||| S:31137 E:31149 ||| NN
that  ||| S:31149 E:31154 ||| IN
the  ||| S:31154 E:31158 ||| DT
transfection  ||| S:31158 E:31171 ||| NN
of  ||| S:31171 E:31174 ||| IN
cells  ||| S:31174 E:31180 ||| NNS
with  ||| S:31180 E:31185 ||| IN
this  ||| S:31185 E:31190 ||| DT
plasmid  ||| S:31190 E:31198 ||| JJ
construct  ||| S:31198 E:31208 ||| NN
can  ||| S:31208 E:31212 ||| MD
result  ||| S:31212 E:31219 ||| VB
in  ||| S:31219 E:31222 ||| IN
the  ||| S:31222 E:31226 ||| DT
production  ||| S:31226 E:31237 ||| NN
of  ||| S:31237 E:31240 ||| IN
a  ||| S:31240 E:31242 ||| DT
stable  ||| S:31242 E:31249 ||| JJ
cell  ||| S:31249 E:31254 ||| NN
line  ||| S:31254 E:31259 ||| NN
that  ||| S:31259 E:31264 ||| WDT
produces  ||| S:31264 E:31273 ||| VBZ
a  ||| S:31273 E:31275 ||| DT
humanized  ||| S:31275 E:31285 ||| JJ
chimeric  ||| S:31285 E:31294 ||| JJ
version  ||| S:31294 E:31302 ||| NN
of  ||| S:31302 E:31305 ||| IN
the  ||| S:31305 E:31309 ||| DT
13C4  ||| S:31309 E:31314 ||| FW
mouse  ||| S:31314 E:31320 ||| FW
hybridoma  ||| S:31320 E:31330 ||| FW
antibody  ||| S:31330 E:31339 ||| FW
( ||| S:31339 E:31340 ||| -LRB-
designated  ||| S:31340 E:31351 ||| VBN
H13C4 ||| S:31351 E:31356 ||| CD
) ||| S:31356 E:31357 ||| -RRB-
.  ||| S:31357 E:31361 ||| .
The  ||| S:36844 E:36848 ||| DT
heavy  ||| S:36848 E:36854 ||| JJ
chain  ||| S:36854 E:36860 ||| NN
PCR  ||| S:36860 E:36864 ||| NN
products  ||| S:36864 E:36873 ||| NNS
( ||| S:36873 E:36874 ||| -LRB-
approximately  ||| S:36874 E:36888 ||| RB
400  ||| S:36888 E:36892 ||| CD
bp ||| S:36892 E:36894 ||| CD
)  ||| S:36894 E:36896 ||| -RRB-
and  ||| S:36896 E:36900 ||| CC
the  ||| S:36900 E:36904 ||| DT
light  ||| S:36904 E:36910 ||| JJ
chain  ||| S:36910 E:36916 ||| NN
PCR  ||| S:36916 E:36920 ||| NN
products  ||| S:36920 E:36929 ||| NNS
( ||| S:36929 E:36930 ||| -LRB-
approximately  ||| S:36930 E:36944 ||| RB
350  ||| S:36944 E:36948 ||| CD
bp ||| S:36948 E:36950 ||| CD
)  ||| S:36950 E:36952 ||| -RRB-
were  ||| S:36952 E:36957 ||| VBD
then  ||| S:36957 E:36962 ||| RB
cloned  ||| S:36962 E:36969 ||| VBN
into  ||| S:36969 E:36974 ||| IN
a  ||| S:36974 E:36976 ||| DT
bacterial  ||| S:36976 E:36986 ||| JJ
vector  ||| S:36986 E:36993 ||| NN
for  ||| S:36993 E:36997 ||| IN
DNA  ||| S:36997 E:37001 ||| NNP
sequence  ||| S:37001 E:37010 ||| NN
determination ||| S:37010 E:37023 ||| NN
.  ||| S:37023 E:37025 ||| .
Ligations  ||| S:37025 E:37035 ||| NNP
of  ||| S:37035 E:37038 ||| IN
the  ||| S:37038 E:37042 ||| DT
PCR  ||| S:37042 E:37046 ||| NNP
fragments  ||| S:37046 E:37056 ||| NNS
were  ||| S:37056 E:37061 ||| VBD
carried  ||| S:37061 E:37069 ||| VBN
out  ||| S:37069 E:37073 ||| RP
into  ||| S:37073 E:37078 ||| IN
the  ||| S:37078 E:37082 ||| DT
pCR2.1  ||| S:37082 E:37089 ||| JJ
T ||| S:37089 E:37090 ||| NN
/ ||| S:37090 E:37091 ||| VBZ
A  ||| S:37091 E:37093 ||| DT
style  ||| S:37093 E:37099 ||| NN
cloning  ||| S:37099 E:37107 ||| NN
vector  ||| S:37107 E:37114 ||| NN
( ||| S:37114 E:37115 ||| -LRB-
Invitrogen ||| S:37115 E:37125 ||| NNP
)  ||| S:37125 E:37127 ||| -RRB-
following  ||| S:37127 E:37137 ||| VBG
the  ||| S:37137 E:37141 ||| DT
manufacturer ||| S:37141 E:37153 ||| NN
's  ||| S:37153 E:37156 ||| POS
procedures  ||| S:37156 E:37167 ||| NNS
using  ||| S:37167 E:37173 ||| VBG
a  ||| S:37173 E:37175 ||| DT
3 ||| S:37175 E:37176 ||| CD
: ||| S:37176 E:37177 ||| :
1  ||| S:37177 E:37179 ||| CD
insert  ||| S:37179 E:37186 ||| NN
to  ||| S:37186 E:37189 ||| TO
vector  ||| S:37189 E:37196 ||| VB
molar  ||| S:37196 E:37202 ||| JJ
ratio ||| S:37202 E:37207 ||| NN
.  ||| S:37207 E:37209 ||| .
Two  ||| S:37209 E:37220 ||| CD
l  ||| S:37220 E:37222 ||| NN
of  ||| S:37222 E:37225 ||| IN
the  ||| S:37225 E:37229 ||| DT
ligation  ||| S:37229 E:37238 ||| JJ
reactions  ||| S:37238 E:37248 ||| NNS
were  ||| S:37248 E:37253 ||| VBD
used  ||| S:37253 E:37258 ||| VBN
to  ||| S:37258 E:37261 ||| TO
transform  ||| S:37261 E:37271 ||| VB
the  ||| S:37271 E:37275 ||| DT
INV  ||| S:37275 E:37285 ||| NNP
F  ||| S:37285 E:37295 ||| NNP
competent  ||| S:37295 E:37305 ||| JJ
cells  ||| S:37305 E:37311 ||| NNS
( ||| S:37311 E:37312 ||| -LRB-
Invitrogen ||| S:37312 E:37322 ||| NNP
)  ||| S:37322 E:37324 ||| -RRB-
as  ||| S:37324 E:37327 ||| IN
per  ||| S:37327 E:37331 ||| IN
the  ||| S:37331 E:37335 ||| DT
manufacturer ||| S:37335 E:37347 ||| NN
's  ||| S:37347 E:37350 ||| POS
procedure ||| S:37350 E:37359 ||| NN
.  ||| S:37359 E:37361 ||| .
Plasmid  ||| S:37361 E:37369 ||| JJ
clones  ||| S:37369 E:37376 ||| NNS
containing  ||| S:37376 E:37387 ||| VBG
DNA  ||| S:37387 E:37391 ||| NN
inserts  ||| S:37391 E:37399 ||| NNS
were  ||| S:37399 E:37404 ||| VBD
identified  ||| S:37404 E:37415 ||| VBN
using  ||| S:37415 E:37421 ||| VBG
diagnostic  ||| S:37421 E:37432 ||| JJ
restriction  ||| S:37432 E:37444 ||| NN
enzyme  ||| S:37444 E:37451 ||| NN
digests ||| S:37451 E:37458 ||| NN
,  ||| S:37458 E:37460 ||| ,
with  ||| S:37460 E:37465 ||| IN
EcoRI  ||| S:37465 E:37471 ||| NNP
( ||| S:37471 E:37472 ||| -LRB-
New  ||| S:37472 E:37476 ||| NNP
England  ||| S:37476 E:37484 ||| NNP
Biolabs ||| S:37484 E:37491 ||| NNP
) ||| S:37491 E:37492 ||| -RRB-
.  ||| S:37492 E:37494 ||| .
The  ||| S:37494 E:37498 ||| DT
DNA  ||| S:37498 E:37502 ||| NN
sequence  ||| S:37502 E:37511 ||| NN
of  ||| S:37511 E:37514 ||| IN
plasmids  ||| S:37514 E:37523 ||| NNS
containing  ||| S:37523 E:37534 ||| VBG
the  ||| S:37534 E:37538 ||| DT
heavy  ||| S:37538 E:37544 ||| JJ
chain  ||| S:37544 E:37550 ||| NN
inserts  ||| S:37550 E:37558 ||| NNS
of  ||| S:37558 E:37561 ||| IN
the  ||| S:37561 E:37565 ||| DT
appropriate  ||| S:37565 E:37577 ||| JJ
size  ||| S:37577 E:37582 ||| NN
( ||| S:37582 E:37583 ||| -LRB-
400  ||| S:37583 E:37587 ||| CD
bp ||| S:37587 E:37589 ||| CD
)  ||| S:37589 E:37591 ||| -RRB-
was  ||| S:37591 E:37595 ||| VBD
then  ||| S:37595 E:37600 ||| RB
determined ||| S:37600 E:37610 ||| VBN
.  ||| S:37610 E:37612 ||| .
The  ||| S:37612 E:37616 ||| DT
final  ||| S:37616 E:37622 ||| JJ
consensus  ||| S:37622 E:37632 ||| NN
DNA  ||| S:37632 E:37636 ||| NN
sequence  ||| S:37636 E:37645 ||| NN
of  ||| S:37645 E:37648 ||| IN
the  ||| S:37648 E:37652 ||| DT
heavy  ||| S:37652 E:37658 ||| JJ
chain  ||| S:37658 E:37664 ||| NN
variable  ||| S:37664 E:37673 ||| NN
region  ||| S:37673 E:37680 ||| NN
of  ||| S:37680 E:37683 ||| IN
11E10  ||| S:37683 E:37689 ||| NNP
is  ||| S:37689 E:37692 ||| VBZ
shown  ||| S:37692 E:37698 ||| VBN
in  ||| S:37698 E:37701 ||| IN
FIG.  ||| S:37701 E:37706 ||| CD
6  ||| S:37706 E:37708 ||| CD
with  ||| S:37708 E:37713 ||| IN
the  ||| S:37713 E:37717 ||| DT
CDRs  ||| S:37717 E:37722 ||| NN
indicated  ||| S:37722 E:37732 ||| VBD
by  ||| S:37732 E:37735 ||| IN
underlining ||| S:37735 E:37746 ||| NN
.  ||| S:37746 E:37750 ||| .
The  ||| S:37750 E:37754 ||| DT
light  ||| S:37754 E:37760 ||| JJ
chain  ||| S:37760 E:37766 ||| NN
plasmid  ||| S:37766 E:37774 ||| NNS
clones  ||| S:37774 E:37781 ||| VBP
needed  ||| S:37781 E:37788 ||| VBN
to  ||| S:37788 E:37791 ||| TO
be  ||| S:37791 E:37794 ||| VB
further  ||| S:37794 E:37802 ||| RB
characterized  ||| S:37802 E:37816 ||| VBN
because  ||| S:37816 E:37824 ||| IN
the  ||| S:37824 E:37828 ||| DT
hybridoma  ||| S:37828 E:37838 ||| JJ
cell  ||| S:37838 E:37843 ||| NN
line  ||| S:37843 E:37848 ||| NN
that  ||| S:37848 E:37853 ||| WDT
expresses  ||| S:37853 E:37863 ||| VBZ
the  ||| S:37863 E:37875 ||| DT
11E10  ||| S:37875 E:37889 ||| JJ
antibody  ||| S:37889 E:37898 ||| NN
was  ||| S:37898 E:37902 ||| VBD
made  ||| S:37902 E:37907 ||| VBN
by  ||| S:37907 E:37910 ||| IN
fusing  ||| S:37910 E:37917 ||| JJ
mouse  ||| S:37917 E:37923 ||| NN
splenocytes  ||| S:37923 E:37935 ||| NN
with  ||| S:37935 E:37940 ||| IN
SP20  ||| S:37940 E:37945 ||| CD
myeloma  ||| S:37945 E:37953 ||| CD
cells ||| S:37953 E:37958 ||| NNS
.  ||| S:37958 E:37960 ||| .
The  ||| S:37960 E:37964 ||| DT
SP20  ||| S:37964 E:37969 ||| JJ
cell  ||| S:37969 E:37974 ||| NN
line  ||| S:37974 E:37979 ||| NN
transcribes  ||| S:37979 E:37991 ||| VBD
a  ||| S:37991 E:37993 ||| DT
pseudogene  ||| S:37993 E:38004 ||| NN
for  ||| S:38004 E:38008 ||| IN
the  ||| S:38008 E:38012 ||| DT
kappa  ||| S:38012 E:38018 ||| JJ
light  ||| S:38018 E:38024 ||| JJ
chain ||| S:38024 E:38029 ||| NN
.  ||| S:38029 E:38031 ||| .
The  ||| S:38031 E:38035 ||| DT
pseudogene  ||| S:38035 E:38046 ||| JJ
transcript ||| S:38046 E:38056 ||| NN
,  ||| S:38056 E:38058 ||| ,
when  ||| S:38058 E:38063 ||| WRB
converted  ||| S:38063 E:38073 ||| VBN
to  ||| S:38073 E:38076 ||| TO
cDNA  ||| S:38076 E:38081 ||| JJ
by  ||| S:38081 E:38084 ||| IN
RT-PCR ||| S:38084 E:38090 ||| NNP
,  ||| S:38090 E:38092 ||| ,
contains  ||| S:38092 E:38101 ||| VBZ
an  ||| S:38101 E:38104 ||| DT
AflIII  ||| S:38104 E:38111 ||| JJ
restriction  ||| S:38111 E:38123 ||| NN
site ||| S:38123 E:38127 ||| NN
.  ||| S:38127 E:38129 ||| .
For  ||| S:38129 E:38133 ||| IN
this  ||| S:38133 E:38138 ||| DT
reason ||| S:38138 E:38144 ||| NN
,  ||| S:38144 E:38146 ||| ,
the  ||| S:38146 E:38150 ||| DT
plasmid  ||| S:38150 E:38158 ||| JJ
clones  ||| S:38158 E:38165 ||| NNS
for  ||| S:38165 E:38169 ||| IN
the  ||| S:38169 E:38173 ||| DT
light  ||| S:38173 E:38179 ||| JJ
chain  ||| S:38179 E:38185 ||| NN
variable  ||| S:38185 E:38194 ||| NN
region  ||| S:38194 E:38201 ||| NN
were  ||| S:38201 E:38206 ||| VBD
digested  ||| S:38206 E:38215 ||| VBN
with  ||| S:38215 E:38220 ||| IN
AflIII  ||| S:38220 E:38227 ||| JJ
and  ||| S:38227 E:38231 ||| CC
those  ||| S:38231 E:38237 ||| DT
products  ||| S:38237 E:38246 ||| NNS
that  ||| S:38246 E:38251 ||| WDT
did  ||| S:38251 E:38255 ||| VBD
not  ||| S:38255 E:38259 ||| RB
cut  ||| S:38259 E:38263 ||| VB
were  ||| S:38263 E:38268 ||| VBD
then  ||| S:38268 E:38273 ||| RB
submitted  ||| S:38273 E:38283 ||| VBN
for  ||| S:38283 E:38287 ||| IN
DNA  ||| S:38287 E:38291 ||| NNP
sequencing ||| S:38291 E:38301 ||| NN
.  ||| S:38301 E:38303 ||| .
The  ||| S:38303 E:38307 ||| DT
final  ||| S:38307 E:38313 ||| JJ
consensus  ||| S:38313 E:38323 ||| NN
sequence  ||| S:38323 E:38332 ||| NN
of  ||| S:38332 E:38335 ||| IN
the  ||| S:38335 E:38339 ||| DT
light  ||| S:38339 E:38345 ||| JJ
chain  ||| S:38345 E:38351 ||| NN
variable  ||| S:38351 E:38360 ||| NN
region  ||| S:38360 E:38367 ||| NN
is  ||| S:38367 E:38370 ||| VBZ
shown  ||| S:38370 E:38376 ||| VBN
in  ||| S:38376 E:38379 ||| IN
FIG.  ||| S:38379 E:38384 ||| CD
6 ||| S:38384 E:38385 ||| CD
,  ||| S:38385 E:38387 ||| ,
with  ||| S:38387 E:38392 ||| IN
the  ||| S:38392 E:38396 ||| DT
CDRs  ||| S:38396 E:38401 ||| NN
indicated  ||| S:38401 E:38411 ||| VBD
by  ||| S:38411 E:38414 ||| IN
underlining ||| S:38414 E:38425 ||| NN
.  ||| S:38425 E:38429 ||| .
The  ||| S:39551 E:39555 ||| DT
heavy  ||| S:39555 E:39561 ||| JJ
chain  ||| S:39561 E:39567 ||| NN
variable  ||| S:39567 E:39576 ||| NN
region  ||| S:39576 E:39583 ||| NN
PCR  ||| S:39583 E:39587 ||| NNP
product  ||| S:39587 E:39595 ||| NN
was  ||| S:39595 E:39599 ||| VBD
then  ||| S:39599 E:39604 ||| RB
subcloned  ||| S:39604 E:39614 ||| VBN
into  ||| S:39614 E:39619 ||| IN
a  ||| S:39619 E:39621 ||| DT
mammalian  ||| S:39621 E:39631 ||| FW
expression  ||| S:39631 E:39642 ||| FW
plasmid  ||| S:39642 E:39650 ||| FW
vector  ||| S:39650 E:39657 ||| FW
( ||| S:39657 E:39658 ||| -LRB-
pJRS315 ||| S:39658 E:39665 ||| NNP
,  ||| S:39665 E:39667 ||| ,
produced  ||| S:39667 E:39676 ||| VBD
as  ||| S:39676 E:39679 ||| RB
set  ||| S:39679 E:39683 ||| VBN
forth  ||| S:39683 E:39689 ||| RB
below  ||| S:39689 E:39695 ||| RB
in  ||| S:39695 E:39698 ||| IN
Example  ||| S:39698 E:39706 ||| NNP
5 ||| S:39706 E:39707 ||| CD
)  ||| S:39707 E:39709 ||| -RRB-
for  ||| S:39709 E:39713 ||| IN
production  ||| S:39713 E:39724 ||| NN
of  ||| S:39724 E:39727 ||| IN
recombinant  ||| S:39727 E:39739 ||| FW
chimeric  ||| S:39739 E:39748 ||| FW
mouse ||| S:39748 E:39753 ||| FW
/ ||| S:39753 E:39754 ||| FW
human  ||| S:39754 E:39760 ||| FW
antibody  ||| S:39760 E:39769 ||| FW
molecules ||| S:39769 E:39778 ||| FW
.  ||| S:39778 E:39780 ||| .
The  ||| S:39780 E:39784 ||| DT
resulting  ||| S:39784 E:39794 ||| VBG
vector  ||| S:39794 E:39801 ||| JJ
clone  ||| S:39801 E:39807 ||| NN
was  ||| S:39807 E:39811 ||| VBD
designated  ||| S:39811 E:39822 ||| VBN
pACE1 ||| S:39822 E:39827 ||| CD
.  ||| S:39827 E:39829 ||| .
Before  ||| S:39829 E:39836 ||| IN
the  ||| S:39836 E:39840 ||| DT
light  ||| S:39840 E:39846 ||| JJ
chain  ||| S:39846 E:39852 ||| NN
variable  ||| S:39852 E:39861 ||| NN
region  ||| S:39861 E:39868 ||| NN
could  ||| S:39868 E:39874 ||| MD
be  ||| S:39874 E:39877 ||| VB
subcloned  ||| S:39877 E:39887 ||| VBN
into  ||| S:39887 E:39892 ||| IN
the  ||| S:39892 E:39896 ||| DT
mammalian  ||| S:39896 E:39906 ||| JJ
expression  ||| S:39906 E:39917 ||| NN
vector ||| S:39917 E:39923 ||| NN
,  ||| S:39923 E:39925 ||| ,
it  ||| S:39925 E:39928 ||| PRP
was  ||| S:39928 E:39932 ||| VBD
subcloned  ||| S:39932 E:39942 ||| VBN
into  ||| S:39942 E:39947 ||| IN
the  ||| S:39947 E:39951 ||| DT
pCR2.1  ||| S:39951 E:39958 ||| JJ
T ||| S:39958 E:39959 ||| NN
/ ||| S:39959 E:39960 ||| VBZ
A  ||| S:39960 E:39962 ||| DT
style  ||| S:39962 E:39968 ||| NN
cloning  ||| S:39968 E:39976 ||| NNS
vector  ||| S:39976 E:39983 ||| VBP
previously  ||| S:39983 E:39994 ||| RB
described ||| S:39994 E:40003 ||| VBN
.  ||| S:40003 E:40005 ||| .
The  ||| S:40005 E:40009 ||| DT
resulting  ||| S:40009 E:40019 ||| VBG
plasmid  ||| S:40019 E:40027 ||| NNS
was  ||| S:40027 E:40031 ||| VBD
designated  ||| S:40031 E:40042 ||| VBN
pACELC  ||| S:40042 E:40049 ||| JJ
and  ||| S:40049 E:40053 ||| CC
digested ||| S:40053 E:40061 ||| NN
,  ||| S:40061 E:40063 ||| ,
with  ||| S:40063 E:40068 ||| IN
BstBI ||| S:40068 E:40073 ||| NNP
/ ||| S:40073 E:40074 ||| NNP
EcoRV ||| S:40074 E:40079 ||| NNP
,  ||| S:40079 E:40081 ||| ,
to  ||| S:40081 E:40084 ||| TO
cut  ||| S:40084 E:40088 ||| VB
out  ||| S:40088 E:40092 ||| RP
the  ||| S:40092 E:40096 ||| DT
light  ||| S:40096 E:40102 ||| JJ
chain  ||| S:40102 E:40108 ||| NN
variable  ||| S:40108 E:40117 ||| NN
region ||| S:40117 E:40123 ||| NN
.  ||| S:40123 E:40125 ||| .
The  ||| S:40125 E:40129 ||| DT
variable  ||| S:40129 E:40138 ||| JJ
region  ||| S:40138 E:40145 ||| NN
was  ||| S:40145 E:40149 ||| VBD
then  ||| S:40149 E:40154 ||| RB
subcloned  ||| S:40154 E:40164 ||| VBN
into  ||| S:40164 E:40169 ||| IN
the  ||| S:40169 E:40173 ||| DT
mammalian  ||| S:40173 E:40183 ||| JJ
expression  ||| S:40183 E:40194 ||| NN
vector  ||| S:40194 E:40201 ||| NN
containing  ||| S:40201 E:40212 ||| VBG
the  ||| S:40212 E:40224 ||| DT
11E10  ||| S:40224 E:40238 ||| JJ
heavy  ||| S:40238 E:40244 ||| JJ
chain  ||| S:40244 E:40250 ||| NN
variable  ||| S:40250 E:40259 ||| NN
region  ||| S:40259 E:40266 ||| NN
( ||| S:40266 E:40267 ||| -LRB-
pACE1 ||| S:40267 E:40272 ||| NNP
) ||| S:40272 E:40273 ||| -RRB-
.  ||| S:40273 E:40275 ||| .
The  ||| S:40275 E:40279 ||| DT
final  ||| S:40279 E:40285 ||| JJ
expression  ||| S:40285 E:40296 ||| NN
vector  ||| S:40296 E:40303 ||| NN
clone  ||| S:40303 E:40309 ||| NNS
was  ||| S:40309 E:40313 ||| VBD
designated  ||| S:40313 E:40324 ||| VBN
pACE4 ||| S:40324 E:40329 ||| CD
.  ||| S:40329 E:40331 ||| .
This  ||| S:40331 E:40336 ||| DT
vector  ||| S:40336 E:40343 ||| JJ
results  ||| S:40343 E:40351 ||| NNS
in  ||| S:40351 E:40354 ||| IN
the  ||| S:40354 E:40358 ||| DT
production  ||| S:40358 E:40369 ||| NN
of  ||| S:40369 E:40372 ||| IN
recombinant  ||| S:40372 E:40384 ||| JJ
antibody  ||| S:40384 E:40393 ||| NN
molecules  ||| S:40393 E:40403 ||| NNS
under  ||| S:40403 E:40409 ||| IN
the  ||| S:40409 E:40413 ||| DT
control  ||| S:40413 E:40421 ||| NN
of  ||| S:40421 E:40424 ||| IN
the  ||| S:40424 E:40428 ||| DT
CMV  ||| S:40428 E:40432 ||| NNP
transcriptional  ||| S:40432 E:40448 ||| NN
promoters ||| S:40448 E:40457 ||| NNS
.  ||| S:40457 E:40459 ||| .
The  ||| S:40459 E:40463 ||| DT
heavy  ||| S:40463 E:40469 ||| JJ
chain  ||| S:40469 E:40475 ||| NN
molecules  ||| S:40475 E:40485 ||| NNS
are  ||| S:40485 E:40489 ||| VBP
direct  ||| S:40489 E:40496 ||| JJ
cDNA  ||| S:40496 E:40501 ||| JJ
constructs  ||| S:40501 E:40512 ||| NN
that  ||| S:40512 E:40517 ||| IN
fuse  ||| S:40517 E:40522 ||| VBG
the  ||| S:40522 E:40526 ||| DT
variable  ||| S:40526 E:40535 ||| JJ
region  ||| S:40535 E:40542 ||| NN
sequence  ||| S:40542 E:40551 ||| NN
directly  ||| S:40551 E:40560 ||| RB
into  ||| S:40560 E:40565 ||| IN
the  ||| S:40565 E:40569 ||| DT
human  ||| S:40569 E:40575 ||| JJ
IgG1  ||| S:40575 E:40580 ||| CD
constant  ||| S:40580 E:40589 ||| JJ
domain ||| S:40589 E:40595 ||| NN
.  ||| S:40595 E:40597 ||| .
The  ||| S:40597 E:40601 ||| DT
light  ||| S:40601 E:40607 ||| JJ
chain  ||| S:40607 E:40613 ||| NN
molecules ||| S:40613 E:40622 ||| NNS
,  ||| S:40622 E:40624 ||| ,
on  ||| S:40624 E:40627 ||| IN
the  ||| S:40627 E:40631 ||| DT
other  ||| S:40631 E:40637 ||| JJ
hand ||| S:40637 E:40641 ||| NN
,  ||| S:40641 E:40643 ||| ,
have  ||| S:40643 E:40648 ||| VBP
a  ||| S:40648 E:40650 ||| DT
mouse  ||| S:40650 E:40656 ||| NN
kappa  ||| S:40656 E:40662 ||| VBZ
intron  ||| S:40662 E:40669 ||| JJ
region  ||| S:40669 E:40676 ||| NN
3  ||| S:40676 E:40686 ||| CD
of  ||| S:40686 E:40689 ||| IN
the  ||| S:40689 E:40693 ||| DT
variable  ||| S:40693 E:40702 ||| JJ
region  ||| S:40702 E:40709 ||| NN
coding  ||| S:40709 E:40716 ||| NN
fragment ||| S:40716 E:40724 ||| NN
.  ||| S:40724 E:40726 ||| .
After  ||| S:40726 E:40732 ||| IN
splicing ||| S:40732 E:40740 ||| NN
,  ||| S:40740 E:40742 ||| ,
the  ||| S:40742 E:40746 ||| DT
variable  ||| S:40746 E:40755 ||| JJ
region  ||| S:40755 E:40762 ||| NN
becomes  ||| S:40762 E:40770 ||| VBZ
fused  ||| S:40770 E:40776 ||| VBN
to  ||| S:40776 E:40779 ||| TO
a  ||| S:40779 E:40781 ||| DT
human  ||| S:40781 E:40787 ||| JJ
kappa  ||| S:40787 E:40793 ||| JJ
constant  ||| S:40793 E:40802 ||| JJ
region  ||| S:40802 E:40809 ||| NN
exon  ||| S:40809 E:40814 ||| NNS
( ||| S:40814 E:40815 ||| -LRB-
see  ||| S:40815 E:40819 ||| VB
FIG.  ||| S:40819 E:40824 ||| CD
7 ||| S:40824 E:40825 ||| CD
) ||| S:40825 E:40826 ||| -RRB-
.  ||| S:40826 E:40828 ||| .
The  ||| S:40828 E:40832 ||| DT
selectable  ||| S:40832 E:40843 ||| JJ
marker  ||| S:40843 E:40850 ||| NN
for  ||| S:40850 E:40854 ||| IN
the  ||| S:40854 E:40858 ||| DT
vector  ||| S:40858 E:40865 ||| NN
in  ||| S:40865 E:40868 ||| IN
mammalian  ||| S:40868 E:40878 ||| JJ
cells  ||| S:40878 E:40884 ||| NNS
is  ||| S:40884 E:40887 ||| VBZ
neomycin  ||| S:40887 E:40896 ||| JJ
( ||| S:40896 E:40897 ||| -LRB-
G418 ||| S:40897 E:40901 ||| NNP
) ||| S:40901 E:40902 ||| -RRB-
.  ||| S:40902 E:40906 ||| .
The  ||| S:41264 E:41276 ||| DT
11E10  ||| S:41276 E:41290 ||| JJ
light  ||| S:41290 E:41296 ||| JJ
chain  ||| S:41296 E:41302 ||| NN
PCR  ||| S:41302 E:41306 ||| NNP
product  ||| S:41306 E:41314 ||| NN
( ||| S:41314 E:41315 ||| -LRB-
approximately  ||| S:41315 E:41329 ||| RB
350  ||| S:41329 E:41333 ||| CD
bp ||| S:41333 E:41335 ||| CD
)  ||| S:41335 E:41337 ||| -RRB-
was  ||| S:41337 E:41341 ||| VBD
cloned  ||| S:41341 E:41348 ||| VBN
into  ||| S:41348 E:41353 ||| IN
the  ||| S:41353 E:41357 ||| DT
T ||| S:41357 E:41358 ||| NN
/ ||| S:41358 E:41359 ||| VBZ
A  ||| S:41359 E:41361 ||| DT
cloning  ||| S:41361 E:41369 ||| JJ
vector  ||| S:41369 E:41376 ||| NN
as  ||| S:41376 E:41379 ||| IN
per  ||| S:41379 E:41383 ||| IN
manufacturer ||| S:41383 E:41395 ||| NN
's  ||| S:41395 E:41398 ||| POS
instructions ||| S:41398 E:41410 ||| NNS
.  ||| S:41410 E:41412 ||| .
The  ||| S:41412 E:41416 ||| DT
resulting  ||| S:41416 E:41426 ||| JJ
clone ||| S:41426 E:41431 ||| NN
,  ||| S:41431 E:41433 ||| ,
pACELC ||| S:41433 E:41439 ||| NNP
,  ||| S:41439 E:41441 ||| ,
was  ||| S:41441 E:41445 ||| VBD
digested  ||| S:41445 E:41454 ||| VBN
with  ||| S:41454 E:41459 ||| IN
EcoRV  ||| S:41459 E:41465 ||| JJ
and  ||| S:41465 E:41469 ||| CC
BstBI  ||| S:41469 E:41475 ||| NNP
( ||| S:41475 E:41476 ||| -LRB-
New  ||| S:41476 E:41480 ||| NNP
England  ||| S:41480 E:41488 ||| NNP
Biolabs ||| S:41488 E:41495 ||| NNP
)  ||| S:41495 E:41497 ||| -RRB-
and  ||| S:41497 E:41501 ||| CC
the  ||| S:41501 E:41505 ||| DT
light  ||| S:41505 E:41511 ||| JJ
chain  ||| S:41511 E:41517 ||| NN
fragment  ||| S:41517 E:41526 ||| NN
was  ||| S:41526 E:41530 ||| VBD
gel-purified ||| S:41530 E:41542 ||| JJ
.  ||| S:41542 E:41544 ||| .
This  ||| S:41544 E:41549 ||| DT
fragment  ||| S:41549 E:41558 ||| NN
was  ||| S:41558 E:41562 ||| VBD
then  ||| S:41562 E:41567 ||| RB
ligated  ||| S:41567 E:41575 ||| VBN
into  ||| S:41575 E:41580 ||| IN
the  ||| S:41580 E:41584 ||| DT
EcoRV ||| S:41584 E:41589 ||| JJ
/ ||| S:41589 E:41590 ||| CD
BstBI  ||| S:41590 E:41596 ||| JJ
digested  ||| S:41596 E:41605 ||| NN
and  ||| S:41605 E:41609 ||| CC
gel-purified  ||| S:41609 E:41622 ||| NNP
pACE1 ||| S:41622 E:41627 ||| NNP
,  ||| S:41627 E:41629 ||| ,
resulting  ||| S:41629 E:41639 ||| VBG
in  ||| S:41639 E:41642 ||| IN
plasmid  ||| S:41642 E:41650 ||| CD
pACE4  ||| S:41650 E:41656 ||| CD
( ||| S:41656 E:41657 ||| -LRB-
see  ||| S:41657 E:41661 ||| VB
FIG.  ||| S:41661 E:41666 ||| CD
7 ||| S:41666 E:41667 ||| CD
) ||| S:41667 E:41668 ||| -RRB-
.  ||| S:41668 E:41670 ||| .
The  ||| S:41670 E:41674 ||| DT
sequence  ||| S:41674 E:41683 ||| NN
of  ||| S:41683 E:41686 ||| IN
the  ||| S:41686 E:41690 ||| DT
heavy  ||| S:41690 E:41696 ||| JJ
and  ||| S:41696 E:41700 ||| CC
light  ||| S:41700 E:41706 ||| JJ
chain  ||| S:41706 E:41712 ||| NN
variable  ||| S:41712 E:41721 ||| NN
regions  ||| S:41721 E:41729 ||| NNS
was  ||| S:41729 E:41733 ||| VBD
verified  ||| S:41733 E:41742 ||| VBN
prior  ||| S:41742 E:41748 ||| RB
to  ||| S:41748 E:41751 ||| TO
mammalian  ||| S:41751 E:41761 ||| VB
cell  ||| S:41761 E:41766 ||| NN
transfection ||| S:41766 E:41778 ||| NN
.  ||| S:41778 E:41781 ||| .
The  ||| S:41840 E:41844 ||| DT
plasmid  ||| S:41844 E:41852 ||| JJ
pJRS315  ||| S:41852 E:41860 ||| NN
is  ||| S:41860 E:41863 ||| VBZ
the  ||| S:41863 E:41867 ||| DT
expression  ||| S:41867 E:41878 ||| NN
plasmid  ||| S:41878 E:41886 ||| NN
into  ||| S:41886 E:41891 ||| IN
which  ||| S:41891 E:41897 ||| WDT
the  ||| S:41897 E:41901 ||| DT
variable  ||| S:41901 E:41910 ||| JJ
regions  ||| S:41910 E:41918 ||| NNS
of  ||| S:41918 E:41921 ||| IN
the  ||| S:41921 E:41925 ||| DT
11E10  ||| S:41925 E:41931 ||| JJ
antibody  ||| S:41931 E:41940 ||| NN
were  ||| S:41940 E:41945 ||| VBD
cloned ||| S:41945 E:41951 ||| VBN
.  ||| S:41951 E:41953 ||| .
This  ||| S:41953 E:41958 ||| DT
plasmid  ||| S:41958 E:41966 ||| NN
is  ||| S:41966 E:41969 ||| VBZ
a  ||| S:41969 E:41971 ||| DT
derivative  ||| S:41971 E:41982 ||| JJ
of  ||| S:41982 E:41985 ||| IN
a  ||| S:41985 E:41987 ||| DT
basic  ||| S:41987 E:41993 ||| JJ
expression  ||| S:41993 E:42004 ||| NN
vector ||| S:42004 E:42010 ||| NN
,  ||| S:42010 E:42012 ||| ,
plasmid  ||| S:42012 E:42020 ||| CD
pSUN15 ||| S:42020 E:42026 ||| CD
,  ||| S:42026 E:42028 ||| ,
that  ||| S:42028 E:42033 ||| WDT
contains  ||| S:42033 E:42042 ||| VBZ
no  ||| S:42042 E:42045 ||| DT
antibody  ||| S:42045 E:42054 ||| NN
variable  ||| S:42054 E:42063 ||| NN
region  ||| S:42063 E:42070 ||| NN
coding  ||| S:42070 E:42077 ||| NN
information ||| S:42077 E:42088 ||| NN
,  ||| S:42088 E:42090 ||| ,
pJRS315  ||| S:42090 E:42098 ||| NNP
was  ||| S:42098 E:42102 ||| VBD
created  ||| S:42102 E:42110 ||| VBN
using  ||| S:42110 E:42116 ||| VBG
DNA  ||| S:42116 E:42120 ||| NN
fragment  ||| S:42120 E:42129 ||| NN
ligations  ||| S:42129 E:42139 ||| NNS
and  ||| S:42139 E:42143 ||| CC
site  ||| S:42143 E:42148 ||| NN
directed  ||| S:42148 E:42157 ||| VBD
mutagenesis  ||| S:42157 E:42169 ||| JJ
steps ||| S:42169 E:42174 ||| NNS
.  ||| S:42174 E:42176 ||| .
The  ||| S:42176 E:42180 ||| DT
result  ||| S:42180 E:42187 ||| NN
was  ||| S:42187 E:42191 ||| VBD
a  ||| S:42191 E:42193 ||| DT
vector  ||| S:42193 E:42200 ||| NN
that  ||| S:42200 E:42205 ||| WDT
expresses  ||| S:42205 E:42215 ||| VBZ
both  ||| S:42215 E:42220 ||| DT
antibody  ||| S:42220 E:42229 ||| NN
chains  ||| S:42229 E:42236 ||| NNS
with  ||| S:42236 E:42241 ||| IN
CMV  ||| S:42241 E:42245 ||| NNP
promoter  ||| S:42245 E:42254 ||| FW
driven  ||| S:42254 E:42261 ||| FW
transcription  ||| S:42261 E:42275 ||| FW
( ||| S:42275 E:42276 ||| -LRB-
see  ||| S:42276 E:42280 ||| VB
FIG.  ||| S:42280 E:42285 ||| CD
17 ||| S:42285 E:42287 ||| CD
) ||| S:42287 E:42288 ||| -RRB-
.  ||| S:42288 E:42290 ||| .
Neomycin  ||| S:42290 E:42299 ||| JJ
resistance  ||| S:42299 E:42310 ||| NN
serves  ||| S:42310 E:42317 ||| VBZ
as  ||| S:42317 E:42320 ||| IN
the  ||| S:42320 E:42324 ||| DT
dominant  ||| S:42324 E:42333 ||| JJ
selectable  ||| S:42333 E:42344 ||| JJ
marker  ||| S:42344 E:42351 ||| NN
for  ||| S:42351 E:42355 ||| IN
transfection  ||| S:42355 E:42368 ||| NN
of  ||| S:42368 E:42371 ||| IN
mammalian  ||| S:42371 E:42381 ||| JJ
cells ||| S:42381 E:42386 ||| NNS
.  ||| S:42386 E:42388 ||| .
In  ||| S:42388 E:42391 ||| IN
addition ||| S:42391 E:42399 ||| NN
,  ||| S:42399 E:42401 ||| ,
it  ||| S:42401 E:42404 ||| PRP
has  ||| S:42404 E:42408 ||| VBZ
been  ||| S:42408 E:42413 ||| VBN
designed  ||| S:42413 E:42422 ||| VBN
to  ||| S:42422 E:42425 ||| TO
allow  ||| S:42425 E:42431 ||| VB
convenient  ||| S:42431 E:42442 ||| JJ
cloning  ||| S:42442 E:42450 ||| NN
of  ||| S:42450 E:42453 ||| IN
any  ||| S:42453 E:42457 ||| DT
light  ||| S:42457 E:42463 ||| JJ
chain  ||| S:42463 E:42469 ||| NN
variable  ||| S:42469 E:42478 ||| NN
region  ||| S:42478 E:42485 ||| NN
as  ||| S:42485 E:42488 ||| IN
an  ||| S:42488 E:42491 ||| DT
EcoRV ||| S:42491 E:42496 ||| JJ
/ ||| S:42496 E:42497 ||| CD
BstBI  ||| S:42497 E:42503 ||| JJ
fragment ||| S:42503 E:42511 ||| NN
,  ||| S:42511 E:42513 ||| ,
any  ||| S:42513 E:42517 ||| DT
heavy  ||| S:42517 E:42523 ||| JJ
chain  ||| S:42523 E:42529 ||| NN
variable  ||| S:42529 E:42538 ||| NN
region  ||| S:42538 E:42545 ||| NN
as  ||| S:42545 E:42548 ||| IN
a  ||| S:42548 E:42550 ||| DT
NruI ||| S:42550 E:42554 ||| JJ
/ ||| S:42554 E:42555 ||| CD
EcoRI  ||| S:42555 E:42561 ||| JJ
fragment ||| S:42561 E:42569 ||| NN
,  ||| S:42569 E:42571 ||| ,
and  ||| S:42571 E:42575 ||| CC
any  ||| S:42575 E:42579 ||| DT
heavy  ||| S:42579 E:42585 ||| JJ
chain  ||| S:42585 E:42591 ||| NN
constant  ||| S:42591 E:42600 ||| JJ
domain  ||| S:42600 E:42607 ||| NN
as  ||| S:42607 E:42610 ||| IN
an  ||| S:42610 E:42613 ||| DT
EcoRI ||| S:42613 E:42618 ||| JJ
/ ||| S:42618 E:42619 ||| CD
NotI  ||| S:42619 E:42624 ||| JJ
fragment ||| S:42624 E:42632 ||| NN
.  ||| S:42632 E:42634 ||| .
These  ||| S:42634 E:42640 ||| DT
restriction  ||| S:42640 E:42652 ||| NN
sites  ||| S:42652 E:42658 ||| NNS
were  ||| S:42658 E:42663 ||| VBD
chosen  ||| S:42663 E:42670 ||| VBN
because  ||| S:42670 E:42678 ||| IN
they  ||| S:42678 E:42683 ||| PRP
occur  ||| S:42683 E:42689 ||| VBP
rarely  ||| S:42689 E:42696 ||| RB
( ||| S:42696 E:42697 ||| -LRB-
if  ||| S:42697 E:42700 ||| IN
ever ||| S:42700 E:42704 ||| RB
)  ||| S:42704 E:42706 ||| -RRB-
in  ||| S:42706 E:42709 ||| IN
human  ||| S:42709 E:42715 ||| JJ
and  ||| S:42715 E:42719 ||| CC
mouse  ||| S:42719 E:42725 ||| JJ
variable  ||| S:42725 E:42734 ||| JJ
regions ||| S:42734 E:42741 ||| NNS
.  ||| S:42741 E:42743 ||| .
There  ||| S:42743 E:42749 ||| EX
is  ||| S:42749 E:42752 ||| VBZ
a  ||| S:42752 E:42754 ||| DT
mouse  ||| S:42754 E:42760 ||| NN
J  ||| S:42760 E:42762 ||| NNP
region ||| S:42762 E:42768 ||| FW
/ ||| S:42768 E:42769 ||| FW
kappa  ||| S:42769 E:42775 ||| FW
intron  ||| S:42775 E:42782 ||| FW
fragment  ||| S:42782 E:42791 ||| FW
fused  ||| S:42791 E:42797 ||| FW
to  ||| S:42797 E:42800 ||| TO
a  ||| S:42800 E:42802 ||| DT
human  ||| S:42802 E:42808 ||| JJ
kappa  ||| S:42808 E:42814 ||| NNS
exon  ||| S:42814 E:42819 ||| VBP
so  ||| S:42819 E:42822 ||| RB
that  ||| S:42822 E:42827 ||| IN
after  ||| S:42827 E:42833 ||| IN
post-transcriptional  ||| S:42833 E:42854 ||| FW
splicing  ||| S:42854 E:42863 ||| FW
a  ||| S:42863 E:42865 ||| FW
mouse ||| S:42865 E:42870 ||| FW
/ ||| S:42870 E:42871 ||| FW
human  ||| S:42871 E:42877 ||| FW
chimeric  ||| S:42877 E:42886 ||| FW
kappa  ||| S:42886 E:42892 ||| FW
light  ||| S:42892 E:42898 ||| JJ
chain  ||| S:42898 E:42904 ||| NN
is  ||| S:42904 E:42907 ||| VBZ
produced ||| S:42907 E:42915 ||| VBN
.  ||| S:42915 E:42919 ||| .
A  ||| S:45310 E:45312 ||| DT
BglII ||| S:45312 E:45317 ||| JJ
/ ||| S:45317 E:45318 ||| CD
NheI  ||| S:45318 E:45323 ||| JJ
fragment  ||| S:45323 E:45332 ||| NN
from  ||| S:45332 E:45337 ||| IN
the  ||| S:45337 E:45341 ||| DT
human  ||| S:45341 E:45347 ||| JJ
heavy  ||| S:45347 E:45353 ||| JJ
chain  ||| S:45353 E:45359 ||| NN
vector  ||| S:45359 E:45366 ||| NN
was  ||| S:45366 E:45370 ||| VBD
then  ||| S:45370 E:45375 ||| RB
cloned  ||| S:45375 E:45382 ||| VBN
into  ||| S:45382 E:45387 ||| IN
the  ||| S:45387 E:45391 ||| DT
human  ||| S:45391 E:45397 ||| JJ
light  ||| S:45397 E:45403 ||| JJ
chain  ||| S:45403 E:45409 ||| NN
vector  ||| S:45409 E:45416 ||| NN
cut  ||| S:45416 E:45420 ||| NN
with  ||| S:45420 E:45425 ||| IN
BamHI ||| S:45425 E:45430 ||| JJ
/ ||| S:45430 E:45431 ||| CD
NheI  ||| S:45431 E:45436 ||| JJ
to  ||| S:45436 E:45439 ||| TO
create  ||| S:45439 E:45446 ||| VB
pSUN15  ||| S:45446 E:45453 ||| NNP
( ||| S:45453 E:45454 ||| -LRB-
see  ||| S:45454 E:45458 ||| VB
FIG.  ||| S:45458 E:45463 ||| CD
16 ||| S:45463 E:45465 ||| CD
) ||| S:45465 E:45466 ||| -RRB-
.  ||| S:45466 E:45470 ||| .
A.  ||| S:46361 E:46364 ||| NNP
Transfection  ||| S:46364 E:46377 ||| NNP
of  ||| S:46377 E:46380 ||| IN
NSO  ||| S:46380 E:46384 ||| NNP
Cells  ||| S:46384 E:46392 ||| NNPS
B.  ||| S:47350 E:47353 ||| NNP
Assay  ||| S:47353 E:47359 ||| NNP
for  ||| S:47359 E:47363 ||| IN
Antibody  ||| S:47363 E:47372 ||| NNP
Production  ||| S:47372 E:47385 ||| NNPS
Together ||| S:49346 E:49354 ||| RB
,  ||| S:49354 E:49356 ||| ,
these  ||| S:49356 E:49362 ||| DT
assays  ||| S:49362 E:49369 ||| JJ
demonstrate  ||| S:49369 E:49381 ||| NN
that  ||| S:49381 E:49386 ||| IN
the  ||| S:49386 E:49390 ||| DT
transfection  ||| S:49390 E:49403 ||| NN
of  ||| S:49403 E:49406 ||| IN
cells  ||| S:49406 E:49412 ||| NNS
with  ||| S:49412 E:49417 ||| IN
this  ||| S:49417 E:49422 ||| DT
plasmid  ||| S:49422 E:49430 ||| JJ
construct  ||| S:49430 E:49440 ||| NN
can  ||| S:49440 E:49444 ||| MD
result  ||| S:49444 E:49451 ||| VB
in  ||| S:49451 E:49454 ||| IN
the  ||| S:49454 E:49458 ||| DT
production  ||| S:49458 E:49469 ||| NN
of  ||| S:49469 E:49472 ||| IN
a  ||| S:49472 E:49474 ||| DT
stable  ||| S:49474 E:49481 ||| JJ
cell  ||| S:49481 E:49486 ||| NN
line  ||| S:49486 E:49491 ||| NN
that  ||| S:49491 E:49496 ||| WDT
produces  ||| S:49496 E:49505 ||| VBZ
a  ||| S:49505 E:49507 ||| DT
humanized  ||| S:49507 E:49517 ||| JJ
chimeric  ||| S:49517 E:49526 ||| JJ
version  ||| S:49526 E:49534 ||| NN
of  ||| S:49534 E:49537 ||| IN
the  ||| S:49537 E:49541 ||| DT
11E10  ||| S:49541 E:49547 ||| JJ
mouse  ||| S:49547 E:49553 ||| NN
hybridoma  ||| S:49553 E:49563 ||| NN
antibody ||| S:49563 E:49571 ||| NN
.  ||| S:49571 E:49574 ||| .
A.  ||| S:49674 E:49677 ||| NNP
Vero  ||| S:49677 E:49682 ||| NNP
Cell  ||| S:49682 E:49687 ||| NNP
Cytotoxicity  ||| S:49687 E:49700 ||| NNP
Assay  ||| S:49700 E:49708 ||| NNPS
B.  ||| S:50974 E:50977 ||| NNP
Antisera  ||| S:50977 E:50986 ||| NNP
Neutralization  ||| S:50986 E:51001 ||| NNP
Assay  ||| S:51001 E:51009 ||| NNPS
Humanized  ||| S:51009 E:51019 ||| JJ
mouse  ||| S:51019 E:51025 ||| NN
antibodies  ||| S:51025 E:51036 ||| NNS
obtained  ||| S:51036 E:51045 ||| VBD
according  ||| S:51045 E:51055 ||| VBG
to  ||| S:51055 E:51058 ||| TO
the  ||| S:51058 E:51062 ||| DT
methods  ||| S:51062 E:51070 ||| NNS
described  ||| S:51070 E:51080 ||| VBN
in  ||| S:51080 E:51083 ||| IN
Examples  ||| S:51083 E:51092 ||| NNP
1  ||| S:51092 E:51094 ||| CD
through  ||| S:51094 E:51102 ||| IN
6  ||| S:51102 E:51104 ||| CD
were  ||| S:51104 E:51109 ||| VBD
tested  ||| S:51109 E:51116 ||| VBN
for  ||| S:51116 E:51120 ||| IN
toxin  ||| S:51120 E:51126 ||| NN
neutralization ||| S:51126 E:51140 ||| NN
.  ||| S:51140 E:51142 ||| .
Neutralization  ||| S:51142 E:51157 ||| NN
of  ||| S:51157 E:51160 ||| IN
cytotoxic  ||| S:51160 E:51170 ||| JJ
activity  ||| S:51170 E:51179 ||| NN
was  ||| S:51179 E:51183 ||| VBD
described  ||| S:51183 E:51193 ||| VBN
in  ||| S:51193 E:51196 ||| IN
great  ||| S:51196 E:51202 ||| JJ
detail  ||| S:51202 E:51209 ||| NN
in  ||| S:51209 E:51212 ||| IN
Schmitt  ||| S:51212 E:51220 ||| NNP
et  ||| S:51220 E:51223 ||| NNP
al. ||| S:51223 E:51226 ||| NNP
,  ||| S:51226 E:51228 ||| ,
Infect.  ||| S:51228 E:51236 ||| NNP
and  ||| S:51236 E:51240 ||| CC
Immun. ||| S:51240 E:51246 ||| NNP
,  ||| S:51246 E:51248 ||| ,
59 ||| S:51248 E:51250 ||| CD
: ||| S:51250 E:51251 ||| :
1065-1073  ||| S:51251 E:51261 ||| CD
( ||| S:51261 E:51262 ||| -LRB-
1991 ||| S:51262 E:51266 ||| CD
) ||| S:51266 E:51267 ||| -RRB-
.  ||| S:51267 E:51269 ||| .
Briefly ||| S:51269 E:51276 ||| RB
,  ||| S:51276 E:51278 ||| ,
lysates  ||| S:51278 E:51286 ||| NN
were  ||| S:51286 E:51291 ||| VBD
incubated  ||| S:51291 E:51301 ||| VBN
with  ||| S:51301 E:51306 ||| IN
serial  ||| S:51306 E:51313 ||| JJ
dilutions  ||| S:51313 E:51323 ||| NN
of  ||| S:51323 E:51326 ||| IN
the  ||| S:51326 E:51330 ||| DT
humanized  ||| S:51330 E:51340 ||| JJ
mouse  ||| S:51340 E:51346 ||| NN
antibodies  ||| S:51346 E:51357 ||| NNS
at  ||| S:51357 E:51360 ||| IN
37  ||| S:51360 E:51369 ||| CD
C.  ||| S:51369 E:51372 ||| NNP
for  ||| S:51372 E:51376 ||| IN
2  ||| S:51376 E:51378 ||| CD
hours ||| S:51378 E:51383 ||| NNS
.  ||| S:51383 E:51385 ||| .
One  ||| S:51385 E:51389 ||| CD
hundred  ||| S:51389 E:51397 ||| CD
microliters  ||| S:51397 E:51409 ||| NN
of  ||| S:51409 E:51412 ||| IN
the  ||| S:51412 E:51416 ||| DT
samples  ||| S:51416 E:51424 ||| NNS
were  ||| S:51424 E:51429 ||| VBD
then  ||| S:51429 E:51434 ||| RB
added  ||| S:51434 E:51440 ||| VBD
to  ||| S:51440 E:51443 ||| TO
Vero  ||| S:51443 E:51448 ||| NNP
cells  ||| S:51448 E:51454 ||| NNS
as  ||| S:51454 E:51457 ||| RB
described  ||| S:51457 E:51467 ||| VBN
above ||| S:51467 E:51472 ||| IN
.  ||| S:51472 E:51482 ||| .
TABLE  ||| S:51482 E:51488 ||| NN
1  ||| S:51488 E:51500 ||| LS
Vero  ||| S:51500 E:51505 ||| NNP
Cell  ||| S:51505 E:51510 ||| NNP
Neutralization  ||| S:51510 E:51525 ||| NNP
Assay  ||| S:51525 E:51541 ||| NNPS
A.  ||| S:51773 E:51776 ||| NNP
Protection  ||| S:51776 E:51787 ||| NNP
Against  ||| S:51787 E:51795 ||| NNP
Injection  ||| S:51795 E:51805 ||| NNP
with  ||| S:51805 E:51810 ||| IN
Crude  ||| S:51810 E:51816 ||| NNP
Stx1  ||| S:51816 E:51821 ||| NNP
Toxin ||| S:51821 E:51826 ||| NNP
.  ||| S:51826 E:51830 ||| .
The  ||| S:52389 E:52393 ||| DT
results  ||| S:52393 E:52401 ||| NNS
( ||| S:52401 E:52402 ||| -LRB-
Table  ||| S:52402 E:52408 ||| NNP
2 ||| S:52408 E:52409 ||| CD
)  ||| S:52409 E:52411 ||| -RRB-
show  ||| S:52411 E:52416 ||| VBP
clearly  ||| S:52416 E:52424 ||| RB
that  ||| S:52424 E:52429 ||| IN
the  ||| S:52429 E:52433 ||| DT
injected  ||| S:52433 E:52442 ||| JJ
antibodies  ||| S:52442 E:52453 ||| NNS
protect  ||| S:52453 E:52461 ||| VB
the  ||| S:52461 E:52465 ||| DT
mice  ||| S:52465 E:52470 ||| NNS
against  ||| S:52470 E:52478 ||| IN
at  ||| S:52478 E:52481 ||| IN
least  ||| S:52481 E:52487 ||| JJS
10  ||| S:52487 E:52490 ||| CD
times  ||| S:52490 E:52496 ||| NNS
the  ||| S:52496 E:52500 ||| DT
normal  ||| S:52500 E:52507 ||| JJ
lethal  ||| S:52507 E:52514 ||| JJ
toxin  ||| S:52514 E:52520 ||| NN
dose ||| S:52520 E:52524 ||| NN
.  ||| S:52524 E:52526 ||| .
As  ||| S:52526 E:52529 ||| IN
a  ||| S:52529 E:52531 ||| DT
negative  ||| S:52531 E:52540 ||| JJ
control ||| S:52540 E:52547 ||| NN
,  ||| S:52547 E:52549 ||| ,
the  ||| S:52549 E:52553 ||| DT
antibodies  ||| S:52553 E:52564 ||| NNS
to  ||| S:52564 E:52567 ||| TO
Stx2  ||| S:52567 E:52572 ||| NNP
did  ||| S:52572 E:52576 ||| VBD
not  ||| S:52576 E:52580 ||| RB
protect  ||| S:52580 E:52588 ||| VB
against  ||| S:52588 E:52596 ||| IN
Stx1  ||| S:52596 E:52601 ||| CD
toxin  ||| S:52601 E:52607 ||| NN
challenge ||| S:52607 E:52616 ||| NN
,  ||| S:52616 E:52618 ||| ,
indicating  ||| S:52618 E:52629 ||| VBG
that  ||| S:52629 E:52634 ||| IN
the  ||| S:52634 E:52638 ||| DT
protection  ||| S:52638 E:52649 ||| NN
was  ||| S:52649 E:52653 ||| VBD
specific  ||| S:52653 E:52662 ||| JJ
to  ||| S:52662 E:52665 ||| TO
the  ||| S:52665 E:52669 ||| DT
toxin ||| S:52669 E:52674 ||| NN
/ ||| S:52674 E:52675 ||| CD
antibody  ||| S:52675 E:52684 ||| NN
pair ||| S:52684 E:52688 ||| NN
,  ||| S:52688 E:52690 ||| ,
and  ||| S:52690 E:52694 ||| CC
was  ||| S:52694 E:52698 ||| VBD
not  ||| S:52698 E:52702 ||| RB
an  ||| S:52702 E:52705 ||| DT
artifact  ||| S:52705 E:52714 ||| NN
of  ||| S:52714 E:52717 ||| IN
the  ||| S:52717 E:52721 ||| DT
antibody  ||| S:52721 E:52730 ||| NN
preparation  ||| S:52730 E:52742 ||| NN
process ||| S:52742 E:52749 ||| NN
.  ||| S:52749 E:52759 ||| .
TABLE  ||| S:52759 E:52765 ||| NN
2  ||| S:52765 E:52777 ||| LS
CD-1  ||| S:52777 E:52782 ||| NNP
Mice  ||| S:52782 E:52787 ||| NNP
Injected  ||| S:52787 E:52796 ||| NNP
Intravenously  ||| S:52796 E:52810 ||| NNP
with  ||| S:52810 E:52815 ||| IN
Crude  ||| S:52815 E:52821 ||| NNP
Stx1  ||| S:52821 E:52844 ||| FW
to  ||| S:52859 E:52862 ||| TO
Protect  ||| S:52862 E:52870 ||| NNP
from  ||| S:52870 E:52877 ||| IN
B.  ||| S:53106 E:53109 ||| NNP
Protection  ||| S:53109 E:53120 ||| NNP
Against  ||| S:53120 E:53128 ||| NNP
Oral  ||| S:53128 E:53133 ||| NNP
Infection  ||| S:53133 E:53143 ||| NNP
with  ||| S:53143 E:53148 ||| IN
Stx2-Producing  ||| S:53148 E:53163 ||| NNP
EHEC  ||| S:53163 E:53168 ||| NNP
Strains ||| S:53168 E:53175 ||| NNP
.  ||| S:53175 E:53180 ||| .
As  ||| S:54603 E:54606 ||| RB
shown  ||| S:54606 E:54612 ||| VBN
in  ||| S:54612 E:54615 ||| IN
Table  ||| S:54615 E:54621 ||| NNP
3 ||| S:54621 E:54622 ||| CD
,  ||| S:54622 E:54624 ||| ,
immunization  ||| S:54624 E:54637 ||| VBG
of  ||| S:54637 E:54640 ||| IN
the  ||| S:54640 E:54644 ||| DT
mice  ||| S:54644 E:54649 ||| NNS
with  ||| S:54649 E:54654 ||| IN
the  ||| S:54654 E:54658 ||| DT
either  ||| S:54658 E:54665 ||| RB
the  ||| S:54665 E:54669 ||| DT
murine  ||| S:54669 E:54676 ||| NN
or  ||| S:54676 E:54679 ||| CC
the  ||| S:54679 E:54683 ||| DT
humanized  ||| S:54683 E:54693 ||| JJ
anti-Stx2  ||| S:54693 E:54703 ||| CD
antibodies  ||| S:54703 E:54714 ||| NNS
resulted  ||| S:54714 E:54723 ||| VBD
in  ||| S:54723 E:54726 ||| IN
complete  ||| S:54726 E:54735 ||| JJ
protection  ||| S:54735 E:54746 ||| NN
from  ||| S:54746 E:54751 ||| IN
a  ||| S:54751 E:54753 ||| DT
lethal  ||| S:54753 E:54760 ||| JJ
oral  ||| S:54760 E:54765 ||| JJ
dose  ||| S:54765 E:54770 ||| NN
of  ||| S:54770 E:54773 ||| IN
EHEC ||| S:54773 E:54777 ||| NNP
.  ||| S:54777 E:54779 ||| .
Immunization  ||| S:54779 E:54792 ||| NNP
with  ||| S:54792 E:54797 ||| IN
mouse  ||| S:54797 E:54803 ||| CD
13C4  ||| S:54803 E:54808 ||| CD
antibody ||| S:54808 E:54816 ||| NN
,  ||| S:54816 E:54818 ||| ,
prepared  ||| S:54818 E:54827 ||| VBN
in  ||| S:54827 E:54830 ||| IN
the  ||| S:54830 E:54834 ||| DT
same  ||| S:54834 E:54839 ||| JJ
way  ||| S:54839 E:54843 ||| NN
but  ||| S:54843 E:54847 ||| CC
immunoreactive  ||| S:54847 E:54862 ||| NN
with  ||| S:54862 E:54867 ||| IN
the  ||| S:54867 E:54871 ||| DT
Stx1  ||| S:54871 E:54876 ||| JJ
toxin  ||| S:54876 E:54882 ||| NN
instead  ||| S:54882 E:54890 ||| RB
of  ||| S:54890 E:54893 ||| IN
the  ||| S:54893 E:54897 ||| DT
Stx2  ||| S:54897 E:54902 ||| JJ
toxin  ||| S:54902 E:54908 ||| NN
did  ||| S:54908 E:54912 ||| VBD
not  ||| S:54912 E:54916 ||| RB
protect  ||| S:54916 E:54924 ||| VB
the  ||| S:54924 E:54928 ||| DT
mice  ||| S:54928 E:54933 ||| NNS
from  ||| S:54933 E:54938 ||| IN
challenge  ||| S:54938 E:54948 ||| NN
with  ||| S:54948 E:54953 ||| IN
86-24 ||| S:54953 E:54958 ||| NNP
,  ||| S:54958 E:54960 ||| ,
a  ||| S:54960 E:54962 ||| DT
result  ||| S:54962 E:54969 ||| NN
that  ||| S:54969 E:54974 ||| WDT
indicates  ||| S:54974 E:54984 ||| VBZ
the  ||| S:54984 E:54988 ||| DT
immunospecificity  ||| S:54988 E:55006 ||| NN
of  ||| S:55006 E:55009 ||| IN
the  ||| S:55009 E:55013 ||| DT
response ||| S:55013 E:55021 ||| NN
.  ||| S:55021 E:55031 ||| .
TABLE  ||| S:55031 E:55037 ||| NN
3  ||| S:55037 E:55049 ||| LS
Similar  ||| S:55250 E:55258 ||| JJ
results  ||| S:55258 E:55266 ||| NNS
are  ||| S:55266 E:55270 ||| VBP
illustrated  ||| S:55270 E:55282 ||| VBN
in  ||| S:55282 E:55285 ||| IN
Table  ||| S:55285 E:55291 ||| NNP
4 ||| S:55291 E:55292 ||| CD
,  ||| S:55292 E:55294 ||| ,
where  ||| S:55294 E:55300 ||| WRB
the  ||| S:55300 E:55304 ||| DT
more  ||| S:55304 E:55309 ||| RBR
resistant  ||| S:55309 E:55319 ||| JJ
CD-1  ||| S:55319 E:55324 ||| CD
mice  ||| S:55324 E:55329 ||| NNS
were  ||| S:55329 E:55334 ||| VBD
fed  ||| S:55334 E:55338 ||| VBN
the  ||| S:55338 E:55342 ||| DT
B2F1  ||| S:55342 E:55347 ||| NNP
E.  ||| S:55347 E:55350 ||| NNP
coli  ||| S:55350 E:55355 ||| JJ
strain  ||| S:55355 E:55362 ||| NN
which  ||| S:55362 E:55368 ||| WDT
produces  ||| S:55368 E:55377 ||| VBZ
Stx2-variant  ||| S:55377 E:55390 ||| CD
toxin ||| S:55390 E:55395 ||| NN
.  ||| S:55395 E:55397 ||| .
Without  ||| S:55397 E:55405 ||| IN
treatment  ||| S:55405 E:55415 ||| NN
with  ||| S:55415 E:55420 ||| IN
antibody ||| S:55420 E:55428 ||| NN
,  ||| S:55428 E:55430 ||| ,
mortality  ||| S:55430 E:55440 ||| NN
was  ||| S:55440 E:55444 ||| VBD
total ||| S:55444 E:55449 ||| JJ
,  ||| S:55449 E:55451 ||| ,
but  ||| S:55451 E:55455 ||| CC
both  ||| S:55455 E:55460 ||| PDT
the  ||| S:55460 E:55464 ||| DT
mouse  ||| S:55464 E:55470 ||| NN
and  ||| S:55470 E:55474 ||| CC
the  ||| S:55474 E:55478 ||| DT
humanized  ||| S:55478 E:55488 ||| JJ
antibodies  ||| S:55488 E:55499 ||| NNS
protected  ||| S:55499 E:55509 ||| VBN
against  ||| S:55509 E:55517 ||| IN
Stx2-variant  ||| S:55517 E:55530 ||| CD
in  ||| S:55530 E:55533 ||| IN
a  ||| S:55533 E:55535 ||| DT
dose  ||| S:55535 E:55540 ||| JJ
dependent  ||| S:55540 E:55550 ||| JJ
manner ||| S:55550 E:55556 ||| NN
.  ||| S:55556 E:55566 ||| .
TABLE  ||| S:55566 E:55572 ||| NN
4  ||| S:55572 E:55584 ||| LS
The  ||| S:56013 E:56017 ||| DT
subject  ||| S:56017 E:56025 ||| JJ
invention  ||| S:56025 E:56035 ||| NN
also  ||| S:56035 E:56040 ||| RB
provides  ||| S:56040 E:56049 ||| VBZ
for  ||| S:56049 E:56053 ||| IN
a  ||| S:56053 E:56055 ||| DT
variety  ||| S:56055 E:56063 ||| NN
of  ||| S:56063 E:56066 ||| IN
methods  ||| S:56066 E:56074 ||| NNS
of  ||| S:56074 E:56077 ||| IN
treating ||| S:56077 E:56085 ||| VBG
,  ||| S:56085 E:56087 ||| ,
ameliorating ||| S:56087 E:56099 ||| NN
,  ||| S:56099 E:56101 ||| ,
or  ||| S:56101 E:56104 ||| CC
preventing ||| S:56104 E:56114 ||| VBG
,  ||| S:56114 E:56116 ||| ,
the  ||| S:56116 E:56120 ||| DT
diseases  ||| S:56120 E:56129 ||| NNS
and  ||| S:56129 E:56133 ||| CC
effects  ||| S:56133 E:56141 ||| NNS
associated  ||| S:56141 E:56152 ||| VBN
with  ||| S:56152 E:56157 ||| IN
exposure  ||| S:56157 E:56166 ||| NN
to  ||| S:56166 E:56169 ||| TO
Shiga  ||| S:56169 E:56175 ||| NNP
toxin ||| S:56175 E:56180 ||| NN
.  ||| S:56180 E:56182 ||| .
Positive  ||| S:56182 E:56191 ||| JJ
clinical  ||| S:56191 E:56200 ||| JJ
responses  ||| S:56200 E:56210 ||| NNS
in  ||| S:56210 E:56213 ||| IN
humans  ||| S:56213 E:56220 ||| NNS
have  ||| S:56220 E:56225 ||| VBP
been  ||| S:56225 E:56230 ||| VBN
obtained  ||| S:56230 E:56239 ||| VBN
with  ||| S:56239 E:56244 ||| IN
monoclonal  ||| S:56244 E:56255 ||| JJ
antibodies ||| S:56255 E:56265 ||| NNS
,  ||| S:56265 E:56267 ||| ,
and  ||| S:56267 E:56271 ||| CC
one  ||| S:56271 E:56275 ||| CD
skilled  ||| S:56275 E:56283 ||| NN
in  ||| S:56283 E:56286 ||| IN
the  ||| S:56286 E:56290 ||| DT
art  ||| S:56290 E:56294 ||| NN
would  ||| S:56294 E:56300 ||| MD
know  ||| S:56300 E:56305 ||| VB
how  ||| S:56305 E:56309 ||| WRB
to  ||| S:56309 E:56312 ||| TO
employ  ||| S:56312 E:56319 ||| VB
anti-Stx  ||| S:56319 E:56328 ||| JJ
humanized  ||| S:56328 E:56338 ||| JJ
monoclonal  ||| S:56338 E:56349 ||| JJ
antibodies  ||| S:56349 E:56360 ||| NNS
in  ||| S:56360 E:56363 ||| IN
humans ||| S:56363 E:56369 ||| NNS
.  ||| S:56369 E:56371 ||| .
( ||| S:56371 E:56372 ||| -LRB-
See  ||| S:56372 E:56376 ||| FW
Fagerberg  ||| S:56376 E:56386 ||| FW
et  ||| S:56386 E:56389 ||| FW
al. ||| S:56389 E:56392 ||| FW
,  ||| S:56392 E:56394 ||| ,
Cancer  ||| S:56394 E:56401 ||| NNP
Research ||| S:56401 E:56409 ||| NNP
,  ||| S:56409 E:56411 ||| ,
55 ||| S:56411 E:56413 ||| CD
: ||| S:56413 E:56414 ||| :
1824-27  ||| S:56414 E:56422 ||| CD
( ||| S:56422 E:56423 ||| -LRB-
1995 ||| S:56423 E:56427 ||| CD
) ||| S:56427 E:56428 ||| -RRB-
;  ||| S:56428 E:56430 ||| :
Eur ||| S:56430 E:56433 ||| NNP
.  ||| S:56433 E:56435 ||| .
J.  ||| S:56435 E:56438 ||| NNP
Cancer ||| S:56438 E:56444 ||| NNP
,  ||| S:56444 E:56446 ||| ,
2 ||| S:56446 E:56447 ||| CD
: ||| S:56447 E:56448 ||| :
261-267  ||| S:56448 E:56456 ||| CD
( ||| S:56456 E:56457 ||| -LRB-
1995 ||| S:56457 E:56461 ||| CD
) ||| S:56461 E:56462 ||| -RRB-
) ||| S:56462 E:56463 ||| -RRB-
.  ||| S:56463 E:56465 ||| .
The  ||| S:56465 E:56469 ||| DT
precise  ||| S:56469 E:56477 ||| JJ
dosage  ||| S:56477 E:56484 ||| NN
of  ||| S:56484 E:56487 ||| IN
humanized  ||| S:56487 E:56497 ||| JJ
anti-Shiga  ||| S:56497 E:56508 ||| JJ
toxin  ||| S:56508 E:56514 ||| NN
antibody  ||| S:56514 E:56523 ||| NN
administered  ||| S:56523 E:56536 ||| VBN
to  ||| S:56536 E:56539 ||| TO
a  ||| S:56539 E:56541 ||| DT
patient  ||| S:56541 E:56549 ||| NN
for  ||| S:56549 E:56553 ||| IN
treatment  ||| S:56553 E:56563 ||| NN
of  ||| S:56563 E:56566 ||| IN
these  ||| S:56566 E:56572 ||| DT
diseases  ||| S:56572 E:56581 ||| NNS
will  ||| S:56581 E:56586 ||| MD
vary  ||| S:56586 E:56591 ||| VB
in  ||| S:56591 E:56594 ||| IN
accordance  ||| S:56594 E:56605 ||| NN
with  ||| S:56605 E:56610 ||| IN
factors  ||| S:56610 E:56618 ||| NNS
appreciated  ||| S:56618 E:56630 ||| VBN
by  ||| S:56630 E:56633 ||| IN
the  ||| S:56633 E:56637 ||| DT
typical  ||| S:56637 E:56645 ||| JJ
clinician ||| S:56645 E:56654 ||| NN
.  ||| S:56654 E:56656 ||| .
These  ||| S:56656 E:56662 ||| DT
factors  ||| S:56662 E:56670 ||| NNS
include  ||| S:56670 E:56678 ||| VBP
( ||| S:56678 E:56679 ||| -LRB-
but  ||| S:56679 E:56683 ||| CC
are  ||| S:56683 E:56687 ||| VBP
not  ||| S:56687 E:56691 ||| RB
limited  ||| S:56691 E:56699 ||| VBN
to ||| S:56699 E:56701 ||| TO
)  ||| S:56701 E:56703 ||| -RRB-
size ||| S:56703 E:56707 ||| NN
,  ||| S:56707 E:56709 ||| ,
age ||| S:56709 E:56712 ||| NN
,  ||| S:56712 E:56714 ||| ,
overall  ||| S:56714 E:56722 ||| JJ
health ||| S:56722 E:56728 ||| NN
,  ||| S:56728 E:56730 ||| ,
the  ||| S:56730 E:56734 ||| DT
extent  ||| S:56734 E:56741 ||| NN
of  ||| S:56741 E:56744 ||| IN
infection ||| S:56744 E:56753 ||| NN
,  ||| S:56753 E:56755 ||| ,
and  ||| S:56755 E:56759 ||| CC
other  ||| S:56759 E:56765 ||| JJ
medications  ||| S:56765 E:56777 ||| NNS
being  ||| S:56777 E:56783 ||| VBG
administered  ||| S:56783 E:56796 ||| VBN
to  ||| S:56796 E:56799 ||| TO
said  ||| S:56799 E:56804 ||| VBD
patient ||| S:56804 E:56811 ||| NN
.  ||| S:56811 E:56813 ||| .
The  ||| S:56813 E:56817 ||| DT
development  ||| S:56817 E:56829 ||| NN
of  ||| S:56829 E:56832 ||| IN
a  ||| S:56832 E:56834 ||| DT
precise  ||| S:56834 E:56842 ||| JJ
treatment  ||| S:56842 E:56852 ||| NN
regimen  ||| S:56852 E:56860 ||| NN
will  ||| S:56860 E:56865 ||| MD
require  ||| S:56865 E:56873 ||| VB
optimization  ||| S:56873 E:56886 ||| VBN
through  ||| S:56886 E:56894 ||| IN
routine  ||| S:56894 E:56902 ||| JJ
medical  ||| S:56902 E:56910 ||| JJ
procedures  ||| S:56910 E:56921 ||| NNS
well  ||| S:56921 E:56926 ||| RB
known  ||| S:56926 E:56932 ||| VBN
to  ||| S:56932 E:56935 ||| TO
those  ||| S:56935 E:56941 ||| DT
in  ||| S:56941 E:56944 ||| IN
the  ||| S:56944 E:56948 ||| DT
medical  ||| S:56948 E:56956 ||| JJ
arts ||| S:56956 E:56960 ||| NNS
.  ||| S:56960 E:56962 ||| .
Examples  ||| S:56962 E:56971 ||| NNS
of  ||| S:56971 E:56974 ||| IN
potential  ||| S:56974 E:56984 ||| JJ
patient  ||| S:56984 E:56992 ||| NN
groups  ||| S:56992 E:56999 ||| NNS
would  ||| S:56999 E:57005 ||| MD
include  ||| S:57005 E:57013 ||| VB
( ||| S:57013 E:57014 ||| -LRB-
but  ||| S:57014 E:57018 ||| CC
not  ||| S:57018 E:57022 ||| RB
be  ||| S:57022 E:57025 ||| VB
limited  ||| S:57025 E:57033 ||| VBN
to ||| S:57033 E:57035 ||| TO
)  ||| S:57035 E:57037 ||| -RRB-
young  ||| S:57037 E:57043 ||| JJ
children  ||| S:57043 E:57052 ||| NNS
with  ||| S:57052 E:57057 ||| IN
bloody  ||| S:57057 E:57064 ||| JJ
diarrhea  ||| S:57064 E:57073 ||| NN
but  ||| S:57073 E:57077 ||| CC
no  ||| S:57077 E:57080 ||| DT
white  ||| S:57080 E:57086 ||| JJ
cells  ||| S:57086 E:57092 ||| NNS
in  ||| S:57092 E:57095 ||| IN
the  ||| S:57095 E:57099 ||| DT
stool ||| S:57099 E:57104 ||| NN
,  ||| S:57104 E:57106 ||| ,
patients  ||| S:57106 E:57115 ||| NNS
with  ||| S:57115 E:57120 ||| IN
indications  ||| S:57120 E:57132 ||| NNS
of  ||| S:57132 E:57135 ||| IN
HUS ||| S:57135 E:57138 ||| NNP
,  ||| S:57138 E:57140 ||| ,
patients  ||| S:57140 E:57149 ||| NNS
with  ||| S:57149 E:57154 ||| IN
positive  ||| S:57154 E:57163 ||| JJ
stool  ||| S:57163 E:57169 ||| JJ
sample  ||| S:57169 E:57176 ||| NN
tests  ||| S:57176 E:57182 ||| NNS
for  ||| S:57182 E:57186 ||| IN
Shiga  ||| S:57186 E:57192 ||| NNP
toxin ||| S:57192 E:57197 ||| NN
,  ||| S:57197 E:57199 ||| ,
siblings  ||| S:57199 E:57208 ||| NNS
or  ||| S:57208 E:57211 ||| CC
daycare  ||| S:57211 E:57219 ||| JJ
cohorts  ||| S:57219 E:57227 ||| NNS
in  ||| S:57227 E:57230 ||| IN
contact  ||| S:57230 E:57238 ||| NN
with  ||| S:57238 E:57243 ||| IN
a  ||| S:57243 E:57245 ||| DT
case  ||| S:57245 E:57250 ||| NN
( ||| S:57250 E:57251 ||| -LRB-
as  ||| S:57251 E:57254 ||| IN
a  ||| S:57254 E:57256 ||| DT
passive  ||| S:57256 E:57264 ||| JJ
preventative  ||| S:57264 E:57277 ||| JJ
measure ||| S:57277 E:57284 ||| NN
) ||| S:57284 E:57285 ||| -RRB-
,  ||| S:57285 E:57287 ||| ,
and  ||| S:57287 E:57291 ||| CC
any  ||| S:57291 E:57295 ||| DT
patient  ||| S:57295 E:57303 ||| NN
with  ||| S:57303 E:57308 ||| IN
diarrhea  ||| S:57308 E:57317 ||| NNS
( ||| S:57317 E:57318 ||| -LRB-
not  ||| S:57318 E:57322 ||| RB
necessarily  ||| S:57322 E:57334 ||| RB
bloody ||| S:57334 E:57340 ||| JJ
)  ||| S:57340 E:57342 ||| -RRB-
that  ||| S:57342 E:57347 ||| WDT
has  ||| S:57347 E:57351 ||| VBZ
been  ||| S:57351 E:57356 ||| VBN
in  ||| S:57356 E:57359 ||| IN
contact  ||| S:57359 E:57367 ||| NN
with  ||| S:57367 E:57372 ||| IN
an  ||| S:57372 E:57375 ||| DT
identified  ||| S:57375 E:57386 ||| JJ
case ||| S:57386 E:57390 ||| NN
.  ||| S:57390 E:57392 ||| .
A  ||| S:57392 E:57394 ||| DT
typical  ||| S:57394 E:57402 ||| JJ
dosage  ||| S:57402 E:57409 ||| NN
of  ||| S:57409 E:57412 ||| IN
about  ||| S:57412 E:57418 ||| IN
5  ||| S:57418 E:57420 ||| CD
mg ||| S:57420 E:57422 ||| CD
/ ||| S:57422 E:57423 ||| CD
kg  ||| S:57423 E:57426 ||| JJ
body  ||| S:57426 E:57431 ||| NN
weight  ||| S:57431 E:57438 ||| NN
of  ||| S:57438 E:57441 ||| IN
humanized  ||| S:57441 E:57451 ||| NNS
13C4  ||| S:57451 E:57456 ||| VBP
combined  ||| S:57456 E:57465 ||| VBN
with  ||| S:57465 E:57470 ||| IN
about  ||| S:57470 E:57476 ||| IN
10  ||| S:57476 E:57479 ||| CD
mg ||| S:57479 E:57481 ||| CD
/ ||| S:57481 E:57482 ||| CD
kg  ||| S:57482 E:57485 ||| JJ
body  ||| S:57485 E:57490 ||| NN
weight  ||| S:57490 E:57497 ||| NN
of  ||| S:57497 E:57500 ||| IN
humanized  ||| S:57500 E:57510 ||| JJ
11E10  ||| S:57510 E:57516 ||| NN
would  ||| S:57516 E:57522 ||| MD
be  ||| S:57522 E:57525 ||| VB
contemplated ||| S:57525 E:57537 ||| VBN
.  ||| S:57537 E:57539 ||| .
This  ||| S:57539 E:57544 ||| DT
combined  ||| S:57544 E:57553 ||| JJ
formulation  ||| S:57553 E:57565 ||| NN
could  ||| S:57565 E:57571 ||| MD
be  ||| S:57571 E:57574 ||| VB
administered  ||| S:57574 E:57587 ||| VBN
to  ||| S:57587 E:57590 ||| TO
the  ||| S:57590 E:57594 ||| DT
patient  ||| S:57594 E:57602 ||| NN
twice  ||| S:57602 E:57608 ||| RB
to  ||| S:57608 E:57611 ||| TO
ensure  ||| S:57611 E:57618 ||| VB
effectiveness ||| S:57618 E:57631 ||| NN
.  ||| S:57631 E:57633 ||| .
Inclusion  ||| S:57633 E:57643 ||| NN
of  ||| S:57643 E:57646 ||| IN
both  ||| S:57646 E:57651 ||| DT
types  ||| S:57651 E:57657 ||| NNS
of  ||| S:57657 E:57660 ||| IN
humanized  ||| S:57660 E:57670 ||| JJ
antibodies  ||| S:57670 E:57681 ||| NNS
together  ||| S:57681 E:57690 ||| RB
provides  ||| S:57690 E:57699 ||| VBZ
assurance  ||| S:57699 E:57709 ||| NN
that  ||| S:57709 E:57714 ||| IN
the  ||| S:57714 E:57718 ||| DT
patient  ||| S:57718 E:57726 ||| NN
will  ||| S:57726 E:57731 ||| MD
be  ||| S:57731 E:57734 ||| VB
protected  ||| S:57734 E:57744 ||| VBN
against  ||| S:57744 E:57752 ||| IN
all  ||| S:57752 E:57756 ||| DT
types  ||| S:57756 E:57762 ||| NNS
of  ||| S:57762 E:57765 ||| IN
Shiga  ||| S:57765 E:57771 ||| NNP
toxin ||| S:57771 E:57776 ||| NN
.  ||| S:57776 E:57780 ||| .
The  ||| S:57780 E:57784 ||| DT
person  ||| S:57784 E:57791 ||| NN
skilled  ||| S:57791 E:57799 ||| NN
in  ||| S:57799 E:57802 ||| IN
the  ||| S:57802 E:57806 ||| DT
art  ||| S:57806 E:57810 ||| NN
would  ||| S:57810 E:57816 ||| MD
understand  ||| S:57816 E:57827 ||| VB
how  ||| S:57827 E:57831 ||| WRB
to  ||| S:57831 E:57834 ||| TO
use  ||| S:57834 E:57838 ||| VB
and  ||| S:57838 E:57842 ||| CC
practice  ||| S:57842 E:57851 ||| VB
the  ||| S:57851 E:57855 ||| DT
invention  ||| S:57855 E:57865 ||| NN
based  ||| S:57865 E:57871 ||| VBN
on  ||| S:57871 E:57874 ||| IN
the  ||| S:57874 E:57878 ||| DT
above  ||| S:57878 E:57884 ||| JJ
disclosure ||| S:57884 E:57894 ||| NN
.  ||| S:57894 E:57896 ||| .
Other  ||| S:57896 E:57902 ||| JJ
embodiments  ||| S:57902 E:57914 ||| NN
of  ||| S:57914 E:57917 ||| IN
the  ||| S:57917 E:57921 ||| DT
invention  ||| S:57921 E:57931 ||| NN
will  ||| S:57931 E:57936 ||| MD
be  ||| S:57936 E:57939 ||| VB
apparent  ||| S:57939 E:57948 ||| JJ
to  ||| S:57948 E:57951 ||| TO
those  ||| S:57951 E:57957 ||| DT
skilled  ||| S:57957 E:57965 ||| JJ
in  ||| S:57965 E:57968 ||| IN
the  ||| S:57968 E:57972 ||| DT
art  ||| S:57972 E:57976 ||| NN
from  ||| S:57976 E:57981 ||| IN
consideration  ||| S:57981 E:57995 ||| NN
of  ||| S:57995 E:57998 ||| IN
the  ||| S:57998 E:58002 ||| DT
specification  ||| S:58002 E:58016 ||| NN
and  ||| S:58016 E:58020 ||| CC
practice  ||| S:58020 E:58029 ||| NN
of  ||| S:58029 E:58032 ||| IN
the  ||| S:58032 E:58036 ||| DT
invention  ||| S:58036 E:58046 ||| NN
disclosed  ||| S:58046 E:58056 ||| VBD
herein ||| S:58056 E:58062 ||| VBN
.  ||| S:58062 E:58064 ||| .
It  ||| S:58064 E:58067 ||| PRP
is  ||| S:58067 E:58070 ||| VBZ
intended  ||| S:58070 E:58079 ||| VBN
that  ||| S:58079 E:58084 ||| IN
the  ||| S:58084 E:58088 ||| DT
specification  ||| S:58088 E:58102 ||| NN
and  ||| S:58102 E:58106 ||| CC
examples  ||| S:58106 E:58115 ||| NNS
be  ||| S:58115 E:58118 ||| VB
considered  ||| S:58118 E:58129 ||| VBN
as  ||| S:58129 E:58132 ||| IN
exemplary  ||| S:58132 E:58142 ||| VBG
only ||| S:58142 E:58146 ||| RB
,  ||| S:58146 E:58148 ||| ,
with  ||| S:58148 E:58153 ||| IN
the  ||| S:58153 E:58157 ||| DT
true  ||| S:58157 E:58162 ||| JJ
scope  ||| S:58162 E:58168 ||| NN
and  ||| S:58168 E:58172 ||| CC
spirit  ||| S:58172 E:58179 ||| NN
of  ||| S:58179 E:58182 ||| IN
the  ||| S:58182 E:58186 ||| DT
invention  ||| S:58186 E:58196 ||| NN
being  ||| S:58196 E:58202 ||| VBG
indicated  ||| S:58202 E:58212 ||| VBN
by  ||| S:58212 E:58215 ||| IN
the  ||| S:58215 E:58219 ||| DT
following  ||| S:58219 E:58229 ||| JJ
claims ||| S:58229 E:58235 ||| NNS
.  ||| S:58235 E:58243 ||| .
What  ||| S:58243 E:58248 ||| WP
is  ||| S:58248 E:58251 ||| VBZ
claimed  ||| S:58251 E:58259 ||| VBN
is ||| S:58259 E:58261 ||| VBZ
:  ||| S:58261 E:58266 ||| :
4 ||| S:59012 E:59013 ||| LS
.  ||| S:59013 E:59015 ||| .
The  ||| S:59015 E:59019 ||| DT
isolated  ||| S:59019 E:59028 ||| JJ
nucleic  ||| S:59028 E:59036 ||| JJ
acid  ||| S:59036 E:59041 ||| NN
molecule  ||| S:59041 E:59050 ||| NN
of  ||| S:59050 E:59053 ||| IN
claim  ||| S:59053 E:59059 ||| NN
2 ||| S:59059 E:59060 ||| CD
,  ||| S:59060 E:59062 ||| ,
wherein  ||| S:59062 E:59070 ||| VBG
the  ||| S:59070 E:59074 ||| DT
isolated  ||| S:59074 E:59083 ||| JJ
nucleic  ||| S:59083 E:59091 ||| JJ
acid  ||| S:59091 E:59096 ||| NN
molecule  ||| S:59096 E:59105 ||| NN
comprises  ||| S:59105 E:59115 ||| VBZ
the  ||| S:59115 E:59119 ||| DT
nucleic  ||| S:59119 E:59127 ||| JJ
acid  ||| S:59127 E:59132 ||| NN
sequence  ||| S:59132 E:59141 ||| NN
of  ||| S:59141 E:59144 ||| IN
SEQ  ||| S:59144 E:59148 ||| NNP
ID  ||| S:59148 E:59151 ||| NNP
NO ||| S:59151 E:59153 ||| NNP
:  ||| S:59153 E:59155 ||| :
43 ||| S:59155 E:59157 ||| CD
.  ||| S:59157 E:59163 ||| .
8 ||| S:59908 E:59909 ||| CD
.  ||| S:59909 E:59911 ||| .
The  ||| S:59911 E:59915 ||| DT
isolated  ||| S:59915 E:59924 ||| JJ
nucleic  ||| S:59924 E:59932 ||| JJ
acid  ||| S:59932 E:59937 ||| NN
molecule  ||| S:59937 E:59946 ||| NN
of  ||| S:59946 E:59949 ||| IN
claim  ||| S:59949 E:59955 ||| NN
6 ||| S:59955 E:59956 ||| CD
,  ||| S:59956 E:59958 ||| ,
wherein  ||| S:59958 E:59966 ||| VBG
the  ||| S:59966 E:59970 ||| DT
isolated  ||| S:59970 E:59979 ||| JJ
nucleic  ||| S:59979 E:59987 ||| JJ
acid  ||| S:59987 E:59992 ||| NN
molecule  ||| S:59992 E:60001 ||| NN
comprises  ||| S:60001 E:60011 ||| VBZ
the  ||| S:60011 E:60015 ||| DT
nucleic  ||| S:60015 E:60023 ||| JJ
acid  ||| S:60023 E:60028 ||| NN
sequence  ||| S:60028 E:60037 ||| NN
of  ||| S:60037 E:60040 ||| IN
SEQ  ||| S:60040 E:60044 ||| NNP
ID  ||| S:60044 E:60047 ||| NNP
NO ||| S:60047 E:60049 ||| NNP
:  ||| S:60049 E:60051 ||| :
41 ||| S:60051 E:60053 ||| CD
.  ||| S:60053 E:60059 ||| .
9 ||| S:60059 E:60060 ||| CD
.  ||| S:60060 E:60062 ||| .
The  ||| S:60062 E:60066 ||| DT
isolated  ||| S:60066 E:60075 ||| JJ
nucleic  ||| S:60075 E:60083 ||| JJ
acid  ||| S:60083 E:60088 ||| NN
molecule  ||| S:60088 E:60097 ||| NN
of  ||| S:60097 E:60100 ||| IN
claims  ||| S:60100 E:60107 ||| NNS
1  ||| S:60107 E:60109 ||| CD
or  ||| S:60109 E:60112 ||| CC
5 ||| S:60112 E:60113 ||| CD
,  ||| S:60113 E:60115 ||| ,
wherein  ||| S:60115 E:60123 ||| NN
said  ||| S:60123 E:60128 ||| VBD
nucleic  ||| S:60128 E:60136 ||| JJ
acid  ||| S:60136 E:60141 ||| NN
molecule  ||| S:60141 E:60150 ||| NN
further  ||| S:60150 E:60158 ||| RB
comprises  ||| S:60158 E:60168 ||| VBZ
a  ||| S:60168 E:60170 ||| DT
sequence  ||| S:60170 E:60179 ||| NN
encoding  ||| S:60179 E:60188 ||| VBD
a  ||| S:60188 E:60190 ||| DT
human  ||| S:60190 E:60196 ||| JJ
constant  ||| S:60196 E:60205 ||| JJ
region ||| S:60205 E:60211 ||| NN
.  ||| S:60211 E:60217 ||| .
11 ||| S:60606 E:60608 ||| CD
.  ||| S:60608 E:60610 ||| .
The  ||| S:60610 E:60614 ||| DT
nucleic  ||| S:60614 E:60622 ||| JJ
acid  ||| S:60622 E:60627 ||| NN
molecule  ||| S:60627 E:60636 ||| NN
of  ||| S:60636 E:60639 ||| IN
claim  ||| S:60639 E:60645 ||| NN
10 ||| S:60645 E:60647 ||| CD
,  ||| S:60647 E:60649 ||| ,
wherein  ||| S:60649 E:60657 ||| VBG
the  ||| S:60657 E:60661 ||| DT
heavy  ||| S:60661 E:60667 ||| JJ
chain  ||| S:60667 E:60673 ||| NN
variable  ||| S:60673 E:60682 ||| NN
domain  ||| S:60682 E:60689 ||| NN
of  ||| S:60689 E:60692 ||| IN
the  ||| S:60692 E:60696 ||| DT
antibody  ||| S:60696 E:60705 ||| NN
comprises  ||| S:60705 E:60715 ||| VBZ
the  ||| S:60715 E:60719 ||| DT
amino  ||| S:60719 E:60725 ||| JJ
acid  ||| S:60725 E:60730 ||| NN
sequence  ||| S:60730 E:60739 ||| NN
of  ||| S:60739 E:60742 ||| IN
SEQ  ||| S:60742 E:60746 ||| NNP
ID  ||| S:60746 E:60749 ||| NNP
NO ||| S:60749 E:60751 ||| NNP
:  ||| S:60751 E:60753 ||| :
44 ||| S:60753 E:60755 ||| CD
.  ||| S:60755 E:60761 ||| .
12 ||| S:60761 E:60763 ||| CD
.  ||| S:60763 E:60765 ||| .
The  ||| S:60765 E:60769 ||| DT
nucleic  ||| S:60769 E:60777 ||| JJ
acid  ||| S:60777 E:60782 ||| NN
molecule  ||| S:60782 E:60791 ||| NN
of  ||| S:60791 E:60794 ||| IN
claim  ||| S:60794 E:60800 ||| NN
10 ||| S:60800 E:60802 ||| CD
,  ||| S:60802 E:60804 ||| ,
wherein  ||| S:60804 E:60812 ||| VBG
the  ||| S:60812 E:60816 ||| DT
heavy  ||| S:60816 E:60822 ||| JJ
chain  ||| S:60822 E:60828 ||| NN
variable  ||| S:60828 E:60837 ||| NN
domain  ||| S:60837 E:60844 ||| NN
of  ||| S:60844 E:60847 ||| IN
the  ||| S:60847 E:60851 ||| DT
antibody  ||| S:60851 E:60860 ||| NN
comprises  ||| S:60860 E:60870 ||| VBZ
the  ||| S:60870 E:60874 ||| DT
amino  ||| S:60874 E:60880 ||| JJ
acid  ||| S:60880 E:60885 ||| NN
sequence  ||| S:60885 E:60894 ||| NN
of  ||| S:60894 E:60897 ||| IN
the  ||| S:60897 E:60901 ||| DT
heavy  ||| S:60901 E:60907 ||| JJ
chain  ||| S:60907 E:60913 ||| NN
variable  ||| S:60913 E:60922 ||| NN
domain  ||| S:60922 E:60929 ||| NN
of  ||| S:60929 E:60932 ||| IN
the  ||| S:60932 E:60936 ||| DT
murine  ||| S:60936 E:60943 ||| JJ
11E10  ||| S:60943 E:60949 ||| CD
antibody  ||| S:60949 E:60958 ||| NN
( ||| S:60958 E:60959 ||| -LRB-
ATCC  ||| S:60959 E:60964 ||| UH
Accession  ||| S:60964 E:60974 ||| UH
No ||| S:60974 E:60976 ||| UH
.  ||| S:60976 E:60978 ||| .
CRL  ||| S:60978 E:60982 ||| NNP
1987 ||| S:60982 E:60986 ||| CD
) ||| S:60986 E:60987 ||| -RRB-
.  ||| S:60987 E:60993 ||| .
13 ||| S:60993 E:60995 ||| CD
.  ||| S:60995 E:60997 ||| .
The  ||| S:60997 E:61001 ||| DT
nucleic  ||| S:61001 E:61009 ||| JJ
acid  ||| S:61009 E:61014 ||| NN
molecule  ||| S:61014 E:61023 ||| NN
of  ||| S:61023 E:61026 ||| IN
claim  ||| S:61026 E:61032 ||| NN
11 ||| S:61032 E:61034 ||| CD
,  ||| S:61034 E:61036 ||| ,
wherein  ||| S:61036 E:61044 ||| VBG
the  ||| S:61044 E:61048 ||| DT
heavy  ||| S:61048 E:61054 ||| JJ
chain  ||| S:61054 E:61060 ||| NN
variable  ||| S:61060 E:61069 ||| NN
domain  ||| S:61069 E:61076 ||| NN
of  ||| S:61076 E:61079 ||| IN
the  ||| S:61079 E:61083 ||| DT
antibody  ||| S:61083 E:61092 ||| NN
comprises  ||| S:61092 E:61102 ||| VBZ
the  ||| S:61102 E:61106 ||| DT
nucleic  ||| S:61106 E:61114 ||| JJ
acid  ||| S:61114 E:61119 ||| NN
sequence  ||| S:61119 E:61128 ||| NN
of  ||| S:61128 E:61131 ||| IN
SEQ  ||| S:61131 E:61135 ||| NNP
ID  ||| S:61135 E:61138 ||| NNP
NO ||| S:61138 E:61140 ||| NNP
:  ||| S:61140 E:61142 ||| :
43 ||| S:61142 E:61144 ||| CD
.  ||| S:61144 E:61150 ||| .
15 ||| S:61419 E:61421 ||| CD
.  ||| S:61421 E:61423 ||| .
The  ||| S:61423 E:61427 ||| DT
nucleic  ||| S:61427 E:61435 ||| JJ
acid  ||| S:61435 E:61440 ||| NN
molecule  ||| S:61440 E:61449 ||| NN
according  ||| S:61449 E:61459 ||| VBG
to  ||| S:61459 E:61462 ||| TO
claim  ||| S:61462 E:61468 ||| VB
14 ||| S:61468 E:61470 ||| CD
,  ||| S:61470 E:61472 ||| ,
wherein  ||| S:61472 E:61480 ||| VBG
the  ||| S:61480 E:61484 ||| DT
light  ||| S:61484 E:61490 ||| JJ
chain  ||| S:61490 E:61496 ||| NN
variable  ||| S:61496 E:61505 ||| NN
domain  ||| S:61505 E:61512 ||| NN
of  ||| S:61512 E:61515 ||| IN
the  ||| S:61515 E:61519 ||| DT
antibody  ||| S:61519 E:61528 ||| NN
comprises  ||| S:61528 E:61538 ||| VBZ
the  ||| S:61538 E:61542 ||| DT
amino  ||| S:61542 E:61548 ||| JJ
acid  ||| S:61548 E:61553 ||| NN
sequence  ||| S:61553 E:61562 ||| NN
of  ||| S:61562 E:61565 ||| IN
SEQ  ||| S:61565 E:61569 ||| NNP
ID  ||| S:61569 E:61572 ||| NNP
NO ||| S:61572 E:61574 ||| NNP
:  ||| S:61574 E:61576 ||| :
42 ||| S:61576 E:61578 ||| CD
.  ||| S:61578 E:61584 ||| .
16 ||| S:61584 E:61586 ||| CD
.  ||| S:61586 E:61588 ||| .
The  ||| S:61588 E:61592 ||| DT
nucleic  ||| S:61592 E:61600 ||| JJ
acid  ||| S:61600 E:61605 ||| NN
molecule  ||| S:61605 E:61614 ||| NN
of  ||| S:61614 E:61617 ||| IN
claim  ||| S:61617 E:61623 ||| NN
14 ||| S:61623 E:61625 ||| CD
,  ||| S:61625 E:61627 ||| ,
wherein  ||| S:61627 E:61635 ||| VBG
the  ||| S:61635 E:61639 ||| DT
light  ||| S:61639 E:61645 ||| JJ
chain  ||| S:61645 E:61651 ||| NN
variable  ||| S:61651 E:61660 ||| NN
domain  ||| S:61660 E:61667 ||| NN
of  ||| S:61667 E:61670 ||| IN
the  ||| S:61670 E:61674 ||| DT
antibody  ||| S:61674 E:61683 ||| NN
comprises  ||| S:61683 E:61693 ||| VBZ
the  ||| S:61693 E:61697 ||| DT
amino  ||| S:61697 E:61703 ||| JJ
acid  ||| S:61703 E:61708 ||| NN
sequence  ||| S:61708 E:61717 ||| NN
of  ||| S:61717 E:61720 ||| IN
the  ||| S:61720 E:61724 ||| DT
light  ||| S:61724 E:61730 ||| JJ
chain  ||| S:61730 E:61736 ||| NN
variable  ||| S:61736 E:61745 ||| NN
domain  ||| S:61745 E:61752 ||| NN
of  ||| S:61752 E:61755 ||| IN
the  ||| S:61755 E:61759 ||| DT
murine  ||| S:61759 E:61766 ||| JJ
11E10  ||| S:61766 E:61772 ||| CD
antibody  ||| S:61772 E:61781 ||| NN
( ||| S:61781 E:61782 ||| -LRB-
ATCC  ||| S:61782 E:61787 ||| UH
Accession  ||| S:61787 E:61797 ||| UH
No ||| S:61797 E:61799 ||| UH
.  ||| S:61799 E:61801 ||| .
CRL  ||| S:61801 E:61805 ||| NNP
1987 ||| S:61805 E:61809 ||| CD
) ||| S:61809 E:61810 ||| -RRB-
.  ||| S:61810 E:61816 ||| .
17 ||| S:61816 E:61818 ||| CD
.  ||| S:61818 E:61820 ||| .
The  ||| S:61820 E:61824 ||| DT
nucleic  ||| S:61824 E:61832 ||| JJ
acid  ||| S:61832 E:61837 ||| NN
molecule  ||| S:61837 E:61846 ||| NN
of  ||| S:61846 E:61849 ||| IN
claim  ||| S:61849 E:61855 ||| NN
15 ||| S:61855 E:61857 ||| CD
,  ||| S:61857 E:61859 ||| ,
wherein  ||| S:61859 E:61867 ||| VBG
the  ||| S:61867 E:61871 ||| DT
light  ||| S:61871 E:61877 ||| JJ
chain  ||| S:61877 E:61883 ||| NN
variable  ||| S:61883 E:61892 ||| NN
domain  ||| S:61892 E:61899 ||| NN
of  ||| S:61899 E:61902 ||| IN
the  ||| S:61902 E:61906 ||| DT
antibody  ||| S:61906 E:61915 ||| NN
comprises  ||| S:61915 E:61925 ||| VBZ
the  ||| S:61925 E:61929 ||| DT
nucleic  ||| S:61929 E:61937 ||| JJ
acid  ||| S:61937 E:61942 ||| NN
sequence  ||| S:61942 E:61951 ||| NN
of  ||| S:61951 E:61954 ||| IN
SEQ  ||| S:61954 E:61958 ||| NNP
ID  ||| S:61958 E:61961 ||| NNP
NO ||| S:61961 E:61963 ||| NNP
:  ||| S:61963 E:61965 ||| :
41 ||| S:61965 E:61967 ||| CD
.  ||| S:61967 E:61973 ||| .
20 ||| S:62153 E:62155 ||| CD
.  ||| S:62155 E:62157 ||| .
A  ||| S:62157 E:62159 ||| DT
method  ||| S:62159 E:62166 ||| NN
of  ||| S:62166 E:62169 ||| IN
producing  ||| S:62169 E:62179 ||| VBG
an  ||| S:62179 E:62182 ||| DT
anti-Stx2  ||| S:62182 E:62192 ||| JJ
antibody  ||| S:62192 E:62201 ||| NN
comprising  ||| S:62201 E:62212 ||| VBG
the  ||| S:62212 E:62216 ||| DT
steps  ||| S:62216 E:62222 ||| NNS
of  ||| S:62222 E:62225 ||| IN
culturing  ||| S:62225 E:62235 ||| VBG
a  ||| S:62235 E:62237 ||| DT
host  ||| S:62237 E:62242 ||| NN
cell  ||| S:62242 E:62247 ||| NN
comprising  ||| S:62247 E:62258 ||| VBG
the  ||| S:62258 E:62262 ||| DT
nucleic  ||| S:62262 E:62270 ||| JJ
acid  ||| S:62270 E:62275 ||| NN
molecule  ||| S:62275 E:62284 ||| NN
according  ||| S:62284 E:62294 ||| VBG
to  ||| S:62294 E:62297 ||| TO
any  ||| S:62297 E:62301 ||| DT
one  ||| S:62301 E:62305 ||| NN
of  ||| S:62305 E:62308 ||| IN
claims  ||| S:62308 E:62315 ||| NNS
1 ||| S:62315 E:62316 ||| CD
,  ||| S:62316 E:62318 ||| ,
5 ||| S:62318 E:62319 ||| CD
,  ||| S:62319 E:62321 ||| ,
10 ||| S:62321 E:62323 ||| CD
,  ||| S:62323 E:62325 ||| ,
and  ||| S:62325 E:62329 ||| CC
14 ||| S:62329 E:62331 ||| CD
,  ||| S:62331 E:62333 ||| ,
under  ||| S:62333 E:62339 ||| IN
conditions  ||| S:62339 E:62350 ||| NNS
suitable  ||| S:62350 E:62359 ||| JJ
for  ||| S:62359 E:62363 ||| IN
expression  ||| S:62363 E:62374 ||| NN
of  ||| S:62374 E:62377 ||| IN
the  ||| S:62377 E:62381 ||| DT
antibody  ||| S:62381 E:62390 ||| NN
and  ||| S:62390 E:62394 ||| CC
recovering  ||| S:62394 E:62405 ||| VBG
the  ||| S:62405 E:62409 ||| DT
antibody ||| S:62409 E:62417 ||| NN
.  ||| S:62417 E:62423 ||| .
